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CHAPTER 1 
 
Introduction and Significance 
 
1.1 Motivation 
Soft tissue wounds, predominantly in the skin and underlying area, represent a major clinical challenge 
in the United States and the rest of the world. Skin wounds can be classified as acute or chronic in nature, 
with acute tissue defects typically arising from trauma or burns and non-healing chronic wounds being 
categorized as either diabetic ulcers, pressure ulcers, or venous ulcers[1]. The treatment costs of managing 
chronic wounds in the United States is estimated at $25B annually, and is predicted to significantly increase 
in the future[1]. This anticipated rise in patients developing chronic wounds is directly tied to the rise in 
diabetic cases over the past three decades, with the CDC reporting that the incidence and prevalence of 
diabetes doubled in the US from 1980-2012[2]. Patients with diabetes are more prone to cardiovascular and 
peripheral arterial disease and impaired wound healing, often helping steer initially simple skin wounds 
towards chronic ulceration and ultimately leading to limb amputation. Approximately 25% of diabetics 
develop chronic ulcers[1], and roughly 60% of non-traumatic lower-limb amputations for patients over 20 
years old occur in diabetics[3]. The correlation between diabetes and poor skin wound healing outcomes is 
clear, and as the prevalence of diabetes continues to grow, so will the incidence of amputation caused by 
chronic skin wounds. These statistics highlight the deleterious impact of diabetes in the United States today 
and clearly define a tremendous clinical need for improved therapeutic strategies to reduce wound related 
morbidity and mortality. 
 
1.2 Molecular basis for chronic wounds 
The hallmark clinical manifestation of diabetes is sustained hyperglycemia resulting from either the 
destruction of insulin-producing beta cells in Type 1 diabetes, or insulin resistance in Type 2 diabetes. 
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Though diabetes is typically managed with a combination of lifestyle modifications and pharmacological 
interventions, prolonged or unmanaged hyperglycemia has been implicated in many pathologies, including 
cardiovascular complications, neuropathy, and poor collateral vessel formation[4]. Consequently, small 
skin wounds or pressure ulcers in diabetic patients may develop into chronic non-healing wounds that do 
not respond to normal standard of care practices for wound care. These non-healing wounds are particularly 
challenging due to local tissue hypoxia, inflammation, and high oxidative stress[5, 6]. To alleviate these 
chronic wounds, more advanced therapies employing biologic drugs or stem cells have been administered 
in attempts to correct the underlying molecular dysfunction. However, delivery of platelet derived growth 
factor (PDGF in Regranex®) resulted in incomplete wound healing in 50% of patients in clinical trials [7], 
while stem cell delivery still suffers from high regulatory burdens and poor clinical outcomes[8]. 
Recent evidence has implicated diminished activation of the transcription factor hypoxia-induced factor 
1-alpha (HIF-1α) in diabetic patients as a key player in the development of chronic wounds[9, 10]. 
Increasing HIF-1α activation in chronic wounds may help restore normal healing processes as stabilized 
HIF-1α promotes the expression of multiple reparative genes, including vascular endothelial growth factor 
(VEGF)[11], angiopoietin-1 (ANG-1)[12], and stromal cell-derived factor-1 (SDF-1)[13]. Prolyl 
hydroxylase domain protein 2 (PHD2) negatively regulates HIF-1α[14, 15] (depicted in Figure 1) and 
represents a promising therapeutic target for stabilizing HIF-1α levels in vivo to improve tissue regeneration 
of skin wounds[16-19]. A number of drug agents have been pursued for pharmacological inhibition of 
PHD2 activity, including small molecule drugs and small interfering RNA (siRNA). Though small 
molecule inhibitors have demonstrated promising results in promoting wound healing[20-23], they do not 
specifically target PHD2 among different PHD isoforms and can cause off-target effects[24-26]. siRNA 
molecules are short, double stranded RNA that load into the RNA induced silencing complex (RISC), a 
cohort of proteins intrinsic to mammalian cells, to undergo complementary base pairing with target 
messenger RNA (mRNA) sequences and facilitate mRNA degradation. To selectively inhibit PHD2 activity 
and promote HIF-1α-mediated wound healing, recent work has pursued the local delivery of PHD2 siRNA 
for wound healing applications[27-30]. 
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Figure 1. PHD2 signaling in normoxia and hypoxia. During normoxia, the oxygen-dependent PHD2 hydrolyxates 
HIF-1α, leading to its recognition by the Von Hippel-Lindau Tumor suppressor (pVHL) and subsequent degradation. 
Alternatively, in hypoxia, PHD2 is inactive from the lack of oxygen and HIF-1α is free to bind with HIF-1β to 
translocate to the nucleus and begin transcribing pro-growth genes. Adapted from [31]. 
Though inhibition of PHD2 to promote local HIF-1α stabilization is a promising strategy for promoting 
healing in chronic wounds, the local delivery of an exogenous PHD2 inhibitory molecule could be limited 
by depletion of the drug over time. In situ delivery of mesenchymal stem cells (MSCs) has been also been 
pursued in wound healing applications as these cells can modulate local inflammation while secreting 
paracrine growth factors that promote tissue repair[32]. MSCs implanted at wound sites have been shown 
to secrete a host of growth factors that can improve wound healing outcomes, including VEGF, insulin-like 
growth factor (IGF), and keratinocyte growth factor (KGF), among others[33]. Therefore, the in vivo 
delivery of viable stem cells could provide a depot of continuously-produced reparative growth factors as 
an alternative strategy to promote the repair of non-healing wounds. 
 
1.3 Biodegradable tissue engineering materials 
The fields of regenerative medicine and tissue engineering are founded on the usage of bulk-scale 
biomaterial implants that help direct the repair of damaged or non-functioning tissues or organs. These 
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biomaterials can have a variety of functions as reviewed previously[34], but often serve as either scaffolds 
for directing 3D tissue growth, vehicles for the delivery of cells, depots for the controlled release of 
therapeutic agents, or some combination of these functions. As the long-term implantation of any foreign 
material inevitably leads to a host response and some degree of immune rejection[35], these biomaterials 
predominantly feature degradable segments that allow the host to remodel the implant and gradually replace 
it with new tissue. To this end, these implantable materials must be non-toxic and also feature degradation 
products that do not promote toxicity or a deleterious immune response. Biodegradable implants fall into 
two broad classes based on their source: synthetic (i.e. polymers synthesized by conventional organic 
chemistry techniques), or natural (i.e. re-processed materials extracted from human or animal tissue). Both 
of these two material classes have different strengths and weaknesses as implantable biomaterials, but the 
work here has been exclusively focused on the development of synthetic polymeric biomaterials due to 
their capacity for repeatable fabrication and ease of functionalization. 
Biodegradable synthetic biomaterials are typically fabricated to leverage either hydrolysis or enzymatic 
cleavage of covalent bonds in the material’s polymeric backbone for in vivo degradation of the construct. 
Hydrolytically-degradable biomaterials have been utilized in a number of FDA-approved products in the 
clinic as they are non-cytotoxic, produce nontoxic degradation byproducts, and are cheaply and easily 
synthesized for a number of applications. However, though the in vivo degradation profile of hydrolytically-
degradable materials can be nominally tuned by modifying their chemical composition, this material 
breakdown happens irrespective of the biological tissue response to the implant. This mismatch between 
new tissue growth and biomaterial degradation can lead to compromised tissue regeneration in certain 
applications[36], thereby motivating the development of environmentally-responsive materials that are 
degraded by cell-mediated mechanisms. This has encouraged the incorporation of protease-degradable 
peptides into a number of tissue engineering materials, thus making these implants specifically degradable 
by cell-generated enzymes. However, the translational potential of bulk-scale, peptide-based biomaterials 
remains in question due to the difficulty in synthesizing peptides at large scales[37, 38]. Therefore, there 
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remains an unmet clinical need for biomaterial implants that are specifically degraded by cell-mediated 
activity but can be affordably synthesized in large scales. 
 
1.4 Reactive oxygen species as a trigger for biomaterial responsiveness 
Reactive oxygen species (ROS), including hydrogen peroxide (H2O2), superoxide (O2-), hypochlorous 
acid (HOCl), hydroxyl radical, and singlet oxygen, serve as important biological mediators in many 
biological processes such as cell signaling and the immune response against invading pathogens[39]. 
However, overproduction of ROS (termed oxidative stress) can damage proteins, rendering them non-
functional, and oxidize DNA, causing mutations. Furthermore, elevated ROS is a hallmark of inflammation 
and the pathogenesis of myriad diseases, including cancer, aging, and neurodegeneration[40]. The number 
of diseases that are caused or exacerbated by oxidative stress has motivated the development and utilization 
of biomaterials that can interact with ROS in either a diagnostic or therapeutic capacity[41-43]. Most ROS-
sensitive polymers are synthetically-derived and employ straight-forward fabrication techniques, though to 
date most biomaterial platforms featuring ROS-degradable chemistries have been primarily employed in a 
nanoscale format to target cell populations with elevated levels of ROS intracellularly. However, polymeric 
biomaterial implants have been shown to elicit a stable three-fold increase in ROS production at surgery 
sites over a four-week timeframe [44], and chronic wounds are characterized by high levels of oxidative 
stress[5, 6]. Consequently, cell-generated ROS represent an intriguing, ubiquitous target for triggering 
biomaterial degradation in vivo. 
 
1.5 Approach 
Our work has focused on the development of a polymer chemistry platform technology to fabricate 
synthetic biomaterials that are specifically degraded by cell-generated ROS. These biomaterials were 
produced from poly(thioketal) (PTK) polymers that were originally applied for development of 
nanoparticles that specifically release their cargo “on demand” at sites of oxidative stress [45]. We have 
extended this polymer chemistry to create a variety of PTK polymers that are amenable to formulation in 
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very different biomaterial systems, namely hydrophobic polyurethane scaffolds and hydrophilic 
poly(ethylene glycol) (PEG) hydrogels. Despite the differences in these two distinct classes of materials, 
both PTK-based polyurethane (PTK-UR) scaffolds and PTK hydrogels are specifically degraded by ROS 
both in vitro and in vivo. Compared to benchmark polyurethane and hydrogel biomaterials, these PTK-
based constructs have both improved degradation kinetics and an enhanced translational potential due to 
their affordability and simple fabrication. Furthermore, these two classes of PTK-based biomaterials are 
both amenable to in situ gelation for minimally-invasive delivery in the clinic and can carry therapeutic 
payloads to improve the healing of chronic wounds.  
As outlined in Figure 2A, PTK-UR scaffolds are formed from a PTK diol polymer, a trifunctional 
isocyanate, and water. The water reacts with the isocyanates to generate carbon dioxide bubbles during the 
reactive gelling process, thus producing a scaffold with a porous, 3D architecture that is well suited for 
hosting cellular infiltration after implantation. PTK-UR scaffolds were sensitive to ROS-mediated 
degradation and underwent controlled biodegradation in vivo while hosting robust new tissue formation in 
implanted materials[30]. These scaffolds were also loaded with siRNA-carrying, environmentally-
responsive nanoparticles (NPs) that locally deliver siRNA to scaffold-infiltrating cells. These NPs 
electrostatically condense siRNA to protect the drug from nuclease degradation, and upon cellular 
internalization can undergo pH-dependent membrane disruption to mediate siRNA release from endo-
lysosomal vesicles into the cytoplasm. Previous efforts demonstrated the utility of this local siRNA delivery 
platform for the formation of new blood vessels in preclinical in vivo proof of concept studies[28], and this 
work was extended by using the more highly regenerative PTK-UR scaffolds loaded with siRNA-NPs 
(siNPs) to enhance healing in excisional diabetic wounds[46]. 
Though PTK polymers are inherently hydrophobic, this chemistry was extended to make thiolated, 
water-soluble PTK molecules. These hydrophilic PTK polymers could then be combined with a thiol-
reactive 4-arm PEG-maleimide (PEG-MAL) macromer to form covalently-linked hydrogels as shown in 
Figure 2B. These injectable hydrogels were sensitive to ROS in vitro and successfully hosted viable MSCs 
over multiple days in culture. Furthermore, PTK hydrogels displayed more favorable in vivo degradation 
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kinetics than gels crosslinked with a protease-cleavable peptide, indicating that targeting ROS as a 
biomaterial degradation trigger could be even more potent than exploiting enzymatic mechanisms to 
promote in vivo material break down. 
 
Figure 2. Schematic of the approaches used in these studies. (A) Injectable PTK-UR scaffolds are fabricated from a 
hydrophobic PTK diol polymer and a trifunctional isocyanate and can also be loaded with siRNA-loaded 
nanoparticles. (B) Injectable PEG-MAL-PTK hydrogels are fabricated by combining water-soluble, thiol-terminated 
PTK polymers with 4-arm PEG-MAL macromers. Dispersed MSCs can also be mixed with the hydrogel precursors 
prior to gelation for 3D cell encapsulation after gel formation. 
 
1.6 Innovation 
PTK-UR scaffolds are the first reported example of injectable polyurethane biomaterials that are 
specifically degraded by ROS, and one of the first synthetic tissue engineering scaffolds overall to feature 
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exclusively cell-mediated degradation. Though PHD2 siRNA has previously been delivered from 
polyurethane scaffolds in vivo[28], the work presented here is the first to deliver PHD2 siRNA from an 
implanted scaffold to enhance healing in diabetic wounds in rats. Targeting PHD2 in chronic diabetic 
wounds to improve healing outcomes is a novel approach and potentially very rewarding scientific pursuit. 
The creation of a water-soluble PTK polymer is the first report of a hydrophilic PTK material, and the 
creation of novel PTK hydrogels is the first example of a covalently-linked PEG hydrogel that is exclusively 
degraded by ROS. Though other hydrogel formulations have featured antioxidant activity or used ROS to 
drive a change in solubility of hydrophobic domains to mediate hydrogel degradation, PTK-based hydrogels 
are the first materials to feature ROS-mediated cleavage of covalent bonds to stimulate degradation. 
 
1.7 Specific aims 
The central hypothesis of this work is that PTK-based implants that use cell-generated ROS to mediate in 
vivo material degradation will provide a more generalizable, clinically-translatable, and better-performing 
biomaterial platform than currently used biodegradable materials. 
Specific Aim 1: Synthesize and characterize a library of PTK-urethane (PTK-UR) scaffolds 
from ROS-degradable PTK polymers. PTK polymers will be synthesized by the condensation 
polymerization of 2,2 dimethoxy propane and different dithiol monomers to create a family of PTK 
polymers. The size and molecular composition of these polymers will be characterized before 
incorporating them into 3D, porous PTK-UR scaffolds by reacting them with tri-functional, 
biocompatible isocyanates and water. Mechanical properties, cytotoxicity, and ROS-dependent 
degradation of the resultant PTK-UR scaffolds will all be assessed in vitro. 
Specific Aim 2: Assess the in vivo performance of PTK-UR scaffolds for basal tissue regeneration 
and as a therapeutic siRNA delivery platform. Initial in vivo biocompatibility, biodegradation, and 
tissue infiltration of PTK-URs will be compared against PEUR materials in both subcutaneous and 
excisional diabetic wounds. Lead PTK-UR and PEUR scaffolds will also be evaluated as local delivery 
vehicles for endosomolytic nanoparticles complexed with siRNA targeting PHD2 to improve wound 
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healing in diabetic rats. Therapeutic response to the siRNA-loaded scaffolds will be assessed by qRT-
PCR, Western blot, and immunohistochemistry. 
Specific Aim 3: Synthesize and characterize PTK-based PEG hydrogels for comparison against 
proteolytically-degradable hydrogels. Water-soluble, thiol-terminated PTK polymers will be 
synthesized and characterized before reacting with multi-arm, maleimide-functionalized PEG 
macromers to form cross-linked PEG hydrogels. PTK hydrogels will be characterized in vitro by 
rheometry, measurements of ROS-dependent gel degradation, and cytotoxicity as benchmarked 
against hydrogels made with a minimally-degradable PEG crosslinker or gels made with a 
proteolytically-degradable peptide. Finally, in vivo degradation of the three hydrogel formulations 
subcutaneously implanted in mice will be evaluated by non-invasive fluorescence imaging. 
 
1.8 Outline 
This dissertation contains a thorough description of the development of a clinically-translatable, ROS-
degradable biomaterial platform. Chapter 2 will provide a concise and targeted review of previous work 
with biodegradable materials in regenerative medicine. Chapter 3 will detail the in vitro development and 
characterization of PTK-UR materials to confirm their degradability and biocompatibility. Chapter 4 will 
describe the in vivo testing of PTK-UR scaffolds against gold-standard PEUR implants, and illustrate the 
utility of these materials as an siRNA delivery platform to improve the healing of diabetic wounds. Chapter 
5 will consider the usage of PTK polymers in the formation of PEG hydrogels that undergo cell-mediated 
degradation in vivo as an alternative to PEG gels made with enzymatically-degradable peptides. Finally, a 
summary outlining the broader impacts, challenges, and future work will conclude this dissertation. Each 
research chapter (3-5) will also contain a short introduction and methods section with their own results and 
discussions.  
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CHAPTER 2 
 
Background: Hydrolytic and Cell-Mediated Degradation Mechanisms of Biomaterials 
 
Text partially adapted from: 
Martin JR, Gupta MK, Page JM, Yu F, Davidson JM, Guelcher SA, Duvall CL. A porous tissue 
engineering scaffold selectively degraded by cell-generated reactive oxygen species. Biomaterials. 2014; 
35: 12, 3766-3776. 
 
Martin JR, Duvall CL. Oxidation State as a Bioresponsive Trigger. In: T. Dziubla T and D.A. Butterfield, 
eds. Oxidative Stress in Biomaterials, Academic Press, Cambridge, MA. 2016; 225-250. 
 
Martin JR, Prarthana P, Gupta MK, Duvall CL. Enhanced In Vivo Degradation of Injectable, Reactive 
Oxygen Species-Sensitive PEG Hydrogels. In preparation. 
 
2.1 Introduction 
Since the approval of biodegradable sutures in the 1960’s, biodegradable tissue engineering materials 
made from synthetic polymers have been explored as therapies for a number of pathologies in the clinic. 
The degradability of these substances allows for the clearance of the material from the body, enabling the 
infiltrated or surrounding host tissue to restore its function after having benefitted from the implanted 
material. These biodegradable polymer systems have found usage in organ/tissue replacement, chronic 
wound healing, restoration of critically sized bone defects, and many other applications. To date, however, 
many biodegradable polymer systems which are degraded by either hydrolytic or enzymatic activity in vivo 
suffer from a number of drawbacks, including high cost of material fabrication and a mismatch between 
the rates of material degradation and new tissue formation. These material shortcomings have spurred the 
exploration of synthetic, biodegradable materials that undergo controlled degradation in response to new 
cellular growth in vivo but are economically manufactured. 
This chapter reviews currently developed biomaterial technologies and also outlines emerging next-
generation material platforms and advanced applications of these systems. The review will begin with a 
description of biomedically-relevant hydrophobic and hydrophilic synthetic polymer systems that are 
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degraded by non-specific hydrolysis or enzymatic activity. Next, the development of environmentally-
responsive polymer systems that are sensitive to ROS will be examined. Finally, tissue engineering polymer 
systems that have been used as vehicles for the local delivery of cells or therapeutic drugs will be discussed. 
As these topic areas are rapidly growing areas of research, the reader is referred to several recent reviews 
on the following subjects: hydrolytically and enzymatically degradable tissue engineering materials[34], 
PEG hydrogels[47], biomaterials for skin wound healing[48], ROS-degradable polymer systems[41, 42], 
local delivery of siRNA therapeutics[49], and stem cell delivery platforms[50]. 
 
2.2 Hydrolytically-degradable tissue engineering materials and PEUR scaffolds 
Synthetic, biocompatible polymers degraded by hydrolysis, including poly(lactic-co-glycolic acid) 
(PLGA)[51, 52], poly(ε-caprolactone) (PCL)[53, 54], polyanhydrides (PAA)[55, 56], and 
polyurethanes[57, 58], are the mostly widely explored class of biomaterials and have a history of use in 
products approved by the FDA[59-62]. These materials are applicable for a diverse range of regenerative 
applications because they offer a high degree of tunability, generate a minimal host inflammatory response, 
and degrade into non-cytotoxic components[63, 64] that are resorbed and cleared from the body[65, 66]. 
Synthetic biomaterials fabricated from polyesters are the most commonly used biodegradable constructs 
and are degraded by hydrolytic cleavage of ester bonds. Glycolide, lactide, and caprolactone, the most 
heavily investigated monomeric constituents of biodegradable polyesters, are most often used to form 
water-insoluble constructs due to the relative hydrophobicity of the monomers, though many hydrogel 
formulations also feature ester bonds and hydrolytic degradation mechanisms[67]. The degradation rate of 
polyesters can be tuned using a number of strategies, including copolymerizing monomers with different 
degradation time scales, tuning the monomer composition of copolymers, and using materials with varying 
degrees of crystallinity. For example, lactide is a chiral molecule (L-lactide and D-lactide) and polymerized 
versions of lactide monomers have very different degradation properties depending on the isomeric 
composition. Poly(L-lactide) (PLLA) is crystalline and takes more than two years for complete in vivo 
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resorption[68], while polymers comprised of a mixture of the two isomers, poly(DL-lactide) (PDLLA), is 
amorphous and can degrade within 12-16 months[69]. 
Though the design parameters of polyesters allow for the fabrication of highly tunable biomaterials 
based on a combination of monomer hydrophobicity, crystallinity, and composition, the hydrolysis of ester 
bonds is also catalyzed by the presence of acidic by-products. As polyester-based materials degrade, low 
molecular weight and soluble α-hydroxy acids diffuse from the polymer bulk into the medium resulting in 
mass loss. However, the scission of ester bonds in the polymer chain forms hydroxyl and carboxylic acid 
end groups in the polymer bulk. Residual carboxylic acids in the polymer reduce the local pH at later stages 
of degradation[70, 71], thereby catalyzing accelerated hydrolysis of the polymer[72].  Although α-hydroxy 
acids are non-toxic and can be cleared from the body[63, 73], autocatalytic degradation of the polyester 
polymer networks driven by residual carboxylic acid groups can result in a mismatch in the rates of scaffold 
degradation and new tissue growth.  
 
Injectable PEUR scaffolds  
In situ curing, injectable scaffolds such as poly(ester urethanes) (PEURs) that support cellular 
infiltration and degrade into non-toxic breakdown products represent a particularly promising class of 
biomaterials[74]. Porous PEUR scaffolds are formed by mixing hydroxyl-functionalized polyols (e.g., 900 
g mol-1 triols comprised of caprolactone, glycolide, and D,L-lactide)[63] with isocyanate-functional 
precursors to form a crosslinked network. Water can be added as a blowing agent to create an inter-
connected pore structure, and the mechanical, chemical, and degradation properties of the scaffold can be 
modified through the selection of the polyol and isocyanate precursors[75, 76]. Unlike many other 
techniques used for fabrication of porous scaffolds, this approach does not require a porogen leaching step.  
This in situ foaming method, combined with the relatively short working time of the reactive liquid 
mixture[77], renders PEURs useful as injectable and settable scaffolds suitable for minimally invasive 
procedures in the clinic. PEUR scaffolds have been utilized in a number of regenerative medicine 
applications, including as scar-reducing skin wound implants[46, 78-80] and as weight-bearing fillers for 
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critically-sized bone defects[36, 77, 81-83]. Furthermore, PEURs can be used as delivery vehicles for 
growth factors[36, 63, 77, 78, 81], antibiotics[84], nanoparticles with therapeutic nucleic acids[28, 85, 86], 
or cell-carrying hydrogel microparticles[87]. Similar to other polyester-based biomaterials, PEUR scaffolds 
are primarily degraded by hydrolysis but are also somewhat sensitive to oxidation[76]. However, due to the 
autocatalytic cleavage of ester bonds in the polymeric network structure, the in vivo degradation of these 
scaffolds does not match the growth rate of new tissue in certain applications, leading to resorption gaps 
and compromised tissue regeneration[36]. 
 
2.3 PEG-based hydrogels 
In creating biomaterials that closely mimic the natural three-dimensional extracellular matrix, synthetic 
hydrogels have emerged as promising materials in regenerative medicine applications due to their highly 
hydrated nature and robust cross-linked polymer networks[88]. Importantly, when compared to naturally 
derived materials such as collagen or gelatin, artificial matrices offer the advantages of much higher degrees 
of control over cellular adhesion molecule presentation, manufacturability, material mechanical 
properties[89]. Due to their intrinsically low protein-adsorption[90], precedent for safe in vivo usage, and 
ease of functionalization[91], PEG-based hydrogels remain the most heavily investigated matrix-
mimicking class of synthetic biomaterials. These hydrogels are most commonly formed by the covalent 
cross-linking of PEG macromers, which swell upon exposure to water due to PEG’s hydrophilic nature but 
do not dissolve due to the covalently linked polymer network. Recent work in the area has focused on in 
situ cross-linking PEG hydrogels that can be delivered in a minimally invasive manner in the clinic 
(preferably by syringe injection) while maintaining an active depot of living cells[92-94], proteins[95], or 
drugs[96]. 
Strategies for inducing in situ hydrogel formation include UV cross-linking of acrylate or ene-
terminated units in the presence of a photo-initiator[92, 95, 97], enzyme-mediated cross-linking with 
horseradish peroxidase[98-100], covalent cross-linking induced by click reactions[101, 102], or Michael-
type addition[103-105]. Of these cross-linking strategies, photo-polymerization and Michael-type addition 
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have been the most popular to date. To cross-link acrylate-terminated PEG macromers, UV light is 
employed to cleave a photoinitiator to spur free-radical polymerization of acrylate end groups[106]. The 
spatial employment of the UV light source allows for location-dependent fine-tuning of biomolecule 
incorporation[107] and mechanical properties[89] through additive or subtractive photo-patterning. 
However, UV light[108] and many photoinitators[109, 110] are inherently cytotoxic and achieving in situ 
photo cross-linking at the hydrogel’s in vivo delivery site remains difficult due to problems with non-
destructively supplying UV light to the tissue area. Conversely, Michael-type addition does not require an 
exogenous light source or free radicals to achieve polymerization, but instead uses a nucleophilic reagent 
(such as triethanolamine) to catalyze the addition reaction between a branched, end-functionalized PEG 
macromer and a bi-functional or multi-functional nucleophilic cross-linker[111]. PEG macromers end-
functionalized with acrylate and vinyl-sulfone groups have been previously investigated as components for 
Michael-addition injectable hydrogels in biomedical applications[103, 105, 112]. 
Recently, García et al. have explored the use of maleimide-functionalized PEG (PEG-MAL) macromers 
as precursors for injectable hydrogels formed by Michael-addition cross-linking[93, 94]. Maleimide groups 
have been extensively used in peptide biochemistry as they quickly and efficiently react with thiol groups 
with very high specificity at physiological pH levels[113]. When compared to more conventional Michael-
addition hydrogel systems featuring acrylate or vinyl-sulfone groups, these PEG-MAL materials possess 
superior cytocompatibility, increased cross-linking efficiency, and appropriate in situ gelation kinetics that 
make this system ideal for in vivo delivery applications[93]. Furthermore, PEG-MAL macromers 
demonstrate limited cytotoxicity and inflammation in vivo while possessing rapid renal clearance of the 
hydrogel degradation products[94]. In a therapeutic capacity, PEG-MAL hydrogels have shown promise as 
delivery vehicles for both bioactive, pro-angiogenic proteins and functional pancreatic islets[94]. In all, 
PEG-MAL hydrogels represent a highly clinically-translatable biomaterial on the cutting edge of 
minimally-invasive therapeutic delivery systems. 
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2.4 Proteolytically-degradable biomaterials 
In order to tie scaffold degradation to cellular growth, environmentally-responsive polymers have been 
heavily investigated for the development of smart materials that respond to specific biological stimuli[114]. 
In particular, biomaterials that degrade by cell-mediated mechanisms, such as materials with protease-
cleavable peptides, have been successfully utilized to synthesize environmentally-sensitive tissue 
engineering constructs such as hydrogels[115, 116] and polyurethanes[117-119]. In particular, recently 
developed PEG-MAL hydrogels[93, 94] featured a protease-cleavable peptide linker that was specifically 
tailored to degrade in response to cell-produced enzymes[120]. However, it is difficult to establish this 
approach as a generalizable tissue engineering platform because these peptide sequences are cleaved by 
specific enzymes that are upregulated in specific pathological environments[120] and feature highly 
variable levels across cellular subtypes[121] and patient populations[122]. Also, manufacturing peptides 
on the scale necessary to fabricate large tissue scaffolds is both expensive and time-consuming with current 
technology[37, 38]. Development of degradable polymers that can be affordably synthesized in large scales 
but that target a ubiquitous cell-mediated signal for scaffold degradation may provide a more generalizable 
and better-performing biomaterial. 
 
2.5 ROS-responsive materials in biomedical applications 
The number of diseases that are caused or exacerbated by oxidative stress motivates the development 
and utilization of biomaterials that can interact with ROS in either a diagnostic or therapeutic capacity. This 
section outlines the chemistry and function of the different oxidation-responsive polymers currently 
researched for therapeutic purposes. The most prevalent, biomedically-relevant, ROS-responsive polymers 
developed to date, along with their degradation products, are summarized in Figure 3. There are two primary 
classes of polymers that react to oxidative stimuli: (1) those with an oxidation-induced polymer solubility 
switch and (2) those that undergo oxidation-induced polymer degradation[41]. The polymers that undergo 
a ROS-mediated solubility switch, including poly(propylene sulfide) (PPS) and selenium-linked polymers, 
are typically formulated into hydrophobic, water-insoluble materials that can be oxidized by cell-generated 
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ROS. These polymers’ reaction with ROS adds double-bonded oxygen atoms onto the polymer chain and 
increases the polarity and thus overall hydrophilicity of the polymer. For the micro- or nano-scale particles, 
this hydrophilic transition drives disassembly of the material[123] and can be leveraged for a number of 
biomedical applications such as triggered drug release. For polymers that fully degrade in the presence of 
ROS, including oxalates, phenylboronic esters, thioketals, and oligoprolines, oxidation of the sensitive 
chemical units in the respective polymer leads to covalent chain scission and the production of low 
molecular weight degradation products[124]. Since these polymers do not rely on a phase change for their 
ROS-mediated responsivity, these units can be more easily incorporated into a wide range of hydrophilic 
or hydrophobic materials.  
 
Figure 3. Oxidation responsive polymers. 
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Utilizing oxidation-responsive polymers in drug delivery 
In the drug delivery field, significant effort over the past twenty years has been aimed at developing 
targeted delivery technologies to enhance drug potency, decrease off-target effects, and reduce overall 
treatment costs. Several currently employed drug delivery strategies utilize biodegradable, nano- and 
macro-scale biomaterials to temporally-sustain drug release[125, 126], though many of these biomaterial 
drug carriers regulate their payload discharge by simple diffusion or hydrolytic degradation and do not 
respond specifically within targeted tissue or subcellular locations. To mediate better-directed therapeutic 
delivery to disease sites, “environmental targeting” that specifically responds to biological stimuli 
characteristic of the pathological cell and tissue environment remains a promising strategy. Oxidative stress 
is tied to a number of pathologies, making ROS targeting an effective strategy for selectively delivering a 
therapeutic payload to diseased cells or tissues. To this end, many groups have employed oxidation-
responsive biomaterial drug delivery systems for the ROS-mediated release of therapeutics in both 
intracellular and extracellular environments. 
 
Polymeric systems for intracellular, oxidation-triggered drug delivery 
To date, the majority of work with oxidation-responsive polymers has been focused on the development 
of nanoparticles that can achieve intracellular drug delivery. Many potential drug targets lie in the cellular 
cytoplasm and are minimally accessible with currently utilized drug formulations due to substantial delivery 
barriers[127]. These barriers include poor drug solubility in an aqueous medium, poor cellular uptake due 
to drug size or charge, and lysosomal degradation following endocytosis. Packaging of a drug into a 
nanoparticle formulation can not only protect the drug molecule during transit to the cell, but can also help 
solubilize a poorly-circulating hydrophobic drug[128] or help facilitate cellular uptake[129]. However, to 
achieve cytosolic drug delivery after endocytic uptake, an ideal nanoparticle formulation must leverage the 
endosomal environment to escape these cellular vesicles. Previous work has utilized the acidic pH in 
endolysosomes[130, 131] to achieve endosomal escape, though this stimulus is somewhat ubiquitous across 
different cell types and does not allow for specific intracellular targeting. However, phagocytic cells[132-
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134] and cancer cells[135, 136] are known to produce high levels of ROS in their intracellular 
compartments, thus making oxidative species a targetable biological stimulus that can facilitate intracellular 
nanoparticle unpackaging and cytosolic drug delivery. Phagocytic cells, such as neutrophils, dendritic cells, 
and macrophages, produce increased ROS when immune activated, though an over-production of oxidative 
species by these cells can also contribute to a number of pathologies[137, 138]. Cancer cells, due to their 
oncogenic dysregulation and decreased expression of endogenous antioxidant genes[135], constitutively 
produce higher levels of ROS than analogous non-cancerous cells and also grow more rapidly in response 
to persistent oxidative stress[136]. Therefore, ROS-mediated targeting of phagocytic and cancerous cells 
represents a promising strategy for achieving selective intracellular drug delivery as outlined in Figure 4, 
and has been explored using a number of different oxidation-responsive biomaterial formulations as 
described in the following sections. 
 
Figure 4. Drug delivery strategy using ROS-responsive materials for intracellular drug delivery. 
 
Poly(propylene sulfide)-based nanoparticles 
Sulfur(II)-containing polymers, or polysulfides, have been the most heavily investigated oxidation-
responsive materials due to their non-toxic nature, robust response to oxidative environments, and ease of 
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synthesis[139]. Though these materials have been used in a number of applications over many years, the 
oxidative-responsiveness of poly(alkylene sulfides) was not reported until 2004 with the pioneering work 
by Tirelli, Hubbell, et al. exploring ROS-responsive polymersomes. These nanoparticles, formed from a 
poly(ethylene glycol)-block-poly(propylene sulfide)-block-poly(ethylene glycol) (PEG-PPS-PEG) triblock 
polymer, quickly unpackaged in oxidative conditions and thus became the foundational work for research 
into ROS-responsive polymers[123]. This ROS-responsiveness is caused by the oxidation of the sulfurs in 
the polymer backbone which increases the hydrophilicity of the bulk polymer and causes a phase change 
in the PPS as it becomes more water-soluble. Recently, this oxidation of PPS was studied in more detail 
with respect to different ROS commonly found in vivo, exploring oxidation kinetics of PPS incubated with 
hydrogen peroxide (H2O2) and hypochlorite (ClO-). The less reactive H2O2 converted the PPS into 
poly(propylene sulfoxide) without significant generation of sulfones, while ClO- treatment caused the rapid 
formation of sulfones and sulfoxides and spurred dramatic PPS depolymerization. Interestingly, fibroblasts 
treated with the H2O2-generated sulfoxides did not experience significant cytotoxicity while ClO--generated 
sulfones were notably cytotoxic[140, 141]. With respect to other commonly encountered oxidative species, 
PPS is also sensitive to peroxynitrite[142-144] but does not respond to superoxide[145]. In addition to its 
inherent sensitivity to oxidation, PPS is also a particularly advantageous polymer for use in the formation 
of self-assembled nanoparticles[142, 146]. PPS is more hydrophobic than its oxygen analogue 
poly(propylene oxide) (PPO), and PEG-PPS polymers have been shown to form more stable self-assembled 
nanostructures than commonly used PEG-PPO-PEG Pluronic micelles[146]. Due to its stable nanoparticle 
formation and sensitivity to a number of different ROS, PPS has thus been used in a host of different 
biomedical applications for intracellular drug delivery. 
 
Small molecule delivery from PPS nanoparticles 
Micellar nanoparticles formed from amphiphilic polymer systems have been recently explored for the 
delivery of small molecule hydrophobic drugs[128]. Under aqueous conditions, the hydrophobic portion of 
the polymer forms the core of the nanoparticle and can sequester hydrophobic molecules, while the 
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hydrophilic polymer segment forms the nanoparticle corona and stabilizes the interface between the 
hydrophobic core and the aqueous medium. This strategy was first employed with PPS-based nanoparticles 
for the encapsulation the immunosuppressive drug cyclosporine A. Using PEG-PPS diblock copolymers 
that readily self-assemble into nanoparticles, up to 19% w/w drug loading was achieved and sustained over 
19 days in an aqueous medium, though the ROS-responsiveness was not directly explored in this 
study[147]. Similar PEG-PPS micelles have also been loaded with an anti-inflammatory drug (mometasone 
furoate) or immunosuppressive drugs (rapamycin and tacrolimus) for delivery to draining lymph 
nodes[148]. Though these previous data demonstrate the effectiveness of solubilizing small hydrophobic 
drugs into PPS-based nanoparticles, they did not specifically study the ROS-responsive nature of PPS for 
environmental targeting with these drug delivery systems.  
However, work by the Tirelli group demonstrated the potential for PPS-based nanoparticles to mediate 
small molecule drug delivery in response to oxidation. PEG-PPS micelles were conjugated to superoxide 
dismutase (SOD), a naturally occurring enzyme that converts highly reactive superoxides to more stable 
H2O2. In the body, SOD is paired with the enzyme catalase, a scavenger of H2O2, but the synthetic system 
described here utilizes the conjugated SOD and the H2O2-absorbing nature of PPS to mimic this paired 
functionality. Therefore, this system acts as an ROS scavenger for both superoxide and H2O2 while also 
leveraging the selective absorption of H2O2 to mediate on demand release of a model small molecule 
hydrophobic drug from the nanoparticles’ PPS core[145]. Work by Gupta et al. also conclusively 
demonstrated the potential of oxidative responsiveness of PPS-based nanoparticles in the context of 
intracellular small molecule delivery.  In their study, PPS was extended with a hydrophilic block made via 
the reversible addition chain transfer (RAFT) polymerization method.  This approach yielded self-
assembling (N,N-dimethylacrylamide)-block-PPS (DMA-PPS) nanoparticles that selectively released their 
drug cargo in an H2O2 dose-dependent manner and also disassembled after incubation with H2O2 as 
confirmed by dynamic light scattering and transmission electron microscopy. Finally, in a Förster resonance 
energy transfer (FRET)-based study, the DMA-PPS micelles loaded with model small molecule 
hydrophobic drugs were shown to selectively release their drug cargo after being engulfed by activated, 
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ROS-producing macrophages[142]. These data collectively indicate the therapeutic potential for PPS-based 
intracellular delivery of poorly soluble drug molecules to cells that produce high levels of ROS. 
 
PPS nanoparticles as immunotherapy vehicles 
As detailed in the previous section, a diblock copolymer architecture has been primarily utilized for 
small molecule delivery from PPS-based nanoparticles. PPS nanoparticles have also been synthesized by 
an anionic emulsion ring-opening polymerization where the propylene sulfide monomer was polymerized 
into PPS while emulsified in an aqueous environment by Pluronic F-127. After PPS polymerization, these 
particles were also exposed to air to spur the formation of oxidized disulfide bridges between free thiol 
groups in the polymer bulk to confer additional stability. This synthesis strategy allows for the creation of 
PEG-stabilized, ROS-responsive PPS nanoparticles that are easily tuned for both size and surface 
functionalization[149]. Subsequently, Reddy et al. found that 20nm PEG-stabilized PPS nanoparticles were 
effectively taken up by dendritic cells in the lymph nodes but that analogous 100nm particles were not 
retained[150]. Further work using these particles as a vaccine delivery system indicated that PPS 
nanoparticles decorated with surface hydroxyl groups acted as an adjuvant by targeting dendritic cells in 
mice and priming their complement activation. Moreover, these PPS nanoparticles were conjugated to the 
model antigen ovalbumin and generated humoral and cellular immunity to the antigen after delivery[151]. 
For the delivery of a small molecule adjuvant in conjunction with a protein antigen, a polymersome-forming 
PEG-PPS diblock polymer was utilized and loaded with the antigen ovalbumin and the small molecule 
gardiquimod or R848. Ovalbumin release was oxidation mediated and promoted antigen presentation, while 
the small molecule adjuvants promoted dendritic cell activation[152]. This work demonstrates another 
ROS-mediated biomaterial strategy for immunotherapies derived from PPS-based materials. 
 
Selenium-linked polymer systems for drug delivery 
As another member of the oxygen family (group 16 on the periodic table), selenium shares many 
common attributes with sulfur, including its responsiveness to oxidation. Since the electronegativity of 
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selenium is lower than that of sulfur, the corresponding bond energy of the C-Se bond is also lower than 
that of C-S (C-S 272 kJ mol-1; C-Se 244 kJ mol-1) thus making the C-Se bond more susceptible to 
oxidation[153]. This higher sensitivity to oxidation has spurred recent investigation into selenium 
containing biomaterials for their potential application in intracellular drug delivery, and much like sulfur-
containing polymers, selenium-doped materials undergo a hydrophobic-to-hydrophilic phase change (i.e. 
minimal covalent bond cleavage) upon oxidation. A number of selenium-containing polymer systems have 
thus been developed to facilitate ROS-mediated intracellular delivery. Using a step-growth polymerization 
scheme, a triblock ABA polymer featuring flanking hydrophilic PEG “A” blocks surrounding a central 
hydrophobic “B” block containing selenium was synthesized and self-assembled into micellar nanoparticles 
in aqueous conditions. As expected, these particles were more sensitive to oxidative conditions than 
analogous nanoparticles formed with sulfur and more quickly released their encapsulated drug 
payload[154].  
Selenium-based, self-assembling micellar nanoparticles have also been formulated using charge 
interactions with a selenium-containing surfactant. A PEG-poly(acrylic acid) (PEG-PAA) diblock polymer 
dissolved in a basic aqueous solution (in which the PAA would be predominantly deprotonated and anionic) 
was added to a positively charged selenium-containing surfactant solution, driving self-assembly of the 
polymer into micelles that disassembled under oxidative conditions[155].  A selenium-containing precursor 
can also be grafted onto PEG-PAA as a side-chain modification by conjugating to PAA’s carboxylic acid, 
yielding nanoparticles that disassemble in an ROS-containing medium after oxidation of the selenium. 
Additionally, these particles could also spontaneously re-assemble with the addition of a reducing 
agent[156]. The Yan group has also reported the synthesis of a selenium-containing, hyperbranched 
amphiphilic polymer that can selectively release loaded doxorubicin under oxidative conditions[157]. 
Interestingly, the selenium-containing nanoparticles alone displayed inherent anticancer activity as they 
were selectively toxic to ROS-generating cancer cells without any drug loading, potentially due to cancer-
specific selenium activation of the apoptosis-mediating enzyme caspase-3[158]. For delivering the 
chemotherapeutic doxorubicin, nanoparticles synthesized with ROS-sensitive selenium were also an order 
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of magnitude more effective at promoting cancer cell apoptosis compared to an oxidation-inert control 
polymer. These data indicate that these hyperbranched selenium-containing nanoparticles can play two 
roles in the treatment of cancer, both as an ROS-targeting drug carrier for efficient intracellular delivery 
and to provide inherent anticancer effects[157].  
 
Polyoxalate-based nanoparticles for drug delivery and theranostic applications 
Polyoxalate polymers are particularly intriguing ROS-responsive biomaterials due to their dual 
functionalities, both degrading in oxidative environments and also producing chemiluminescence upon 
interacting with peroxides in the presence of a fluorophore[159]. As oxalates are oxidized by H2O2, the high 
energy intermediate 1,2-dioxetanedione is produced and can complex with and activate an appropriate 
fluorophore; the decomposition of this complex produces light from the fluorophore’s decaying energy 
state, along with a carbon dioxide (CO2) byproduct[160]. Since oxalate oxidation is very specifically 
mediated by H2O2, oxalate-based probes are attractive for in vitro or in vivo detection of this particular cell-
generated ROS. Work by the Murthy group first incorporated polyoxalates into a nanoparticle for in vivo 
imaging of H2O2, exhibiting this polymer’s high selectivity for H2O2 over other ROS and imaging 
inflammation-generated H2O2 in the peritoneal cavity of mice[161]. Subsequent to this demonstration, a 
number of groups have utilized polyoxalates for both diagnostic and therapeutic research. Combining these 
two aims into a theranostic system, nanoparticles formulated in an emulsion process from Pluronic, 
hydroxy-benzyl alcohol-incorporated copolyoxalate (HPOX), and fluorescent dyes were used to image 
H2O2 in an inflamed mouse ankle, reduce H2O2 in activated macrophages following phagocytosis, and also 
promote cytosolic delivery of nanoparticle-encapsulated drugs. The reduction in intracellular ROS is 
thought to result from both the H2O2-mediated oxidation of the oxalate bond and the release of the 
antioxidant hydroxybenzyl alcohol upon oxalate degradation, making these particles a potent agent for both 
intravital imaging and antioxidant therapies[162]. Besides their intrinsic antioxidant and bio-imaging 
capabilities, HPOX nanoparticles were also amenable to drug delivery. They have been loaded with the 
anti-apoptotic agent 4-amino-1,8-napthalimide (4-AN) and shown to selectively release this payload to sites 
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of elevated H2O2 resulting from ischemia/reperfusion injury[163]. HPOX nanoparticles were also utilized 
for the delivery of the antioxidant/anti-inflammatory vanillyl alcohol (a derivative of the natural product 
vanillin) for the treatment of ischemia/reperfusion injury, reducing ROS levels and exerting potent anti-
apoptotic activity[164]. Vanillin itself can also be polymerized directly into the polyoxalate chain to achieve 
H2O2 and acid-triggered release to inhibit oxidative and inflammatory activity in cells[165].  
 
Phenylboronic ester-based polymer systems for drug delivery 
Phenylboronic esters (PBEs), which are cleaved through reaction with ROS, remain one of the most 
heavily investigated ROS-responsive chemistries in biomaterials research[42]. These chemical units 
selectively interact with H2O2 and generate boronic acid and phenol derivatives upon oxidation[166]. This 
H2O2-selective reaction does not proceed with other ROS such as superoxide, hypochlorous acid, hydroxyl 
radicals, etc., making PBEs particularly advantageous in applications as intravital, small molecule H2O2 
imaging agents[167]. For example, PBE chemistry was employed to confer H2O2 imaging specificity to an 
activatable cell-penetrating peptide (ACPP) by covalently coupling fluorescently-tagged polycationic and 
polyanionic CPPs through a PBE linker[168]. The two respective fluorophores conjugated to the polycation 
and polyanion CPPs are a FRET pair, causing FRET when covalently linked by the PBE but only displaying 
donor fluorophore emission upon H2O2-mediated PBE cleavage. The cationic CPP is also released upon 
PBE oxidation and can penetrate nearby cells, thus making this a useful platform for both H2O2 imaging 
and selective drug payload delivery to environments with elevated H2O2[168]. Phenylboronic esters have 
also been used to transform small molecule and protein drugs into pro-drugs by making them selectively 
activatable at sites of elevated ROS. PBEs conjugated to a matrix metalloproteinase (MMP) inhibitor show 
promise as a drug that is selectively activated at sites of ischemia and reperfusion injury during stroke[169], 
and PBE modification of an anti-cancer protein therapeutic leads to specific drug toxicity in ROS-producing 
cancer cells[170]. 
PBEs have also recently been utilized to confer ROS-responsiveness to polymeric nanoparticles. The 
Fréchet group was one of the first to create PBE-based, ROS-responsive nanoparticles by modifying the 
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naturally derived, water-soluble polymer dextran with pendant boronic esters and fabricating them into 
particles by oil-in-water emulsion[171]. The PBE-modified dextran was hydrophobic but became water 
soluble through H2O2-mediated cleavage of the PBE groups, causing particle dissolution and drug payload 
release. Similar to results seen with PPS-based nanoparticles[151], PBE-dextran ROS-responsive 
nanoparticles more effectively delivered encapsulated antigens to the cytosol of dendritic cells as compared 
to PLGA particles by targeting these cells’ highly oxidative phagosomes[171]. This unique chemistry was 
also exploited by incorporating PBE units directly into the backbone of a nanoparticle-forming polymer. 
The Almutairi group copolymerized adipoyl chloride either directly with a boronic ester or with a 
benzyloxy-spaced boronic ester to yield two polymers with backbones that were degradable by cell-
generated ROS[172]. Nanoparticles formed from the polymer with the benzyloxy spacer were more 
susceptible to H2O2-mediated chain scission, displaying H2O2 dose-dependent release of an encapsulated 
drug payload at H2O2 concentrations as low as 50μM[172]. These PBE-based nanoparticles have also been 
shown to release gadolinium oxide (a magnetic resonance imaging (MRI) contrast agent) in an H2O2 dose-
dependent manner, potentially making these ROS-responsive particles applicable as in vivo imaging agents 
for locating sites of inflammation with non-invasive MRI[173]. Recent work has also incorporated PBE 
units into β-cyclodextrin (β-CD) nanoparticles for the selective targeting of cancer cells, combining the 
proven in vivo safety and drug-loading capabilities of β-CD with the ROS-responsiveness of phenylboronic 
esters[174]. These nanoparticles decreased intracellular ROS levels in macrophages, promoted higher 
levels of apoptosis in cancer cells when loaded with docetaxel compared to the free drug, and more 
effectively inhibited tumor growth than the free drug after intravenous administration[174].  
PBEs can also be combined with other degradable polymer chemistries to create dual-responsive 
systems. Song et al. synthesized a micelle-forming diblock copolymer with an outer hydrophilic PEG block 
and a hydrophobic inner block comprised of ROS-sensitive phenylboronic esters and acid-sensitive ortho-
esters[175]. As the PBE groups were cleaved off by H2O2, carboxylic acid groups were uncovered and 
catalytically increased the degradation of the ortho-ester groups. By tuning the relative composition 
between boronic and ortho-esters, a family of micellar nanoparticles with a range of dual-responsive 
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properties were synthesized and could be used for intracellular drug delivery applications[175]. In closely 
related work, Song et al. also developed a polymer system that could capture the potentially toxic 
degradation products resulting from boronic ester degradation[176]. Quinone methides, highly reactive 
products generated by the oxidation of phenylboronic ester-containing compounds, can potentially react 
with biomolecules in vivo and cause undesirable side effects. To collect these reactive degradation products, 
an amphiphilic polymer containing ROS-degradable PBE units and primary or secondary amino groups 
was synthesized; with this composition, the toxicity of the PBE was reduced by the amines which 
effectively scavenged the quinone methide byproducts[176].  
 
Thioketal nanoparticles in drug delivery 
Poly(thioketals) (PTKs) are another class of fully oxidation-cleavable polymers that were first 
synthesized by the Murthy group for utilization in an ROS-degradable nanoparticle system[45]. PTK 
polymers are synthesized by a relatively simple condensation polymerization from low molecular weight 
dithiol precursors, yielding hydrophobic polymers that are amenable to the formation of solid polymeric 
particles via oil-in-water emulsion[45].  Furthermore, PTK polymers are very specifically degraded by ROS 
into their original dithiol precursors and acetone (thioketal degradation susceptibility: hydroxyl radical > 
hydrogen peroxide > superoxide[177, 178]) but are impervious to hydrolysis under all pH conditions. PTK 
robustness at extreme pH levels (i.e. pH > 13, pH < 1) was initially leveraged to create an orally- 
administered, small interfering RNA (siRNA) drug delivery system that could traverse the enzymatic and 
acidic conditions in the stomach to selectively deliver the drug payload to inflamed, ROS-producing sites 
in the intestines[45]. The siRNA loaded into the PTK nanoparticles targeted the pro-inflammatory cytokine 
tumor necrosis factor-alpha (TNF-α), primarily produced by activated phagocytes, which plays an essential 
role in the onset and persistence of intestinal inflammation[179]. The ROS-specific degradation of these 
nanoparticles effectively targeted these phagocytes as they generate large quantities of both intracellular 
and extracellular ROS[134, 137]. Therefore, PTK-based nanoparticles synthesized using an emulsion 
process are not only able to protect drug cargo from the harsh environment of the stomach, but also can 
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utilize their oxidation-specific degradation to target high levels of ROS at a tissue or cellular level. Further 
utilizing PTK polymers for the targeting of ROS-producing phagocytic macrophages, Pu et al. incorporated 
PTK polymers into a chitosan-based nanoparticle system for the intracellular delivery of the antioxidant 
drug curcumin[124]. The hydrophobic PTK polymer helps to stabilize the hydrophobic nanoparticle core 
while also conferring ROS-responsiveness for drug release, while the chitosan forms a hydrophilic particle 
corona that is pH-responsive. These particles showed relatively moderate sensitivity to both pH and ROS 
individually, but the presence of both stimuli synergistically triggered release of the encapsulated drug. 
This effect was also translated into in vivo efficacy as curcumin-loaded PTK nanoparticles decreased local 
ROS levels and prevented tissue damage in an inflammation model[124]. This work again demonstrates 
PTK polymers’ ability to target ROS-producing phagocytic cells for drug delivery applications, while also 
displaying the propensity for integration into multi-functional nanoscale technologies.  
Besides targeting phagocytic cells, PTK-based nanoparticle systems have also been utilized to 
specifically deliver drugs to cancer cells. High levels of intracellular ROS production are a hallmark of 
many cancers, and heightened ROS production has also been tied to the aggressiveness of certain prostate 
tumor cells [136]. Therefore, these PTK-based polymer systems utilize elevated intracellular ROS levels to 
enhance cytosolic drug delivery as the nanoparticles will degrade and release their drug payload upon 
cellular internalization. For the delivery of a hydrophobic small molecule chemotherapeutic, water-
insoluble Paclitaxel was loaded into hydrophobic PTK polymers by oil-in-water emulsion and administered 
to prostate cancer cells[178]. Non-loaded particles caused minimal cytotoxicity, while drug-loaded particles 
caused dose-dependent cell death at much lower Paclitaxel doses than previously reported in similar, 
oxidation-inert nanoparticle delivery systems. To deliver plasmid DNA to cancer cells, Shim and Xia 
utilized a novel strategy for incorporating thioketal units into a nanoparticle construct by synthesizing a low 
molecular weight diacrylate thioketal crosslinker and then polymerizing it with a positively-charged 
oligoamine to create a poly(amino thioketal) (PATK)[177]. These polymers were water soluble (unlike 
previous PTK polymers), efficiently condensed plasmid DNA, and promoted ROS-induced intracellular 
drug unpackaging for higher plasmid transfection. This work demonstrates both the potential utility for 
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synthesis of water soluble PTK-based polymers while reinforcing the concept of ROS-mediated drug 
targeting of cancer cells by PTK nanoparticles. 
 
Oxidation-responsive polymeric systems for locally targeted, extracellular drug delivery 
The majority of the work with oxidation-responsive polymer systems has leveraged cell-generated ROS 
as an intracellular drug release mechanism. Nanoparticle systems are particularly amenable to this type of 
drug delivery application as their small size allows for both systemic delivery through intravenous injection 
and access to the intracellular space through size-based cellular uptake mechanisms[126]. However, size-
based diffusion of nanoparticles also decreases their in vivo retention as they more readily diffuse away 
from their site of administration within a few hours[143]. Therefore, larger sized particles or bulk scaffolds 
and hydrogels that are ROS-degradable remain particularly advantageous for locally sustained drug 
delivery and tissue engineering applications. Though many ROS have intracellular origins[132], high levels 
of extracellular ROS are common in many pathologies[134, 180] and thus can be leveraged to achieve drug 
delivery from micro- or macro-scale therapeutic delivery systems. This local, extra-cellular drug delivery 
strategy is outlined in Figure 5.  
 
Figure 5. Localized, extra-cellular drug delivery schematic. 
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Poly(propylene sulfide) microparticles for local drug delivery 
Because it was one of the first polymers developed as an oxidation-responsive biomaterial[123], PPS 
has been tested in several nanoparticle applications as outlined above. The Duvall group was the first to 
apply PPS in a microparticle format, using this polymer to develop a localized ROS-responsive sustained 
release platform for the delivery of the hydrophobic drug curcumin[144]. Curcumin is a naturally-derived 
antioxidant and anti-inflammatory agent that has shown promise in the treatment of ischemia/reperfusion 
injury[181], though the extreme hydrophobicity of the molecule limits its in vivo bioavailability and thus 
its clinical usage[182]. These particles were fabricated from an oil-in-water emulsion method using 
conditions that yielded particles on the micron-scale and were developed as an “on demand” delivery 
system for curcumin; the concept is that the level of environmental ROS present would modulate the rate 
of release of the antioxidant/anti-inflammatory curcumin molecule.  To this end, in vitro curcumin release 
was shown to be dose-dependent in relation to ROS concentrations. Though this microparticle system was 
designed to achieve local retention for sustained extracellular curcumin release, particles between 1-2 μm 
are selectively taken up by activated phagocytic cells[183, 184] thus allowing for a combination of 
extracellular release and selective uptake (due to physical size) of the drug-loaded microparticles by the 
cells which are the primary producers of ROS. PPS is a known scavenger of H2O2[145], and this work also 
highlighted the therapeutic benefit of using PPS for the particle substrate.  Even without drug loading, there 
was a therapeutic benefit of the “blank” PPS particles in that their presence protected fibroblasts from the 
cytotoxic effects of exogenous H2O2 (and the protective effect of the PPS particles was further enhanced 
by loading with curcumin). These results were confirmed in mice as ischemic limbs treated with PPS and 
curcumin-PPS microparticles experienced decreased levels of ROS, while curcumin was also released at a 
faster rate in the highly oxidative ischemic limbs when compared to non-ischemic controls[144]. This work 
demonstrates the ability of PPS microparticles to incorporate hydrophobic drugs and selectively release 
them upon ROS stimulation, while also highlighting the potential therapeutic benefit of these materials as 
ROS-scavengers both in vitro and in vivo. 
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Poly(propylene sulfide)-based hydrogels for local drug delivery 
Previous work has demonstrated the highly stable nature of micelles synthesized with a PPS core, as 
the polymer’s extremely hydrophobic nature drives robust self-assembly in aqueous media[142, 146]. This 
chemistry was extended by Gupta et al. using a unique combination of anionic and RAFT polymerization 
to create an ABC triblock copolymer of PPS-block-(N,N-dimethylacrylamide)-block-(N-
isopropylacrylamide) (PPS-b-PDMA-b-PNIPAAM)[143]. This polymer self-assembles into micellar 
nanoparticles in aqueous conditions (driven by the hydrophobic PPS “A” block) but forms a supramolecular 
hydrogel when heated to physiologic temperatures (driven by the thermo-responsive solubility transition of 
the PNIPAAM “C” block). The hydrophilic PDMA “B” block helps to maintain the hydration of the formed 
gels. These materials were synthesized as a ROS-degradable hydrogel that could use oxidative conditions 
to facilitate on demand drug release and material biodegradation. The hydrophobic PPS domains in the 
nanoparticles were pre-loaded with a model hydrophobic small molecule drug, and after thermo-gelation 
released the drug payload from the bulk hydrogels in an ROS-concentration dependent manner. These drug-
loaded hydrogels also demonstrated in vivo drug release as subcutaneously injected hydrogels gradually 
released their drug payload over 14 days, validating that in vivo ROS concentrations are sufficient to 
promote localized drug delivery from these materials[143]. 
 
Utilizing oxidation-responsive polymers in biodegradable tissue engineering scaffolds 
Biodegradable scaffolds made from synthetic polymers have been extensively investigated for use in 
tissue engineering and regenerative medicine. These materials, including PLGA, PCL, and polyurethanes, 
are applicable for a diverse range of regenerative applications because they offer a high degree of tunability, 
generate a minimal host inflammatory response, and degrade into non-cytotoxic components[63, 64] that 
are resorbed and cleared from the body[65, 66]. However, the biodegradation of these materials, primarily 
mediated by hydrolysis of ester bonds in the polymer backbone, produces acidic byproducts which can 
catalyze accelerated polymer hydrolysis[72] and result in a mismatch in the rates of scaffold degradation 
and tissue in-growth that leads to resorption gaps and compromised tissue regeneration[36]. Therefore, 
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many recent efforts in tissue engineering have focused on the development a more generalizable and better-
performing biomaterial created from degradable polymers that can be affordably synthesized in large scales, 
similar to polyesters, but that target a ubiquitous cell-mediated signal for scaffold degradation. Scaffolds 
degraded by cell-generated ROS are a promising candidate because ROS serve as important biological 
mediators in many normal biological processes[39], and elevated ROS is a hallmark of inflammation and 
the pathogenesis of myriad diseases[40]. Importantly, polymeric biomaterial implants have also been shown 
to elicit a stable three-fold increase in ROS production at surgery sites over a four-week timeframe[44], 
further highlighting the potential utility of this cell-generated signal as a trigger for material degradation. 
This strategy is highlighted in Figure 6. 
 
Figure 6. ROS-degradable tissue engineering scaffolds. (A) Schematic for the cell-mediated degradation of 
oxidation-sensitive scaffolds, which maintain (B) an intact structure before (C) being degraded by ROS. 
 
Oligoproline peptide-crosslinked scaffolds 
The incorporation of cell-degradable peptides into tissue engineering scaffolds has been heavily 
investigated as a strategy to confer specific protease biodegradability to different classes of 
biomaterials[115-118]. Interestingly, many specific amino acids are also susceptible to oxidative 
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degradation[185], and ROS-induced peptide cleavage has been effectively utilized for oxidation-targeted 
nanoparticle delivery of plasmid DNA[186]. These findings motivated the creation of bulk-scale 
biomaterials crosslinked with oxidation sensitive peptides, a material design strategy first employed by the 
Sung group by incorporating proline oligomers into a salt-leached, porous, PCL-based tissue engineering 
scaffold[187]. The oligoproline crosslinked materials underwent significant degradation over 28 days when 
incubated in oxidative conditions, as compared to scaffolds crosslinked with a non-degradable crosslinker 
which remained relatively inert due to the high content of slowly-degrading PCL. Furthermore, when 
incubated with activated, ROS-producing macrophages, the proline-linked scaffolds developed extensive 
surface pitting indicative of cell-mediated material degradation[187]. This proof of concept work 
demonstrated the potential utility of these scaffolds as ROS-degradable tissue engineering constructs, and 
was further expanded to in vivo experimentation by subcutaneously implanting oligoproline-crosslinked 
PCL scaffolds into mice[188]. These scaffolds encouraged a more robust cellular infiltration and increased 
blood vessel formation compared to PCL or non-degradable crosslinked PCL scaffolds, potentially due to 
the degradation of the oligoproline crosslinks through ROS associated with the early inflammatory response 
following scaffold implantation. Thus, the incorporation of oxidation-sensitive oligoprolines into ester-
based biomaterials may be a means to enhance performance of conventional degradable biomaterials.  
 
Injectable poly(thioketal-urethane) scaffolds 
In situ curing, injectable tissue engineering scaffolds such as poly(ester urethanes) (PEURs) represent 
a promising class of biomaterials due to their minimally-invasive delivery mechanism, support of cellular 
infiltration, non-toxic degradation products, and ability to completely fill irregularly-sized tissue defects[74, 
77]. PEUR scaffolds are formed by mixing hydroxyl-functionalized polyols (e.g., 900 g mol-1 triols 
comprised of caprolactone, glycolide, and D,L-lactide) with isocyanate-functional precursors to form a 
crosslinked network. Once implanted in vivo, however, PEUR implants, like all polyester-based materials, 
are sensitive to acid-catalyzed hydrolysis; this autocatalytic degradation mechanism can limit the 
effectiveness of polyesters in slowly healing injury sites as the scaffold can undergo sudden, late-stage 
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failure or pore-collapse prior to being fully infiltrated with new tissue[36]. To overcome this limitation, the 
Duvall group replaced the ester-based polyol with novel, ROS-degradable, hydroxyl-terminated 
poly(thioketal) (PTK) polymers and incorporated them into injectable, porous PTK-urethane (PTK-UR) 
scaffolds[30].  PTK-UR scaffolds were selectively degraded by ROS but were stable under aqueous 
conditions over 25 weeks, indicating their exclusively cell-mediated biodegradation as opposed to PEURs 
and other polyester-containing materials that hydrolytically degrade independent of cellular activity. 
Moreover, the in vitro oxidative degradation rates of the PTK-URs followed first-order degradation kinetics 
and displayed dose-dependent degradation with respect to ROS concentration. The PTK-UR scaffolds also 
supported robust cell infiltration and granulation tissue formation in vivo, and were proven to undergo 
controlled, first-order kinetics of biodegradation in vivo. This was in contrast to PEUR scaffolds which 
experienced accelerated rates of in vivo degradation over time, as predicted by the autocatalytic degradation 
mechanism[30]. These collective results indicate that PTK polymers are particularly amenable to tissue 
engineering scaffold formation due to their selective ROS-mediated degradation, excellent in vivo 
cytocompatibility, and first-order degradation rates. PTK-UR scaffolds have also been recently utilized as 
drug delivery vehicles in diabetic wound healing[46] and as the binder component in bone cements[189]. 
 
Thermoresponsive poly(propylene sulfide)-based hydrogels 
As previously highlighted, thermoresponsive hydrogels formed from ABC triblock polymer micelles 
(PPS-b-PDMA-b-PNIPAAM) show tremendous promise as injectable drug depots for long-term, ROS-
mediated delivery of hydrophobic small molecule drugs[143]. These materials also show great promise in 
regenerative medicine applications as ROS-degradable, injectable hydrogels that are inherently anti-
oxidative and amenable to cell delivery. When the hydrogel is exposed to ROS, the PPS core transitions to 
the more hydrophilic poly(propylene sulfoxide) and finally to poly(propylene sulphone) which triggers 
disassembly of the nanoparticles[123] and degradation of the macro-scale hydrogel. These PPS-based 
hydrogels undergo ROS-mediated degradation as demonstrated by a loss in mechanical integrity after 
incubation with H2O2 and decreasing mechanical properties after incubation with SIN-1 (a peroxynitrite 
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generator[190]). Similar to results seen with PPS microparticles[144], these PPS hydrogels also protected 
fibroblasts from cytotoxic levels of H2O2 and were able to encapsulate and deliver viable fibroblasts in in 
vitro proof of concept testing. Therefore, ROS-degradable PPS hydrogels with “ROS sponge” activity have 
broad potential use in regenerative medicine applications as tissue scaffolds, drug delivery depots, and 
vehicles for cell delivery. 
In summation, oxidation-responsive polymer systems possess a number of benefits for the treatment 
and diagnosis of pathologies characterized by high levels of ROS. Utilizing elevated concentrations of ROS 
to promote intracellular and extracellular drug delivery has shown promise in the treatment of many disease 
states, and the use of ROS-degradable tissue engineering scaffolds represent a new paradigm for the 
fabrication of cell-degradable materials for regenerative medicine applications. Future work is needed to 
properly characterize the in vivo degradation kinetics of these materials, and to explore the toxicity and 
clearance of these materials’ degradation byproducts before full clinical translation is feasible. However, 
the assortment of currently employed ROS-responsive polymers and their varying performance 
characteristics presents a promising platform for new exploration and development of advanced therapies 
for a variety of diseases. 
 
2.6 Biomaterials for local delivery of therapeutics to skin wounds 
Since chronic skin wounds are a highly localized pathology, the systemic administration of pro-healing 
therapeutics can be avoided to minimize off-target effects and maximize the therapeutic concentration 
directly at the wound site. Though local therapeutic delivery also suffers from many challenges[191], a 
biomaterial implanted into a skin wound has direct contact with the target tissue and can potentially mediate 
a more powerful healing response. Chronic wounds have an especially high risk of bacterial infections[192], 
and hydrophobic tissue engineering scaffolds and hydrogels loaded with antibiotics have been used to 
increase local healing[84, 193]. Small hydrophobic drugs have also been locally delivered from 
hydrophobic scaffolds to improve blood vessel formation[194] or increase cell proliferation[195] in skin 
wounds. Though most commonly used hydrogel formulations are not well suited for the sustained delivery 
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of small hydrophobic molecules due to these materials’ hydrophilic nature and large diffusional capacity, 
some strategies have recently emerged for local delivery of small molecules from hydrogels. Recently 
developed hydrogels that feature hydrophobic nanodomains within the gel structure can mediate sustained 
in vivo delivery of hydrophobic drugs[21, 143], while hydrogels that solidify with cyclodextrin-adamantane 
guest/host reactions can sequester small molecules based on drug affinity to the cyclodextrin moieties and 
slowly release them over time[196].  
The local delivery of growth factors from wound-implanted biomaterials has arguably been the most 
highly researched strategy for mediating the regeneration of chronic, non-healing wounds. Epidermal 
growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), have all been extensively investigated for their role in wound repair and 
remain intriguing therapeutic agents to improve wound healing[78, 197-199]. However, the clinical efficacy 
of growth factor delivery remains limited; delivery of PDGF from a hydrogel dressing had minimal 
effectiveness in hypertensive leg ulcers in phase III studies [200], while topical administration of VEGF to 
diabetic foot ulcers had a nonsignificant increase in the healing rate of diabetic ulcers in phase I trials[201]. 
The relatively poor performance of local growth factor delivery for regenerating non-healing wounds can 
potentially be attributed to abundant levels of growth factor-degrading proteases in chronic wounds[202] 
or the over-simplified approach of delivering a single factor to stimulate complex biological healing 
processes[198]. As such, more work is needed to implement this therapeutic delivery strategy in the clinic. 
To promote more advanced healing processes through local therapeutic delivery, many groups have 
recently begun exploring the deployment of nucleic acids (namely plasmid DNA or siRNA) to promote 
wound healing. Plasmid DNA delivery, though less efficient than viral gene transfer, is a promising strategy 
for expressing a therapeutic gene for wound healing applications. Sustained delivery of plasmid DNA from 
implanted scaffolds has been used to increase the local gene expression of PDGF[203], SDF-1[204], or 
KGF[205], with scaffold-mediated plasmid delivery demonstrating better efficacy than direct topical 
delivery of the DNA[206]. The local delivery of siRNA has the potential to selectively silence the 
expression of target genes in order to reduce the expression of deleterious proteins or to block the expression 
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of regeneration-inhibiting protein antagonists. Scaffold-mediated gene silencing through in vivo siRNA 
delivery to improve wound healing has been explored for matrix metalloproteinase-9 (MMP-9)[207], 
connective tissue growth factor (CTGF)[208], p53[209], and PHD2[27-29, 46]. Currently there is one 
ongoing clinical trial utilizing local siRNA delivery to enhance wound healing by decreasing scar formation 
after surgery. RXi-109 (RXi Pharmaceuticals, Marlborough, MA) delivers siRNA against CTGF from a 
collagen/silicone membrane and has been shown to decrease the formation of hypertrophic dermal scars 
and keloids in initial results from phase 2a trials[210], highlighting the potential utility of siRNA in wound 
healing applications. Despite the promising early results, implementation of local nucleic acid delivery in 
wounds is hampered by substantial delivery barriers, including degradation by endogenous nucleases, 
inability to access the cytoplasm, and insufficiently sustained bioactivity in the target tissue[211, 212]. 
However, the potential of nucleic acid therapeutics justifies their continued exploration and refinement for 
the development of next-generation chronic wound therapies. 
Finally, the delivery of regenerative mesenchymal stem cells (MSCs) has also been heavily explored 
as a strategy for improving the healing of chronic wounds. Biomaterial-mediated delivery of single (or even 
several) therapeutic drugs can only partially recapitulate complex regenerative signaling pathways that 
normally collaborate during wound healing, thereby motivating the delivery of regenerative cells to wound 
sites. MSC therapies can orchestrate a diversity of processes, including direct epidermal 
differentiation[213], modulation of inflammatory response[32, 214], and paracrine stimulation of other 
cells to adopt reparative phenotypes[32]. Stem cells delivered in fibrin sprays[215], nanofiber 
scaffolds[216], antioxidant hydrogels[217-219], or in collagen sponges[220, 221] have been successfully 
delivered to chronic wounds and have helped orchestrate an enhanced healing response. Though testing of 
stem cell therapies have indicated that MSC delivery is safe in patients, the overall clinical therapeutic 
efficacy has been relatively modest[222] primarily due to poor cellular retention and survival in the wound 
[217]. To this end, there is a significant need for innovative new strategies to improve the engraftment and 
viability of MSCs after delivery to chronic wounds. 
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CHAPTER 3 
 
Synthesis and In Vitro Characterization of PTK-UR Scaffolds 
 
Text partially adapted from: 
Martin JR, Gupta MK, Page JM, Yu F, Davidson JM, Guelcher SA, Duvall CL. A porous tissue 
engineering scaffold selectively degraded by cell-generated reactive oxygen species. Biomaterials. 2014; 
35: 12, 3766-3776. 
 
Martin JR, Nelson CE, Gupta MK, Yu F, Sarett SM, Hocking KM, Pollins AC, Nanney LB, Davidson 
JM, Guelcher SA, Duvall CL. Local delivery of PHD2 siRNA from ROS-degradable scaffolds to promote 
diabetic wound healing. Advanced Healthcare Materials. 2016; DOI 10.1002/adhm.201600820 
 
 
3.1 Introduction 
Biodegradable scaffolds made from synthetic polymers have been extensively investigated for use in 
tissue engineering and regenerative medicine.  Examples include poly(lactic-co-glycolic acid) (PLGA) [51, 
52], poly(ε-caprolactone) (PCL) [53, 54], polyanhydrides (PAA) [55, 56], and polyurethanes [57, 58], all 
of which have a history of use in products approved by the FDA [59-62]. These materials are applicable for 
a diverse range of regenerative applications because they offer a high degree of tunability, generate a 
minimal host inflammatory response, and degrade into non-cytotoxic components [63, 64] that are resorbed 
and cleared from the body [65, 66].  
In situ curing, injectable scaffolds such as poly(ester urethanes) (PEURs) that support cellular 
infiltration and degrade into non-toxic breakdown products represent a particularly promising class of 
biomaterials [74]. Porous PEUR scaffolds are formed by mixing hydroxyl-functionalized polyols (e.g., 900 
g mol-1 triols comprised of caprolactone, glycolide, and D,L-lactide) [63] with isocyanate-functional 
precursors to form a crosslinked network. Water can be added as a blowing agent to create an inter-
connected pore structure, and the mechanical, chemical, and degradation properties of the scaffold can be 
modified through the selection of the polyol and isocyanate precursors [75, 76]. Unlike many other 
techniques used for fabrication of porous scaffolds, this approach does not require a porogen leaching step.  
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This in situ foaming method, combined with the short working time of the reactive liquid mixture [77], 
renders PEURs useful as injectable and scaffolds suitable for minimally invasive procedures in the clinic. 
PEUR scaffolds are primarily degraded by acid-catalyzed hydrolysis of ester bonds in the amorphous 
soft segment, resulting in chain scission and formation of hydroxyl and carboxylic acid end groups. 
Residual carboxylic acids in the polymer reduce the local pH at later stages of degradation [70, 71], thereby 
catalyzing accelerated hydrolysis of the polymer [72].  As the polymers degrade, low molecular weight and 
soluble α-hydroxy acids diffuse from the scaffold into the medium, resulting in mass loss. Although α-
hydroxy acids are non-toxic and can be cleared from the body [63, 73], autocatalytic degradation of the 
PEUR network driven by residual carboxylic acid groups can result in a mismatch in the rates of scaffold 
degradation and tissue in-growth that leads to resorption gaps and compromised tissue regeneration [36].  
Environmentally-responsive polymers have been heavily investigated for the development of smart 
materials that respond to specific biological stimuli [114]. In particular, biomaterials that degrade by cell-
mediated mechanisms, such as materials with protease-cleavable peptides, have been successfully utilized 
to synthesize environmentally-sensitive nanoparticles [223, 224], hydrogels [115, 116], and polymeric 
scaffolds [117, 118]. However, it is difficult to establish this approach as a generalizable tissue engineering 
platform because these peptide sequences are cleaved by specific enzymes that are upregulated in specific 
pathological [120] and feature highly variable levels across patient populations [122]. Also, manufacturing 
peptides on the scale necessary to fabricate large tissue scaffolds is both expensive and time-consuming 
with current technology [37]. Development of degradable polymers that can be affordably synthesized in 
large scales, similar to polyesters, but that target a ubiquitous cell-mediated signal for scaffold degradation 
may provide a more generalizable and better-performing biomaterial. Scaffolds degraded by cell-generated 
reactive oxygen species (ROS) are a promising candidate because ROS serve as important biological 
mediators in many normal biological processes [39], and elevated ROS, or “oxidative stress”, is a hallmark 
of inflammation and the pathogenesis of myriad diseases [40]. Polymeric biomaterial implants have also 
been shown to elicit a stable three-fold increase in ROS production at surgery sites over a four-week 
timeframe [44], further highlighting the potential utility of this cell-generated signal as a trigger for material 
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degradation. This has motivated the recent emergence of new classes of ROS-responsive polymer-based 
nanoparticles [45, 123, 142, 171, 172, 177] and development of salt-leached, porous scaffolds composed 
of a combination of the polyester PCL and ROS-sensitive, proline-based peptides [187].  
Here we sought to develop a generalizable, cell-degradable polyurethane scaffold formulated from 
polyols exhibiting ROS-dependent degradation. To do so, we synthesized a class of polyols based on ROS-
degradable poly(thioketals). Poly(thioketals) (PTKs) were recently applied in orally-delivered 
nanoparticles that remain stable through the stomach and specifically release their cargo “on demand” at 
sites of ulcerative colitis [45]. To date, however, this unique polymer chemistry has solely been utilized in 
targeted nanoparticle drug delivery applications [45, 177]. Herein, we report the development and testing 
of PTK macrodiols amenable to synthesis of injectable, porous poly(thioketal)-urethane (PTK-UR) tissue 
engineering scaffolds that are selectively degraded by cell-generated ROS. These fully synthetic scaffolds 
have been developed to further explore utilization of an ROS-dependent degradation mechanism in order 
to yield scaffolds with better matched rates of cellular infiltration and degradation. 
 
3.2 Materials and methods 
Materials 
All chemicals were purchased from Sigma-Aldrich (Milwaukee, WI) except the following. 2-
mercaptoethyl ether (MEE), glutaraldehyde, and cobalt chloride were purchased from Fisher Scientific 
(Pittsburgh, PA), and the tertiary amine catalyst (TEGOAMIN33) was obtained from Goldschmidt 
(Hopewell, VA).  Glycolide and D,L-lactide were obtained from Polysciences (Warrington, PA). Coscat83, 
an organobismuth urethane catalyst, was supplied by ChasChem, Inc. (Rutherford, NJ). Hexamethylene 
diisocyanate trimer (HDIt, Desmodur N3300A) was received as a gift from Bayer Material Science 
(Pittsburgh, PA). Lysine triisocyanate (LTI) was obtained from Kyowa Hakko USA (New York, NY). Cell 
culture reagents, including Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), and 
penicillin/streptomycin were supplied by Gibco Cell Culture (Carlsbad, CA). All materials were used as 
received unless otherwise indicated. 
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PTK dithiol synthesis 
The condensation polymerization protocol for PTK prepolymer synthesis was adapted from Wilson et 
al. [45]. Briefly, p-toluenesulphonic acid monohydrate (PTSA) was added to a tri-necked boiling flask 
equipped with an attached addition funnel. The vessels were placed under vacuum for 15 min before being 
purged with nitrogen. The boiling flask was charged with anhydrous acetonitrile and batch-specific amounts 
of MEE (x molar eq) and 1,4 butanedithiol (BDT) (1-x molar eq) where x = 1, 0.75, 0.5, 0.25, and 0 for the 
synthesized PTKs, respectively. The addition funnel was also charged with anhydrous acetonitrile and 2,2-
dimethoxypropane (DMP) (0.83 molar eq). A molar excess of dithiol monomers was utilized relative to 
DMP to ensure the formation of polymers with free terminal thiols. Both the addition funnel and boiling 
flask’s solutions were purged with flowing nitrogen for 30 min before submerging the boiling flask into an 
oil bath at 80°C. After 15 min of temperature equilibration, the addition funnel stopcock was set so that the 
acetonitrile-DMP solution was added drop-wise over a period of 16 h. Post synthesis, the acetonitrile was 
removed by rotary evaporation and the resultant PTKs were isolated by precipitation into cold ethanol and 
dried under vacuum. To evaluate polymer compositions, samples of the respective PTKs were dissolved in 
deuterated chloroform (CDCl3) and analyzed with 1H nuclear magnetic resonance spectroscopy (NMR, 
Bruker 400 MHz Spectrometer). 1H NMR chemical shifts were reported as δ values in ppm relative to the 
deuterated CDCl3 (δ = 7.26). Multiplicities are reported as follows: s (singlet), d (doublet), t (triplet), and 
m (multiplet). 1H NMR (400 MHz, CDCl3): δ = 3.67-3.61 (m, 4H), δ = 2.83 (t, 4H), δ = 2.63 (t, 4H), δ = 
1.72 (t, 4H), δ = 1.60 (s, 6H). 
 
Polyester polyol synthesis 
Trifunctional or bifunctional polyester polyols were synthesized as previously documented [63].  To 
synthesize the trifunctional polyol, glycerol was vacuum dried for 48 h at 80oC and then added to a 100 mL 
three neck flask. By molar amount, 60% ε-caprolactone, 30% glycolide, and 10% D,L-lactide were added 
to the glycerol starter along with a stannous octoate catalyst to yield a 900 g mol-1 triol, a 1000 g mol-1 diol, 
and a 1500 g mol-1 triol.  
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PTK hydroxyl functionalization 
The hydroxyl-functionalization of the PTK dithiols was completed [225] in order to generate polyols 
compatible with standard polyurethane synthesis. Briefly, PTK dithiol polymers were transferred to a 
boiling flask, placed under vacuum, and then exposed to a nitrogen atmosphere. The flask was charged with 
anhydrous dichloromethane (DCM) before adding a 10x molar excess of β-mercaptoethanol to the solution. 
This solution was stirred continuously at room temperature to reduce any disulfide bonds and recover the 
reactive thiol end groups. After 3 h of stirring, the DCM was evaporated and the residue was washed three 
times in cold ethanol to remove residual β-mercaptoethanol. The reduced PTK polymers were dissolved in 
anhydrous tetrahydrofuran (THF) before adding a 10x molar excess of cesium carbonate (CsCO3) under 
nitrogen and stirring for 30 min at room temperature. A 5x molar excess of 2-bromoethanol was next added 
to the solution and stirred for 18 h under nitrogen at room temperature. After stirring, the solution was 
added to a separation funnel with an excess of deionized water to effectively separate the PTK-solubilizing 
THF layer from the water-soluble CsCO3 catalyst. The hydroxyl-functionalized PTKs were extracted in 
THF before removing the solvent by rotary evaporation, followed by precipitation three times in cold 
ethanol before vacuum drying for 24 h. Molecular weights and polydispersities of the five synthesized PTK 
diols were analyzed by gel permeation chromatography (GPC, Agilent Technologies, Santa Clara, CA). 
Polymer molecular weights were quantified using a calibration curve generated from poly(ethylene glycol) 
(PEG) standards (400 – 4000 g mol-1). Hydroxyl-functionalization was confirmed by 1H NMR (400 MHz, 
CDCl3): δ = 2.74 (t, 4H) and attenuated total reflectance Fourier transform infrared spectroscopy (ATR-
FTIR; Bruker Tensor 27 FTIR, Billerica, MA). For ATR-FTIR, thiol-terminated and hydroxyl-terminated 
PTK polymers were placed in contact with a ZnSe ATR crystal to quantify absorbance at 2550 cm-1 and 
3400 cm-1, which correspond to absorbance peaks of free thiol and free hydroxyl groups, respectively. The 
hydroxyl (OH) numbers of the different PTK diols were determined by titration (Metrohm 798 MPT 
Titrino, Herisan, Switzerland) according to ASTM E1899 – 08 [226], and this number was used to 
determine the OH number molecular weight of each polymer[83]. 
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PTK-UR and PEUR synthesis 
The PTK-UR and PEUR scaffolds were prepared using two-component reactive liquid molding of: (a) 
hexamethylene diisocyanate trimer (HDIt) or lysine triisocyanate (LTI), and (b) a hardener component 
comprising the PTK diol or polyester triol, water, TEGOAMIN33 catalyst, sulfated castor oil stabilizer, 
and calcium stearate pore opener [63]. The makeup of the hardener components for the different respective 
PTK diols was individually optimized to yield scaffolds with mechanical integrity and an intact porous 
structure. PEUR scaffolds were respectively designated by their polyester precursor as 900t-PEUR, 1000d-
PEUR, and 1500t-PEUR and served as hydrolytically-degradable controls. The hardener component 
elements were first mixed for 30 s at 3300 rpm in a Hauschild DAC 150 FVZ-K SpeedMixer (FlackTek, 
Inc., Landrum, SC) before adding the HDIt and mixing for an additional 30 s. This reactive liquid mixture 
was allowed to rise freely for 10-20 min for complete setting and hardening. The targeted index (ratio of 
NCO to OH equivalents times 100) was 115, where the number of OH equivalents is calculated from the 
experimentally measured OH number for the relevant PTK diol. 
 
Characterization of scaffold physical properties  
The core densities of PTK-UR and PEUR scaffolds made with HDIt were determined by measuring the 
mass and volume of cylindrical porous scaffold core samples, with the core porosities being subsequently 
calculated from these density values [63]. The porous morphologies of the different PTK-UR scaffolds 
were qualitatively assessed by scanning electron microscopy (Hitachi S-4200 SEM, Finchampstead, UK). 
The amount of unreacted components (sol fraction) in the cross-linked network was measured from the 
mass loss of dried scaffold cylinders (25 mm × 12 mm) previously incubated in DCM for 24 h. To measure 
the molecular weight between crosslinks (Mc), scaffold samples (n = 3) were weighed dry and then 
incubated in DCM for 24 h. After incubation, samples were gently blotted to remove excess DCM and then 
the samples’ swollen mass was measured. These values, along with the solvent parameters, were used in 
the Flory-Rhener equation to determine Mc. For measuring scaffold hydrophilicity, PTK-UR films of 100%, 
50%, and 0% MEE-PTK diols were synthesized using an index of 105 and the gelling catalyst Coscat83 at 
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1000 ppm. After mixing the catalyst and PTK diol for 30 s at 3300 rpm, HDIt was added and mixed for an 
additional 30 s. The mixtures were cast into Teflon compression molds and allowed to cure for 18 h at 
60°C. The contact angle of water on these PTK-UR films was measured using a Rame-Hart (Mountain 
Lakes, NJ) Model A-100 contact angle goniometer. A 4 μL water drop was added to the film surface, and 
after 10 min, an equilibrium contact angle was measured to account for molecular surface reorganization 
which increased the hydrophilicity at the contact site [227]. 
 
Thermal and mechanical properties 
Thermal transitions were measured by a TA Instruments (New Castle, DE) Q200 DSC and Q800 DMA.  
For DSC analysis, samples ranging in mass from 10-15 mg were heated from -80o C to 200o C at a rate of 
10o C min-1, cooled to -80o C at a rate of -20o C min-1, and heated a second time to 200o C at a rate of 10o C 
min-1.  All transitions were obtained from the second heating run.  For dynamic mechanical analysis (DMA, 
Q800 DMA, TA Instruments, New Castle, DE), cylindrical samples (6 mm diameter × 6 mm height) were 
analyzed from -80o to 55o C at a ramp rate of 1o C min-1.  Scaffolds were compressed at a frequency of 1 
Hz with 1% strain during the thermal treatment.  Glass transitions were obtained at the peak of tan δ. 
The mechanical properties of the different PTK-UR and PEUR scaffold formulations made with HDIt 
were measured in compression at 37°C in a submersion compression clamp using the Q800 DMA. 
Cylindrical 6 × 6 mm scaffolds were tested after incubation in phosphate buffered saline (PBS) for 7 days 
at 37°C. Using a preload force of 0.1 N, samples were compressed along the longitudinal axis at a strain 
rate of 10% per min until 60% compressive strain was achieved. The Young’s modulus for each sample 
was calculated from the slope of the initial linear region of each respective stress-strain curve after toe-in.  
 
In vitro degradation of PTK-UR and PEUR scaffolds made with HDIt 
Long-term hydrolytic stability of PTK-UR and PEUR scaffolds made with HDIt was determined by 
incubating 10 mg samples in PBS at 37°C on a shaker and measuring the mass loss at each time point (n = 
3). Before beginning the experiment, scaffolds were soaked in an excess of DCM for 24 h to remove any 
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unreacted components before vacuum drying for 24 h. Scaffold samples were removed from the buffer at 
each time point, rinsed in deionized water, vacuum dried for 48 h, and weighed. The buffer medium was 
not changed between time points. Short term oxidative degradation rates of PTK-UR scaffolds were 
similarly assessed using an oxidative degradation medium that simulates in vivo oxidative degradation at 
an accelerated rate [228, 229]. This oxidative medium comprised 20 wt% hydrogen peroxide (H2O2) in 0.1 
M cobalt chloride (CoCl2), with the H2O2 and cobalt ion reacting to stimulate oxidative radical formation 
[228].  As with the long-term study, triplicate samples were pre-soaked in DCM for 24 h before vacuum 
drying and incubated at 37°C in the oxidative medium on a shaker. At specified time points over 10 days, 
samples were removed, rinsed with deionized water, vacuum dried, and weighed. The oxidative medium 
was replaced every 3 days, and the morphology of both PBS-incubated and H2O2-incubated scaffolds was 
qualitatively assessed with SEM. 
The effect of radical concentration on PTK-UR (HDIt) scaffold degradation kinetics was also explored. 
The original 20% H2O2 in 0.1 M CoCl2 degradation medium was diluted ten and one hundred fold to yield 
a 2% H2O2 in 0.01 M CoCl2 solution and a 0.2% H2O2 in 0.001 M CoCl2 solution. These three degradation 
media were used to incubate 100%, 50%, and 0% MEE-PTK-UR scaffolds along with 900t-PEUR control 
samples, with material preparation steps and incubation conditions being the same as previously described.  
 
Mathematical modeling of PTK-UR oxidative degradation 
The degradation behavior of the PTK-UR scaffold formulations made with HDIt were fit to first-order 
decay kinetics equation to create a mathematical model of scaffold degradation with respect to H2O2 
concentration. The first-order degradation model is given in Equation 1. 
𝑴𝒕
𝑴𝟎
⁄ = 𝒆−𝒌𝒕 
Equation 1. First order mass loss model. 
In this equation, Mt is the scaffold mass remaining at time t, M0 is the initial scaffold mass, and k is the 
degradation rate constant. Non-linear regression was used to fit this first-order degradation model to the 
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experimentally determined degradation data. This method was used to determine the degradation rate 
constant k for the scaffolds incubated in the different media. 
 
Degradation of PTK and PEUR scaffolds made with different isocyanate chemistries 
Before beginning degradation experiments, 900t-PEUR and 100% MEE-PTK-UR scaffold samples 
made with either HDIt or LTI were soaked in an excess of DCM for 24 h to remove any unreacted 
components. Samples were dried under vacuum and pre-weighed before being placed in degradation 
media. Triplicate samples were incubated in accelerated hydrolytic conditions (phosphate buffered saline 
(PBS) at 77°C), high oxidative conditions (20 wt% hydrogen peroxide (H2O2) in 0.1 M cobalt chloride 
(CoCl2) at 37°C), or low oxidative conditions (2 wt% H2O2 in 0.01 M CoCl2 at 37°C). At specified time 
points, the samples were removed from the degradation media, rinsed with deionized water, vacuum 
dried, and weighed. The oxidative media were changed every three days. 
 
Degradation of PTK-UR scaffolds in specific ROS 
100% MEE-PTK-UR scaffolds were fabricated with LTI and weighed pre-degradation. Triplicate 5-10 
mg scaffold samples were incubated at 37°C for three days in 1mL of either water, 5 mM hydrogen peroxide 
(H2O2), 5 mM H2O2 with 0.08 mM CoCl2, (generates hydroxyl radicals)[228], 5 mM KO2 (superoxide), or 
5 mM 3-Morpholino-sydnonimine (SIN-1, generates peroxynitrite)[230]. The media was replaced once 
after 24hr. After three days of incubation, scaffolds were removed, rinsed with water, lyophilized, and then 
weighed to determine mass loss. 
 
In vitro culture of macrophages on PTK-UR scaffolds 
RAW 264.7 macrophages were cultured in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin. 100% and 0% MEE-PTK-UR scaffolds made with HDIt were cut into 6.5 × 1-mm 
discs, sterilized by UV-radiation for 1 h (30 min per side), placed into 96-well plates, and incubated with 
culture medium for 30 min. Macrophages were seeded onto the scaffolds at a density of 2.5 × 105 
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cells/scaffold. The cells were allowed to adhere to the scaffolds for 3 h, at which point the media were 
removed and the cells were treated with either fresh culture media or activation media containing 5 μg mL-
1 lipopolysaccharide (LPS) and 1000 U mL-1 interferon gamma (IFN-γ). Cells were incubated on the 
scaffolds for 3 days with fresh culture media being applied daily. After the 3-day incubation, the scaffolds 
were fixed in 5% glutaraldehyde for 2 h followed by 2% osmium tetroxide for 1 h. These fixed scaffolds 
were dehydrated in ascending grades of ethanol before being vacuum dried, sputter-coated, and imaged 
with SEM to evaluate surface pitting. 
 
Cytotoxicity of PTK-UR and PEUR scaffolds 
NIH 3T3 mouse fibroblasts stably transfected with a firefly luciferase reporter gene were cultured in 
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. 100% MEE-PTK-UR, 0% MEE-
PTK-UR, and 900t-PEUR scaffolds made with HDIt were cut into 6.5 × 1-mm discs, sterilized by UV-
radiation for 1 h (30 min per side), placed into a black-walled 96-well plate, and incubated with culture 
medium for 30 min. Fibroblasts were seeded at a density of 5.0 × 104 cells/scaffold on n=3 scaffolds and 
allowed to grow for 0, 1, and 3 days in 200 μL of culture media per well (changed every two days). At the 
endpoint, the cell-seeded scaffolds were treated with culture media containing a luciferin substrate. After 
10 min, the scaffolds were imaged with an IVIS 200 (Xenogen, Alameda, CA) bioluminescence imaging 
system with an exposure time of 2 min to quantify the luciferase-based bioluminescence signal from each 
scaffold’s viable cell population.  All readings were normalized to day 0 bioluminescence values. 
 
3.3 Results 
PTK polymer synthesis and characterization 
Thiol-terminated PTK polymers were successfully synthesized from the condensation polymerization 
of MEE, BDT, and DMP monomers using PTSA as a catalyst (Figure 7A). Five copolymers were 
synthesized with varying percent molar composition of MEE and BDT, and each polymer is designated by 
its relative mol% MEE. 1H-NMR spectra confirmed that the composition of the synthesized polymers 
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closely matched the monomer ratios in the feed (Figure 7B, Table 1), and gel permeation chromatography 
(GPC) analysis showed that the polymers had Mn values of around 1000 g mol-1 with polydispersity index 
(PDI) values near 1.35 (Figure A1, Table 1).  
Efficient conversion of terminal thiols to hydroxyls was demonstrated by ATR-FTIR. The thiol 
absorbance peak at 2550 cm-1 was apparent in the thiol-terminated, parent PTKs but did not appear with 
the hydroxyl-terminated polymers, which generated a characteristic ATR-FTIR hydroxyl peak at 3400 cm-
1 (Figure 7C). OH numbers experimentally measured with titration were utilized to calculate a titration Mn 
(Table 1) that was used to balance the hydroxyl-isocyanate reaction used to form PTK-URs. Consistent 
with previous findings, the experimental OH numbers trended higher than theoretical values [75].  
 
Figure 7. Synthesis and characterization of a family of PTK diols. (A) Scheme for the condensation polymerization 
of thiol-terminated PTKs and their conversion into PTK diols. (B) 1H-NMR spectra of the PTK copolymer diols.  
Peaks associated with MEE and BDT monomers closely matched the molar composition used in the polymer feed. 
(C) ATR-FTIR spectra of thiol- and hydroxyl-terminated PTKs. The thiol absorbance peak is seen at 2550 cm-1 (black 
arrow) and the hydroxyl absorbance peak is seen at 3400 cm-1 (grey arrow). These spectra demonstrate efficient 
conversion of PTK terminal thiols into hydroxyls. 
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PTK-UR scaffold formation and physical properties 
PTK-UR scaffolds were successfully synthesized from the PTK diols and HDIt, yielding porous, 
mechanically robust 3D scaffolds (SEM images shown in Figure A2). PEUR control scaffolds were also 
successfully formed from HDIt and the three different polyester prepolymers (1000d, 1500t, and 900t). The 
resulting PTK-UR and PEUR scaffolds possessed similar sol fraction and porosity, as seen in Table 2.  The 
average molecular weight between crosslinks (Mc) for 1000d- and 1500t-PEUR was statistically equal to 
all of the PTK-UR scaffolds, while the 900t-
PEURs had a significantly lower Mc (p < 0.05) 
relative to all other formulations except for the 
100% and 0% MEE-PTK-UR scaffolds (Table 2). 
The relative surface hydrophilicity of the PTK-UR 
materials was assessed using contact angle 
measurements on films, with 100%, 50%, and 0% 
MEE-PTK-URs having contact angle values of 
66°, 77°, and 80°, respectively. PTK-UR and 
PEUR scaffolds were also formed with lysine 
triisocyanate (LTI), and the structures of both 
HDIt and LTI tri-functional isocyanate molecules 
is give in Figure 8.  
 
Figure 8. Tri-functional isocyanates used in the formation of PTK-UR and PEUR polyurethane scaffolds. 
 
Table 1. Characterization of PTK diols. 
Copolymer 
(PTK diol) 
Feed 
MEE% 
Actual 
MEE%a 
GPC 
Mnb 
PDIb 
Titration 
Mnc 
100%  
MEE-PTK 
100% 100% 1027 1.38 825 
75%  
MEE-PTK 
75% 76% 1005 1.34 850 
50%  
MEE-PTK 
50% 52% 947 1.35 810 
25%  
MEE-PTK 
25% 26% 1053 1.36 745 
0%  
MEE-PTK 
0% 0% 807 1.32 680 
aCalculated from NMR peaks at δ=1.72 and δ=3.64 ppm. 
bCalculated from GPC standards. 
cCalculated from measured titration OH numbers. 
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Thermal and mechanical analysis of PTK-UR scaffolds 
The glass-transition temperature (Tg) of PTK polyols was determined by differential scanning 
calorimetry (DSC), and the Tg of the PTK-UR scaffolds made with HDIt was measured by DSC and 
dynamic mechanical analysis (DMA) (Table A1). The wet compressive moduli of the PTK-UR scaffolds 
ranged from 100 - 250 kPa, and the PEUR moduli ranged from 20 – 100 kPa (Figure 9). All the PTK-UR 
formulations had significantly higher modulus values than the 1500t-PEUR and 1000d-PEUR materials, 
while the lower Mc 900t-PEUR scaffolds possessed stiffness values closer to the PTK-UR samples. 
However, even this more tightly crosslinked formulation was significantly less stiff than the 100% and 0% 
MEE-PTK-UR materials. 
 
Figure 9. PTK-UR and PEUR scaffold mechanical properties. The compressive moduli of porous scaffolds were 
determined under aqueous conditions at 37°C. *p < 0.05 compared to 1500t- and 1000d-PEUR. #p < 0.05 compared 
to 900t-PEUR. 
 
In vitro degradation of PTK-UR scaffolds under aqueous and oxidative conditions 
The hypothesized oxidative degradation mechanism of PTK copolymers is seen in Figure A3. 
Qualitative degradation of PTK-UR scaffolds made with HDIt was demonstrated by SEM as scaffolds 
incubated for 10 days in oxidative media illustrated loss of porous architecture and surface pitting, while 
these morphological changes in scaffold architecture were not apparent following PTK-UR scaffold 
incubation in PBS for 25 weeks (Figure 10 and A2). The PTK-UR scaffolds were stable over a long-term, 
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25-week study in PBS at 37°C, while the 900t-PEUR scaffolds underwent significant hydrolytic 
degradation over this time period (Figure 11A). Conversely, the PTK-URs rapidly degraded under 
accelerated oxidative conditions (20% H2O2 in 0.1 M CoCl2) as seen in Figure 11B. The comprehensive 
temporal degradation data for all PTK-URs tested in the 20% H2O2 media are displayed in Figure A4.   
Figure 10. Representative SEM images of in vitro PTK-UR degradation. Freshly made scaffolds (left column), 
scaffolds incubated in PBS for 25 weeks (middle column), and scaffolds incubated in 20% H2O2 media for 10 days 
(right column). Scale bars = 231 μm. The ROS-degraded PTK-URs feature more irregular pore morphology and 
surface pitting while PBS-incubated scaffolds appear unchanged relative to freshly made scaffolds. 
 
Mathematical model of ROS-dependent PTK-UR scaffold degradation 
To further elucidate the relationship between ROS concentration and the degradation rates of the 
different PTK-UR scaffold formulations made with HDIt, degradation was measured in oxidative media 
comprising 20%, 2%, and 0.2% H2O2 and 0.1, 0.01, and 0.001 M CoCl2, respectively.  The degradation 
rates of PTK-UR scaffolds made with HDIt were dependent on the concentration of H2O2 (Figure 11C-F). 
The mass loss profiles of the PTK-UR scaffolds were fit to first-order degradation kinetics (Equation 1) to 
mathematically model the process of scaffold degradation with respect to H2O2 concentration. The model-
generated degradation profiles are concurrently shown with the respective experimental data as dotted lines 
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in Figure 11B-E, with the derived degradation rate constants being shown in Figure 11F. The 900t-PEUR 
samples incubated in these same oxidative media did not display significant degradation over the same 
timeframe (Figure 11F and Figure A5). 
 
Figure 11. In vitro degradation kinetics of PTK-UR scaffolds. Data are presented as mean ± standard error with n = 
3. (A) Long-term stability of PTK-UR scaffolds incubated in PBS. (B) Percent degradation of PTK-UR scaffolds 
incubated in oxidative medium (20% H2O2 in 0.1M CoCl2) as a function of PTK composition. Dashed lines 
represent model-generated curves for first-order degradation kinetics, *p < 0.05. Percent mass remaining of (C) 
100% MEE-PTK-UR, (D) 50% MEE-PTK-UR, and (E) 0% MEE-PTK-UR scaffolds incubated in oxidative media 
containing 20%, 2%, and 0.2% H2O2. (F) Degradation constants used to generate the best-fit curves in (B-E), as 
determined by non-linear regression analysis. The PTK-UR but not the PEUR scaffolds exhibited H2O2 dose-
dependent degradation. 
A B 
D C 
E F 
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Effect of isocyanate chemistry on PTK-UR and PEUR 
scaffold degradation 
100% MEE-PTK-UR and 900t-PEUR scaffolds 
made with either HDIt or LTI were incubated in 
accelerated hydrolytic conditions (PBS at 77°C), high 
oxidative conditions (20 wt% H2O2 in 0.1 M CoCl2 at 
37°C), or low oxidative conditions (2 wt% H2O2 in 
0.01 M CoCl2 at 37°C). PTK-UR scaffolds made with 
either isocyanate experienced dose-dependent 
degradation with respect to ROS concentrations 
(Figure 12A-B), though LTI-based materials degraded 
significantly faster than HDIt scaffolds. PEUR 
scaffolds with HDIt were relatively inert to oxidation 
at either ROS concentration, while PEURs with LTI underwent significant degradation in 20 wt% H2O2. 
Both PTK-UR and PEUR materials made with LTI degraded significantly faster than analogous scaffolds 
made with HDIt, while PEUR scaffolds were sensitive to hydrolysis with both isocyanate chemistries as 
seen in Figure 12C. PTK-UR scaffolds with HDIt were completely inert to hydrolysis. 
 
 
PTK-UR degradation in response to different ROS 
100% MEE-PTK-UR scaffolds made with LTI were incubated in media containing either water, H2O2, 
H2O2 with hydroxyl radicals, superoxide, or peroxynitrite to test the degradative capacity of each specific 
ROS with respect to PTK-UR materials as seen in Figure A6. There was virtually no degradation of the 
scaffold samples in water, while H2O2 with hydroxyl radicals produced the most degradation. Samples 
Table 2. Physical properties of PTK-UR and PEUR 
scaffolds.  
Scaffold 
Sol 
Fraction 
(%) 
Core 
Porosity 
(vol. %) 
Mc  
(kg mol-1) 
100% MEE 
PTK-UR 
6.9%±1.6% 90.9%±0.4% 7.6±4.2 
75% MEE 
PTK-UR 
8.4%±1.4% 89.0%±1.2% 10.1±4.9 
50% MEE 
PTK-UR 
9.7%±6.1% 86.9%±1.4% 13.8±6.5 
25% MEE 
PTK-UR 
9.1%±2.7% 90.6%±1.5% 9.0±5.0 
0% MEE 
PTK-UR 
8.3%±3.2% 88.8%±1.4% 9.0±5.8 
900t 
PEUR 
4.1%±1.6% 89.8%±1.2% 2.5±1.6 
1500t 
PEUR 
4.7%±0.1% 91.3%±0.2% 13.2±5.4 
1000d 
PEUR 
7.7%±0.1% 92.7%±0.7% 7.7±2.8 
*All values presented as mean ± standard deviation 
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incubated in solely superoxide or H2O2 underwent slightly less degradation, while scaffolds in peroxynitrite 
underwent the least degradation. 
 
Figure 12. In vitro degradation kinetics of PTK-UR and PEUR scaffolds made with either LTI or HDIt isocyanate 
chemistries. PTK-UR scaffolds made with both LTI and HDIt were sensitive to ROS when incubated in (A) 20% 
H2O2 in 0.1M CoCl2 or (B) 2% H2O2 in 0.01M CoCl2, though LTI-based samples were degraded faster than HDIt 
scaffolds. PEUR (LTI) scaffolds were also more degraded at the high ROS dose than PEUR (HDIt) samples. However, 
PTK-UR (HDIt) samples were (C) hydrolytically inert while LTI-based scaffolds were sensitive to hydrolysis. PEUR 
scaffolds with either isocyanate chemistry were degraded by hydrolysis. 
 
 
In vitro cell-mediated degradation and cytocompatibility of PTK-UR scaffolds 
100% and 0% MEE-PTK-UR scaffolds made with HDIt were seeded with murine-derived RAW 267.4 
macrophages. Seeded cells were treated with either control culture media or macrophage-activating media 
containing LPS and IFN-γ.  Qualitative SEM imaging of scaffolds after 3 days illustrated potential surface 
pitting by activated macrophages, but cell-mediated scaffold degradation was not as apparent for the 
scaffolds seeded with non-activated cells (Figure A7A). NIH 3T3 mouse fibroblasts stably transduced to 
express luciferase were also seeded onto 100% MEE-PTK-UR, 0% MEE-PTK-UR, and 900t-PEUR 
scaffolds made with HDIt, and relative cell number was measured based on luciferase activity over 3 days 
of culture (Figure A7B). Cell-generated bioluminescent signal was constant over the culture period, and 
there were no significant differences between the scaffold compositions tested.    
 
3.4 Discussion 
Most currently utilized tissue engineering scaffolds feature hydrolytically degradable ester bonds that 
nonspecifically degrade in the presence of water. Cleavage of ester bonds produces free carboxylic acids 
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which can acidify the local microenvironment and cause autocatalytic degradation [72], with this 
accelerated scaffold breakdown leading to reduced tissue regeneration [36]. Here, a PTK-based scaffold 
technology is presented that is specifically degraded by cell-generated ROS while remaining insensitive to 
hydrolysis (Figure 11A) [45]. Because these PTK-UR materials selectively degrade by cell-mediated 
activity, they avoid autocatalytic degradation and are anticipated to yield better matched rates of cellular 
infiltration and scaffold degradation. To this end, PTK copolymers were successfully synthesized with 
varying chain compositions but similar Mn and PDI values (Figure 7, Table 1). The Mn and PDI values 
observed here are both lower than for PTK polymers reported by Wilson et al.  In this previous study, the 
authors utilized an excess of the DMP monomer with respect to the dithiol monomers to achieve a higher 
degree of polymerization [45]. In the current work, an excess of the dithiol monomer was used to ensure 
that the resulting polymers possessed telechelic dithiol chain ends that could be subsequently converted to 
hydroxyls and utilized for polyurethane formation.   This modification potentially limited the step-wise 
growth of the PTK chain, leading to lower Mn.  As part of the polymer purification in the current studies, 
the PTK polymers were washed with ethanol which presumably preferentially removed both unreacted 
monomer and lower molecular weight PTKs, leading to isolation of a larger molecular weight population 
of PTKs with lower polydispersity relative to the crude product.  The resulting dithiol-terminated MEE-
PTK polymers were converted into diols to generate telechelic end groups compatible with standard 
polyurethane synthesis and to provide PTK polyols amenable to direct comparison with polyesters used in 
PEUR scaffold formation.   
The PTK-UR scaffolds were fabricated using HDIt and compared to PEUR scaffolds made from 900t, 
1000d, and 1500t polyester-based PEUR scaffolds. The 900t-PEUR represented a biological control that 
has been successfully used for in vivo applications [76, 79, 83] while the 1000d-PEUR and 1500t-PEUR 
were synthesized for a more direct material comparison to the PTK-URs because they yield PEUR scaffolds 
with crosslink densities that are more similar to the PTK-UR scaffolds. The PTK-UR scaffolds produced 
from the PTK macrodiols were approximately 90% porous and were morphologically similar to more 
conventional PEUR 3D porous scaffolds.  This level of porosity is optimal for promoting cellular in-growth, 
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nutrient exchange, and neo-vascularization in tissue engineering applications [231-233]. The PTK-URs also 
featured relatively low sol fraction values, indicating that the isocyanates and diols were well matched and 
efficiently reacted during scaffold formation. As expected, the scaffolds’ relative hydrophilicity was 
influenced by the composition of the PTK polyol, and the contact angle was inversely correlated with the 
mol% of the more hydrophilic MEE monomer in the PTK copolymer. These data suggest that the 100% 
MEE-PTK-UR with a contact angle of 66° may be optimal for cellular adhesion and tissue formation in 
vivo, since more hydrophobic surfaces with contact angles > 76° (such as the 50% and 0% MEE-PTK-UR 
formulations) preferentially adsorb hydrophobic serum proteins such as albumin over cellular adhesion 
proteins like fibronectin and vitronectin [234, 235]. 
Thermal analysis of PTK-UR and PEUR scaffolds, along with their polymeric precursors, indicated 
that the scaffolds are phase-mixed materials since the 3D materials all possessed a Tg exceeding that of the 
polyol precursor soft segment [75]. The scaffold Tg values determined by DMA also exceeded those 
measured by DSC by 30 – 50°C, as has been previously reported for similar 3D PEUR materials [63]. Wet 
compression testing of these materials indicated that although the 1500t-PEUR, 1000d-PEUR, and PTK-
UR scaffolds had similar Mc values (Table 2), all of the PTK-UR formulations had significantly higher 
modulus values than the 1500t-PEUR and 1000d-PEUR materials (Figure 9). However, there was no 
consistent trend between PTK-UR scaffold composition and modulus. Due to its higher crosslink density, 
the 900t-PEUR achieved stiffness values closer to the PTK-UR samples, though even this formulation was 
significantly less stiff than the 100% and 0% MEE-PTK-UR materials.  
Previous work has demonstrated the selective, ROS-mediated degradation of poly(thioketal) 
nanoparticles [45]. The PTK-UR scaffolds were formulated with HDIt because it is more oxidatively stable 
relative to lysine-derived isocyanates [74, 76, 79], allowing more specific study of the degradation behavior 
of the polyol component. Degradation of PTK-UR and 900t-PEUR scaffolds was tested in an oxidative 
degradation medium comprising H2O2 and CoCl2 that produces hydroxyl radicals [228]. These radicals 
destabilize the thioketal bond, leading to chain scission and breakdown into the original constitutive 
monomers (MEE and BDT) and acetone (Figure A3). It is predicted that these small byproducts would be 
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rapidly cleared and would not cause cytotoxicity in an in vivo environment. This is supported by previous 
work showing that when incorporated into a similar polyurethane system, MEE monomers cause limited in 
vitro cytotoxicity [236] and a minimal host inflammatory response in vivo [237].  
The long-term stability of PTK-UR scaffolds made with HDIt over 25 weeks in PBS (Figure 11A) was 
significantly different than these materials’ behavior under accelerated oxidative conditions as seen in 
Figure 11B, highlighting the ROS-specific degradation mechanism of the PTK-UR scaffolds. Furthermore, 
there was a relationship between the PTK composition and degradation rate, as the scaffolds with higher 
MEE content in the PTK polyol degraded faster (Figure 11B). It has been previously reported that ethers 
are stable in aqueous media but that oxidative radicals can degrade them in vitro and in vivo [228]. Thus, it 
is hypothesized that the faster ROS-dependent degradation seen in both the 100% and 50% MEE-PTK-UR 
materials may result from a combination of oxidative degradation of both thioketals and ethers, while the 
0% MEE-PTK-UR scaffolds are degraded solely by thioketal scission. These results indicate that ROS-
dependent scaffold degradation rates can be tuned by the composition of the PTK polyol.  
For all PTK-UR compositions tested, the degradation rate was dependent on ROS concentrations 
(Figure 11C-E). This dose-dependent relationship between ROS levels and degradation rate coupled with 
the agreement between the model and experimental data confirm that the PTK-UR scaffolds degrade by 
first-order kinetics with respect to ROS concentration. The degradation rate constants derived from the non-
linear regression fitting of the experimental data gathered in 20% H2O2 media (Figure 11F) also illustrate 
the relationship between degradation rate and the %MEE-PTK polyol used in PTK-UR scaffold fabrication, 
though this trend was decreased under lower H2O2 concentrations. In contrast, the 900t-PEUR samples 
incubated in these same oxidative media did not display H2O2 dose-dependent degradation (Figure 11F and 
A4), highlighting the unique degradation mechanism of the PTK-UR relative to PEUR scaffolds. These 
collective data confirm that PTK-based polyols are selectively cleaved by ROS and that their rate of 
degradation is first-order with respect to the concentration of radical species in the local environment. 
The effect of isocyanate chemistry and specific ROS on scaffold degradation was also explored. PTK-
UR and PEUR scaffolds made with either HDIt or LTI were incubated in varying doses of ROS or in 
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accelerated hydrolytic conditions. Confirming results seen in previous work[76], both PTK-UR and PEUR 
samples made with LTI were more sensitive to both oxidation and hydrolysis compared to HDIt scaffolds 
(Figure 12). However, PTK-UR scaffolds were significantly more degraded than PEURs in oxidative 
conditions and were inert to hydrolysis when fabricated with the non-degradable HDIt, while PEURs were 
hydrolytically degradable with both isocyanate chemistries as expected. These results indicate that the 
inclusion of LTI in scaffold formulations greatly increases the degradability of these materials compared to 
HDIt, presenting another pathway for tuning the degradation kinetics of these scaffolds. The sensitivity of 
PTK-UR scaffolds to specific ROS was also explored as previous work has shown differential degradation 
patterns in thioketal-containing materials exposed to different ROS[177]. Similar to previous results, PTK-
UR scaffolds underwent the most degradation when exposed to hydroxyl radicals but less degradation when 
exposed to H2O2 or superoxide (Figure A6). This data also demonstrated that thioketal bonds are sensitive 
to peroxynitrite, a particularly cytotoxic radical species[238], that had not been previously explored as a 
degrading agent of PTK materials. In all, these degradation data demonstrate the strong effect scaffold 
chemical composition and different reactive species have on material degradation kinetics. 
PTK-UR scaffolds made with HDIt were shown to display low levels of in vitro cytotoxicity with both 
RAW 267.4 macrophages and NIH 3T3 fibroblasts. Seeded macrophages were treated with either control 
culture media or media containing LPS and IFN-γ to activate the macrophages through the classical 
pathway [239, 240], which is known to lead to ROS production [76, 187]. Scaffolds with activated 
macrophages displayed low levels of surface pitting while cell-mediated remodeling of the scaffold surface 
was less evident for the control cells (Figure A7A), potentially indicating that the PTK-UR scaffolds were 
degraded by physiologically relevant concentrations of ROS. Further highlighting these materials’ limited 
cytotoxicity, luciferase-expressing fibroblasts seeded on PTK-UR and PEUR scaffolds steadily maintained 
their bioluminescent signal over the culture period (Figure A7B), similar to cell growth profiles seen in 
other non-cytotoxic 3D scaffolds [241, 242]. Furthermore, none of the scaffold formulations displayed a 
significant difference in bioluminescence over time or relative to each other, indicating that PTK-UR 
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scaffolds had cytotoxicity profiles similar to analogous PEUR scaffolds that have been successfully utilized 
in vivo [76]. 
 
3.5 Conclusion 
ROS are key mediators of cell function in both health and disease, especially at sites of inflammation 
and tissue healing. Utilizing these cell-generated species as triggers for selective polymer degradation 
represents a promising methodology for creating tissue engineering scaffolds with well-matched rates of 
tissue in-growth and cell-mediated scaffold degradation. Here, poly(thioketal) polymers featuring tunable 
chain compositions and ROS-mediated degradation rates have been developed towards this end. These PTK 
polymers were successfully incorporated into 3D porous tissue engineering scaffolds, generating materials 
with more robust mechanical properties than similar constructs fabricated from standard polyesters. These 
PTK-UR scaffolds made with HDIt were selectively degraded by ROS but were stable under aqueous 
conditions, highlighting the specificity of this degradation mechanism. To this end, the in vitro oxidative 
degradation rates of the HDIt-containing PTK-URs followed first-order degradation kinetics and displayed 
dose-dependent degradation with respect to ROS concentration. The effect of the isocyanate chemistry on 
scaffold degradation was also determined, as LTI-based materials degraded faster under oxidative 
conditions than HDIt scaffolds, further expanding the tunability options of these materials. PTK-UR 
scaffolds also displayed evidence of cell-mediated degradation by activated, ROS-producing macrophages. 
Finally, PTK-UR materials had cytotoxicity levels similar to analogous PEUR scaffolds, demonstrating the 
biocompatibility and therapeutic in vivo potential of these novel scaffolds. In all, these data provide an 
effective in vitro characterization of PTK-UR scaffolds in comparison to benchmark PEUR biomaterials 
and support the implementation of novel PTK-URs in in vivo studies. 
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CHAPTER 4 
 
Local Delivery of siRNA from PTK-UR Scaffolds to Promote Diabetic Wound Healing 
 
Text partially adapted from: 
Martin JR, Gupta MK, Page JM, Yu F, Davidson JM, Guelcher SA, Duvall CL. A porous tissue 
engineering scaffold selectively degraded by cell-generated reactive oxygen species. Biomaterials. 2014; 
35: 12, 3766-3776. 
 
Martin JR, Nelson CE, Gupta MK, Yu F, Sarett SM, Hocking KM, Pollins AC, Nanney LB, Davidson 
JM, Guelcher SA, Duvall CL. Local delivery of PHD2 siRNA from ROS-degradable scaffolds to promote 
diabetic wound healing. Advanced Healthcare Materials. 2016; DOI 10.1002/adhm.201600820 
 
 
4.1 Introduction 
Diabetes mellitus affects 9.3% of the US population and is increasing in prevalence[3], with a doubling 
of incidence in the US from 1980-2012[2]. Diabetic patients are more prone to peripheral arterial disease 
and impaired wound healing, often exacerbating simple skin wounds towards chronic ulceration and in the 
worst cases, limb amputation. Approximately 25% of diabetics develop chronic ulcers[1], and roughly 60% 
of non-traumatic lower-limb amputations for patients over 20 years old occur in diabetics[3]. Impaired 
wound healing in diabetic patients is attributable to multiple factors[243], but is especially affected by 
deterioration in the microvasculature and subsequent development of ischemia[4]. In normal wound 
healing, injury-associated hypoxia activates the transcription factor hypoxia-inducible factor-1α (HIF-1α), 
which is primarily regulated by prolyl hydroxylase domain protein 2 (PHD2). PHD2 actively triggers HIF-
1α degradation under normoxia[14, 15] but is inactive under hypoxia, thereby stabilizing HIF-1α. Stabilized 
HIF-1α dimerizes with HIF-1β to promote expression of multiple reparative genes, including vascular 
endothelial growth factor (VEGF)[11], angiopoietin-1 (ANG-1)[12], stromal cell-derived factor-1 (SDF-
1)[13], and others that induce cell proliferation/recruitment and angiogenesis. Despite the presence of 
ischemia, HIF-1α is destabilized in diabetic wounds of both rodents[20] and human patients[9]. While 
inhibition of PHD2 through small molecule drugs has shown promise in re-establishing HIF-1α activity and 
healing skin wounds[20-23], these compounds also inhibit other PHD isoforms (PHD1 and PHD3) and can 
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result in off-target effects[24-26, 244]. In particular, concurrent inhibition of PHD1 and PHD3 has been 
shown to increase accumulation of HIF-2α[245]; conversely to HIF-1α, increased HIF-2α may impede 
wound closure and increase infection[246], further motivating specific reduction of PHD2 activity rather 
than pan-inhibition of PHDs. 
Small interfering RNA (siRNA) holds great potential as a therapeutic due to its precise mode of action 
(complementary base-pairing and degradation of specific messenger RNA sequences) and ability to 
effectively silence targeted gene expression[247]. However, the in vivo efficacy of siRNA has been limited 
by substantial delivery barriers, including degradation by endogenous nucleases, inability to access the 
cytoplasm, and insufficiently sustained bioactivity in the target tissue[211, 212]. Much recent work has 
focused on the development of nanoparticle carriers that can shield siRNA from degradation[248, 249] 
while facilitating intracellular payload delivery[130, 250]. Furthermore, local delivery of siRNA avoids 
many of the challenges associated with systemic administration and helps to ensure that a sufficient siRNA 
dose reaches the target tissue while lessening the potential for side effects due to off-target gene silencing 
in healthy tissues[49, 251]. To date, local siRNA delivery strategies for wound healing applications have 
targeted matrix metalloproteinase-9 (MMP-9)[207], connective tissue growth factor (CTGF)[208], 
p53[209], and PHD2[27, 29] using a host of biomaterial delivery depots, including layer-by-layer coatings 
on non-degradable bandages, alginate hydrogels, and acellular dermal matrix. Here we sought to expand 
our ongoing work to develop cell-degradable synthetic scaffolds that promote robust cellular infiltration 
and tissue regeneration and that can be also used for sustained, local drug or nanomedicine release. 
The available chemistries used for fabrication of synthetic scaffolds offer the opportunity to produce 
templates for guiding new tissue growth in critically-sized defects with adjustable biodegradation 
mechanisms and rates; moreover, these materials can serve as a depot for delivering a diversity of 
therapeutic molecules including growth factors[78, 252], small molecule drugs[23, 84], or 
nanoparticles[85]. In order to leverage these scaffold properties, we have recently developed strategies for 
delivering siRNA-carrying nanoparticles (siNPs) from hydrolytically-biodegradable poly(ester urethane) 
(PEUR) tissue engineering scaffolds[85] and demonstrated in vivo knockdown of PHD2 with increased 
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local angiogenesis in a subcutaneous mouse wound model[28]. Herein, we have applied this system in a 
more clinically-relevant diabetic rat skin excisional wound model. In addition, we have for the first time 
explored siNP delivery from a new poly(thioketal urethane) (PTK-UR) scaffold chemistry that features a 
cell-mediated (i.e. not hydrolytic) degradation mechanism driven by reactive oxygen species (ROS)[45]. 
Relative to ester-based PEUR materials, the PTK-UR chemistry enables better matched rates of degradation 
and cell infiltration while more effectively inhibiting wound contraction[30]. Here, we pursued PTK-UR 
scaffolds to locally deliver siNPs for the in vivo knockdown of PHD2 to promote angiogenesis, cell 
proliferation, and an increased rate of new tissue formation within diabetic excisional skin wounds. 
 
4.2 Materials and methods 
Materials 
All chemical reagents were obtained from Sigma-Aldrich (Milwaukee, WI) unless otherwise indicated. 
2-mercaptoethyl ether (MEE) was purchased from Tokyo Chemical Industry Co (Tokyo, Japan). Glycolide 
and D,L-lactide were obtained from Polysciences (Warrington, PA). Lysine triisocyanate (LTI) was 
obtained from Kyowa Hakko USA (New York, NY). Hexamethylene diisocyanate trimer (HDIt, Desmodur 
N3300A) was received as a gift from Bayer Material Science (Pittsburgh, PA). The tertiary amine catalyst 
(TEGOAMIN33), composed of 33 wt% triethylene diamine in dipropylene glycol, was obtained from 
Goldschmidt (Hopewell, VA). Tegaderm was obtained from 3M (St. Paul, MN) and the hydrogel dressing 
was obtained from ReliaMed (Fort Worth, TX). Lipofectamine 2000 was obtained from Life Technologies 
(Grand Island, NY), and all cell culture reagents, including Dulbecco’s Modified Eagle Medium (DMEM), 
fetal bovine serum (FBS), and penicillin/streptomycin were supplied by Gibco Cell Culture (Carlsbad, CA). 
Dicer substrate siRNAs were obtained from Integrated DNA technologies (IDT, Coralville, IA).  
 
siNP Synthesis and Characterization 
A diblock copolymer composed of 2-(dimethylamino) ethyl methacrylate (DMAEMA), 2-
propylacrylic acid (PAA), and butyl methacrylate (BMA) was synthesized by reversible addition-
 62 
fragmentation chain transfer (RAFT) polymerization as previously described[85, 130]. The final polymer, 
DMAEMA-block-(DMAEMA-co-BMA co-PAA), was characterized by gel permeation chromatography 
(GPC, Agilent Technologies, Santa Clara, CA) with an inline Wyatt mini-DAWNTREOS light scattering 
detector (Wyatt Technology Corp., Santa Barabara, CA) and 1H nuclear magnetic resonance spectroscopy 
(NMR, Bruker 400 MHz Spectrometer) for molecular weight, polydispersity, and polymer composition. 
For the formation of NPs, the polymer was dissolved in a minimal volume of ethanol in a 2 mL RNAse free 
polypropylene tube followed by slow addition of deionized water to trigger spontaneous micelle formation 
(final polymer concentration 1 mg in 1 mL). Micellar size and polydispersity was characterized by Dynamic 
Light Scattering (DLS, Zetasizer nano-ZS Malvern Instruments Ltd, Worcestershire, U.K.). 5 nmol (0.08 
mg) siRNA was added to the NP solution and allowed to electrostatically complex for 30 min to form siNPs. 
5 mg of trehalose (60:1 weight ratio to siRNA), a lyophilization excipient, was added to the siNP solution 
and allowed to dissolve for 30 min. The siNP solutions were then frozen and lyophilized.  
 
Polyester Polyol and PTK Diol Synthesis and Characterization 
A trifunctional polyester polyol (PE) was synthesized as previously described[63]. Briefly, glycerol 
was vacuum dried for 48h at 80°C and then added to a 100mL three neck flask. By molar amount, 60% ε-
caprolactone, 30% glycolide, and 10% D,L-lactide were added to the glycerol starter with a stannous 
octoate catalyst to yield a 900 g mol-1 triol. 100% MEE-PTK or 0% MEE-PTK diol polymers were 
synthesized as previously documented[30], as adapted from Wilson et al.[45]. P-toluenesulphonic acid 
monohydrate was dried by azeotropic distillation with toluene, dissolved in 60°C hydrochloric acid, and 
then recrystallized at -20°C. Crystals were extracted, rinsed with cold HCl, and dried under vacuum for 1 
h. The catalyst was added to a tri-neck boiling flask with an attached addition funnel. Both vessels were put 
under positive nitrogen pressure and charged with anhydrous acetonitrile. MEE or 1,4 butanedithiol (BDT) 
was added to the boiling flask (1x molar eq), while 1x molar eq of 2,2 dimethoxypropane (DMP) was added 
to the addition funnel. The solutions in both the addition funnel and boiling flask were purged with flowing 
nitrogen for 30 min before submerging the boiling flask into an oil bath at 80°C. After 15 min of temperature 
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equilibration, the acetonitrile-DMP solution was added drop-wise into the continuously–stirring, boiling 
flask for 1 h and allowed to mix for an additional 16 h. Post synthesis, the acetonitrile was removed by 
rotary evaporation, and the resultant PTK polymer was isolated by precipitation into cold ethanol and dried 
under vacuum. The resulting dithiol precursor was analyzed by GPC using poly(ethylene glycol) (PEG) 
standards (400 – 4000 g mol-1) to determine molecular weight. To convert the thiol end-groups to hydroxyl 
groups, the PTK dithiol polymers was transferred to a boiling flask and put under positive nitrogen pressure, 
dissolved in anhydrous dichloromethane (DCM), and treated with a 5× molar excess of b-mercaptoethanol 
to reduce any disulfide bonds and recover the reactive thiol end groups. After 2 h of stirring, the DCM was 
evaporated and the residue was washed three times in cold ethanol under nitrogen to remove residual b-
mercaptoethanol. The reduced PTK polymers were dissolved in anhydrous tetrahydrofuran (THF) before 
adding a 5× molar excess of cesium carbonate (CsCO3) under nitrogen and stirring for 30 min at room 
temperature. A 4× molar excess of 2-bromoethanol was next added to the solution and stirred for 18 h under 
nitrogen at room temperature. After stirring, the solution was added to a separation funnel with an excess 
of deionized water to effectively separate the respective PTK-containing THF layer from the water-soluble 
CsCO3 catalyst. The hydroxyl-functionalized PTKs were extracted in THF before removing the solvent by 
rotary evaporation, followed by dissolving the product in water-immiscible DCM to remove any residual 
water. Finally, the PTK diol polymers was analyzed by GPC and NMR before vacuum drying for 24 h. 
 
PEUR and PTK-UR Synthesis 
100% MEE-PTK-UR, 0% MEE-PTK-UR, and PEUR scaffolds (100 mg) were prepared using reactive 
liquid molding with or without lyophilized siNPs. The respective polyol was added to a micro-centrifuge 
tube along with water, TEGOAMIN33 catalyst, and calcium stearate pore opener. These components, with 
or without the lyophilized siNPs, were first mixed for 30 s at 3300 rpm in a Hauschild DAC 150 FVZ-K 
SpeedMixer (FlackTek, Inc., Landrum, SC). After a homogenous mixture was obtained, the respective 
isocyanate (HDIt or LTI) was added and mixed for an additional 30 sec before allowing the liquid mixture 
to freely rise and harden for at least 2 hrs. The targeted index (ratio of isocyanate to hydroxyl equivalents 
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times 100) was 115, where the number of OH equivalents is calculated from the respective polyol’s 
molecular weight. The amounts of each component for the respective scaffold formulations, given as 
equivalent amounts in parts per hundred parts polyol (PPHP), are given in Table A2. 
 
In vivo degradation of PTK-UR and PEUR scaffolds in diabetic and non-diabetic rats 
All surgical procedures were reviewed and approved by Vanderbilt University’s Institutional Animal 
Care and Use Committee. 100% MEE-PTK-UR, 0% MEE-PTK-UR, and PEUR scaffolds made with HDIt 
were cut into 10 × 2.5 mm discs, sterilized with ethylene oxide, and implanted into ventral subcutaneous 
sites in adult male (non-diabetic) Sprague-Dawley rats. Scaffolds were excised from euthanized animals at 
weeks 1, 3, 5 and 7 to evaluate new granulation tissue formation in the implants. The excised tissues were 
fixed in formalin, processed, sectioned, and stained with hematoxylin & eosin. Histological sections were 
evaluated with Metamorph Imaging Software (Molecular Devices Inc., Sunnyvale, CA) to assess wound 
dimensions and scaffold degradation. The wound area was defined as the cross-sectional area occupied by 
the scaffold and new tissue growth. Values for the percentage of scaffold area occupying the wound area 
were normalized to week 1 values to eliminate the effect of scaffold compression over time, and 100% 
MEE-PTK-UR degradation was fit to the first-order degradation kinetics model seen in Equation 1. 100% 
MEE-PTK-UR scaffolds were also made with LTI, sterilized, and implanted subcutaneously in rats for 1 
week before analyzing the tissue explants as previously described. 
To evaluate scaffold degradation in diabetic animals, male Sprague-Dawley rats were injected with 
streptozotocin (STZ, 45 mg kg-1) and allowed to develop hyperglycemia for 10 days. Pre-implantation, 
scaffold sections were sterilized with ethylene oxide and allowed to ventilate for 3 days. 10 mm diameter 
× 2.5 mm thickness 100% MEE-PTK-UR scaffolds made with HDIt were implanted subcutaneously in 
diabetic and non-diabetic rats (four scaffolds per rat), and the subcutaneous tissue samples (skin and muscle 
surrounding the scaffold) were excised from euthanized animals at 1 and 7 weeks post-surgery and 
transferred into PBS. To quantify the tissue’s background autofluorescent signal, the tissue sections 
(muscle-side facing upwards) were imaged with a Xenogen IVIS 200 (ex: 640 nm, em: 735 nm). The tissue 
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sections were then incubated with an ROS-sensitive fluorescent dye (ROSstar 650, Li-Cor Biosciences, 
Lincoln, NE) at 100 μM for 45 min in the dark before being imaged again with the IVIS 200 using the same 
fluorescent filter settings[144, 253]. The excised tissues were fixed in formalin, processed, sectioned, and 
stained with hematoxylin & eosin (H&E). Histological sections were evaluated with Metamorph Imaging 
Software (Molecular Devices Inc., Sunnyvale, CA) to assess scaffold degradation. 
 
In Vitro Screen of PHD2 siRNA 
Dicer substrate siRNA designed against rat PHD2 messenger RNA (mRNA) was obtained from IDT 
(sequence modified from well-validated mouse PHD2 siRNA[28]) and screened for mRNA silencing in 
A7r5 rat smooth muscle cells. Cells were seeded at 24,000 per well in a 12-well plate and allowed to adhere 
for 24 h in DMEM media supplemented with 1% FBS and 1% penicillin/streptomycin. After 24 h of 
incubation, cells were treated with fresh media, scrambled siRNA at 50 nM, or PHD2 siRNA at 50 nM. 
The respective siRNA treatments were pre-complexed with Lipofectamine 2000 in OptiMEM and diluted 
into culture media following the manufacturer’s protocol. After 24 h of incubation with the siRNA, the 
media was removed and replaced with fresh media. After another 24 h (48 h following original siRNA 
treatment), cells were washed, lysed, and processed using a QiaShredder kit (Qiagen, Venlo, Netherlands). 
RNA was extracted using a Qiagen RNeazy column following the manufacturer’s protocol and quantified 
for quality and concentration using a NanoQuant plate on a Tecan microplate reader. cDNA was 
synthesized using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA), and quantitative real-time 
polymerase chain reaction (qRT-PCR) was performed using Bio-Rad iQ SYBR Green Supermix. Relative 
PHD2 expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using 
the ΔΔCt method. Primer sequences are given in Table A3. 
 
In Vitro Nanoparticle Release from PTK-UR Scaffolds 
1 mg of the nanoparticle-forming polymer was dissolved in a minimal volume of ethanol in a 2 mL 
RNAse free polypropylene tube followed by slow addition of deionized water to trigger spontaneous 
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micelle formation (final polymer concentration 1 mg in 1 mL). 5 nmol (0.08 mg) of Cy5-labeled, double-
stranded DNA, similar to siRNA molecular weight, was added to the NP solution and allowed to 
electrostatically complex for 30 min to form fluorescently-labeled DNA-NPs. 5 mg of trehalose (60:1 
weight ratio to DNA), a lyophilization excipient, was added to the siNP solution and allowed to dissolve 
for 30 min. The siNP solutions were then frozen and lyophilized. 100 mg PTK-UR (LTI) scaffolds were 
made with the lyophilized DNA-NPs, allowed to harden, and cut into six sections. The individual scaffold 
sections were incubated in 1 mL of phosphate buffered saline (PBS), with the PBS being removed at 
designated time points and evaluated for Cy5 fluorescence using a microplate reader (Tecan Infinite F500, 
Männedorf, Switzerland). The concentration of labeled nanoparticles in solution, and therefore the drug 
release rate, was determined based on fluorescence measurement of Cy5-labeled DNA-NPs. 
 
Diabetic Excisional Wound Healing with PTK-UR and PEUR Scaffolds 
To evaluate diabetic wound healing in rats, male Sprague-Dawley rats with STZ-induced diabetes were 
shaved and sterilized with iodine. Six full-thickness excisional wounds were made on the rats’ dorsal skin 
with an 8-mm biopsy punch. Ethylene oxide-sterilized PEUR or PTK-UR scaffolds (8 mm diameter × 1.5 
mm thickness) made with LTI or HDIt were placed in the wounds, covered with a non-adherent, absorbent 
ReliaMed hydrogel dressing, and then covered with an adherent Tegaderm outer dressing which was stapled 
to non-wounded skin to provide additional stability. Finally, each rat was fitted with a velcro-fastened jacket 
(Lomir Biomedical, Inc., Malone, NY) to prevent self-tampering with the dressings[254] and singly housed 
in the rodent facility. Rats were euthanized at 4, 7, and 14 days post-surgery and excised scaffold/tissue 
sections were processed for histology with H&E staining. Stained tissue sections were analyzed for scaffold 
tissue infiltration (% scaffold wound area containing tissue), thickness of tissue in-growth (distance tissue 
has infiltrated from bottom of scaffold upwards into the scaffold interior), and macrophage presence in the 
scaffold tissue (% CD68-positive pixel area per cross-sectional scaffold pixel area stained) with ImageJ 
1.48v software (National Institute of Health, Bethesda, MD). 
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In Vivo Silencing of PHD2 in Diabetic Excisional Wounds 
PEUR and PTK-UR scaffolds were fabricated with or without lyophilized siNPs plus trehalose (1 mg 
NP polymer, 5 nmol siRNA, and 5 mg trehalose per 100 mg scaffold). Scaffold implants were designated 
by their siNP payload: no treatment (NT), scrambled siRNA (SCR-siNP), and anti-PHD2 siRNA (PHD2-
siNP). siRNA sequences are given in Table A3. Ethylene oxide-sterilized scaffold sections were implanted 
in excisional wounds in diabetic rats as described previously. As an initial screen to measure the effects of 
PHD2-siNP delivery from PEUR vs PTK-UR scaffolds, both scaffold formulations with NT, SCR-siNP, 
and PHD2-siNPs were implanted into diabetic rats which were euthanized at day 7 post surgery for blood 
vessel analysis. Vessel area per scaffold was measured from H&E stained tissue sections. A follow-up study 
was completed using only using the better-performing PTK-UR scaffolds with NT, SCR-siNP, and PHD2-
siNP treatments. At days 4 and 7 post-surgery, scaffold/tissue sections were extracted from euthanized rats 
and processed for histology with H&E and trichrome blue staining. Small pieces of tissue-infiltrated 
scaffolds (~20mg) from all three time points were also extracted and saved in RNAlater (ThermoFisher 
Scientific, Grand Island, NY). Tissues were put into 2 mL microcentrifuge tubes with 5 mm stainless steel 
beads and Qiazol (Qiagen, Venlo, Netherlands) and pulsed at 300 Hz for 2 min in a Qiagen Tissuelyser II 
to completely disrupt the tissue and extract RNA. Extracted RNA was purified with RNeasy spin columns, 
including on-column genomic DNA elimination using a Qiagen RNase-free DNase kit, and quantified for 
quality and concentration using a NanoQuant plate on a Tecan microplate reader. cDNA was synthesized 
using an iScript cDNA Synthesis Kit, and qRT-PCR was performed using Bio-Rad iQ SYBR Green 
Supermix. Relative gene expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and cyclophilin B (PPIB) using the ΔΔCt method. Primer sequences are given in Table A3. 
 
Western blot analysis of extracted tissues 
Western blot analysis was also performed on scaffold/tissue samples extracted from day 4 animals. 
Frozen samples were extracted with UDC buffer (8 M urea, 10 mM dithiothreitol (DTT), 4% CHAPS 
containing Phosphatase I and II protease inhibitor cocktail (Sigma, St. Louis, MO)) by vortexing at room 
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temperature overnight and centrifugation at 14,000 rpm for 15 min at 4°C. Soluble protein concentrations 
were determined using the Bradford assay (Pierce Chemical, Rockfort, IL). Equal amounts (30 μg) of 
proteins were added to Laemmli sample buffer (Bio-Rad), heated for 5 min at 100°C, and separated on 12% 
SDS polyacrylamide gels. Proteins from the gels were transferred onto nitrocellulose membranes (Li-COR 
Biosciences, Lincoln, NE) and blocked with blocking buffer for 1 hour at room temperature (Li-COR 
Biosciences) prior to incubation overnight at 4°C with antisera against VEGF (1:1000, Santa Cruz 
Biotechnology), HIF-1α (1:1000, Santa Cruz Biotechnology), and GAPDH (1:1000, Millipore). 
Membranes were washed three times with TBS containing Tween 20 (0.1%) (TBST) and incubated with 
680 nm and 800 nm infrared-labeled secondary antibodies (Li-Cor, Lincoln, NE) for 1h at room 
temperature. The membranes were subsequently washed with TBST, and protein-antibody complexes were 
visualized and quantified using an Odyssey direct infrared fluorescence imaging system (Li-Cor). 
 
Immunohistochemical staining of tissue sections 
Immunohistochemical staining was performed using commercial antibodies specifically directed 
against rat CD68 (MCA341GA, Bio-Rad), collagen IV (ColIV) (ab6586, Abcam, Cambridge, MA), α-
smooth muscle actin (α-SMA) (RB-9010, Labvision, Freemont, CA), Ki67 (ab16667, Abcam) and S100A4 
(ab197896, Abcam). Formalin-fixed paraffin embedded tissues were sectioned at 5 m, placed on slides 
and warmed overnight at 60C. Slides were deparaffinized and rehydrated with graded alcohols ending in 
Tris buffered saline (TBS-T Wash Buffer, LabVision, Freemont, CA). Heat mediated target retrieval was 
performed in 1X Target Retrieval Buffer (Citrate, pH 6.0, DAKO, Carpenteria, CA). Endogenous 
peroxidases and non-specific background were blocked by subsequent incubations in 3% H2O2 (Fisher, 
Suwanee, GA) in TBS-T and protein block (DAKO). For CD68, primary antibody was used at 1:800 for 
1hr, followed by secondary incubation in biotinylated rabbit anti-mouse IgG (1:200; Vector, Burlingame, 
CA) and subsequent tertiary incubation in SA-HRP (RTU, BD Pharmingen, San Jose, CA). For Col IV, 
primary antibody was used at 1:600 for 1 hr, with the Bond Refine Polymer detection system used for 
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visualization. For α-SMA, primary antibody was used at 1:1000 for 1 hr, with the Bond Refine Polymer 
detection system used for visualization. For Ki67, primary antibody was used at 1:100 for 1 hr, with the 
Bond Refine Polymer detection system used for visualization. For S100A4, primary antibody was used at 
1:2000 for 1 hr, followed by secondary incubation in anti-rabbit EnVision + labeled polymer (DAKO). 
Slides were rinsed with TBS-T between each reagent treatment and all steps were carried out at room 
temperature. Visualization was achieved with DAB+ chromogen (DAKO). Slides were counterstained with 
Mayer’s hematoxylin, dehydrated through a series of alcohols and xylenes, and then coverslipped with 
Acrytol Mounting Media (Surgipath, Richmond, IL). 
 
Histological analysis of wound healing outcomes 
Quantitative analysis of healing outcomes between scaffold formulations and siNP treatments was 
determined histologically from day 7 tissue samples. The excised tissues were fixed in formalin, processed, 
embedded in paraffin, sectioned, and prepared for staining or immunohistochemistry (IHC). IHC using 
CD68, Col IV, α-SMA, Ki67, and S100A4 antibodies was performed on scaffold/tissue sections and 
quantified using ImageJ. Macrophage presence between PEUR and PTK-UR scaffolds was quantified as 
the CD68-positive pixel area per cross-sectional scaffold pixel area. Overall blood vessel counts per cross-
sectional scaffold area were determined from Col IV IHC sections, while more mature vessels were 
similarly quantified from α-SMA IHC sections. Ki67-positive pixel area per cross-sectional scaffold pixel 
area was quantified for the presence of proliferating cells, and concurrent S100A4 IHC tissue sections were 
compared to Ki67 sections to broadly verify if the proliferating cells positively expressed the S100A4 
marker. Trichrome blue-stained sections were analyzed for tissue infiltration differences between SCR-
siNP and PHD2-siNP as previously described. 
 
Statistical Analysis 
All data are reported as the mean and standard error of the mean unless otherwise indicated. Statistical 
analysis was performed using single factor analysis of variance (ANOVA) and Tukey post-hoc comparison 
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tests for multiple comparisons, and the Student’s t-test was used for single comparisons. P-values less than 
0.05 were considered statistically significant. 
 
4.3 Results and discussion 
The PTK-UR scaffolds’ lack of cytotoxicity and compatibility with cellular infiltration (Chapter 1) 
were confirmed in vivo by histological analysis of subcutaneous implants. The biocompatibility and 
degradability of PTK-UR scaffolds made with HDIt was confirmed after implanting 100% MEE-PTK-UR, 
0% MEE-PTK-UR, and 900t-PEUR scaffolds subcutaneously into male, non-diabetic Sprague-Dawley 
rats. The 100% MEE-PTK-UR, and 900t-PEUR scaffolds demonstrated robust cellular infiltration, a 
minimal inflammatory response, and granulation tissue formation by 3 weeks post implantation (Figure 
13A). However, the 0% MEE-PTK-UR scaffolds supported much less robust tissue infiltration into the 
scaffold interior relative to the 100% MEE-PTK-UR or 900t-PEUR scaffolds. One possible explanation for 
this result is that the relative hydrophobicity of the 0% MEE-PTK-UR scaffolds (80° contact angle) did not 
allow cells to properly adhere and migrate into the scaffold interior. As a result, only the 100% MEE-PTK-
UR and 900t-PEUR histology samples were quantitatively analyzed. Both of these formulations supported 
new tissue growth and displayed significant biodegradation over 7 weeks (Figure 13B). The 900t-PEURs 
experienced accelerated degradation after 3 weeks as expected from previous work with these materials 
[76], while the 100% MEE-PTK-UR scaffolds displayed first-order degradation over time. This finding 
confirms the initial hypothesis that PTK-UR scaffolds degrade by a cell-mediated mechanism compared to 
the hydrolytic degradation of the more conventional PEUR materials, which have been shown to undergo 
autocatalytic degradation in vivo resulting in a reduced wound healing response [36].  
Furthermore, the PTK-UR samples were more mechanically resilient and were more effective in 
maintaining implant geometry as seen in Figure 13A and C. Though all scaffolds initially possessed 90% 
porosity and were cut to the same dimensions pre-implantation, the PEUR materials were significantly more 
compressed than the PTK-UR scaffolds by week 1. As the wound length was relatively consistent between 
PTK-UR and PEUR scaffolds (Figure A8), the total wound area values closely mirrored the trends seen in 
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the scaffold thickness measurements (Figure A9). This in vivo compression of PEUR scaffolds can be 
potentially attributed to both the significantly higher modulus of the 100% MEE-PTK-UR samples relative 
to the 900t-PEUR formulation (Figure 9) and also to the 900t-PEUR Tg value (34.4 °C) which is close to 
body temperature (Table A1). This relatively high Tg predicts that the PEUR scaffolds would be less 
mechanically resilient at body temperature because they would be in their glass transition viscoelastic 
region. The stenting effect seen in these PTK-UR scaffolds is advantageous because it ensures that the 
scaffold pores remain open, maximizing cell infiltration and new tissue formation and potentially 
decreasing scarring in clinical applications [255]. 
As PTK-UR materials exhibited dose-dependent degradation with respect to ROS concentrations in 
vitro, animal experiments were carried out to confirm ROS-dependent degradation kinetics in vivo. PTK-
UR scaffolds made with HDIt were subcutaneously implanted in non-diabetic and streptozotocin-induced 
diabetic rats and allowed to integrate for 1 or 7 weeks. Chronic diabetic wounds have elevated oxidative 
stress compared to acute wounds[256, 257], signifying that diabetic wounds could increase the degradation 
rate of PTK-UR scaffolds in vivo. After incubating tissue/scaffold explants in an ROS-responsive dye 
(Figure 14A), samples from diabetic and non-diabetic rats did not possesses statistically different levels of 
ROS at 1-week post-surgery (17 days post STZ injection). However, tissue-level ROS signal was 
significantly different at 7 weeks with the diabetic rats exhibiting higher levels of ROS as predicted (Figure 
14B). The 100% MEE-PTK-UR scaffolds implanted in these tissue sections exhibited corresponding levels 
of degradation, with scaffolds implanted for only 1 week exhibiting no difference between diabetic and 
non-diabetic rats and scaffolds implanted for 7 weeks being significantly more degraded in diabetic rats 
(Figure 14C). These findings further confirm that ROS concentrations significantly impact degradation of 
PTK-based materials both in vitro and in vivo.  
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Figure 13. In vivo response of  subcutaneous PTK-UR scaffolds in Sprague-Dawley rats. (A) Histological illustration 
of cellular infiltration into PTK-UR and control PEUR scaffolds (residual scaffold material is designated with ‘S’ in 
the week 5 high magnification panels). The 100% MEE-PTK-URs supported robust tissue in-growth, but the 0% 
MEE-PTK-UR formulation did not. (B) In vivo scaffold degradation normalized to week 1. Though initially 90% 
porous, the PEURs were compressed post-implantation and experienced more accelerated degradation after 3 weeks, 
while the PTK-URs degraded more slowly and with more temporally-constant first-order degradation kinetics (dashed 
line represents model-generated curve). §p < 0.05 compared to week 1, #p < 0.05 compared to week 3, $p < 0.05 
compared to week 5. (C) Compression of PTK-UR vs. PEUR scaffolds in vivo. The PTK-UR scaffolds maintained 
their mechanical integrity/thickness and provided a greater stenting effect relative to the PEUR implants, *p < 0.05. 
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Figure 14. In vivo degradation of subcutaneous PTK-UR (HDIt) scaffolds in diabetic and non-diabetic Sprague-
Dawley rats. Tissue/scaffold explants from diabetic rats after 7 weeks (A) soaked in an ROS-responsive fluorescent 
dye have (B) higher levels of ROS than non-diabetic animals. These higher levels of tissue ROS also correspond with 
significantly greater degradation of ROS-sensitive PTK-UR scaffolds after 7 weeks (*p<0.05). 
 
As determined from histological sections with hematoxylin and eosin (H&E) staining (Figure 15A), 
both implanted scaffold formulations had substantial tissue infiltration throughout the scaffold at day 4 post 
implantation. Tissue infiltration was defined as the cross-sectional area of the scaffold wound site that was 
occupied by granulation tissue (i.e. area not occupied by scaffold, intact dermis, or blank space). At day 7, 
both material formulations had significantly more tissue infiltration compared to day 4 levels, but the PTK-
UR implants had both significantly greater infiltration (Figure 15B) and (similar to previous in vivo 
observations)[30] significantly greater stenting of the wound leading to a thicker layer of tissue growth 
within the PTK-UR scaffolds than within analogous PEURs (Figure 15C). The newly formed tissue was 
also evaluated in day 7 tissue sections by CD68 immunohistochemistry (IHC) to determine the presence of 
inflammatory cells. Quantification of IHC staining for this macrophage marker[258] revealed that there 
was no significant difference in macrophage presence between tissues surrounding PEUR and PTK-UR 
implants (Figure A12), suggesting that these materials elicited a similar inflammatory response. Both 
scaffold types were nearly fully resorbed by day 14, indicating that the use of LTI in the material 
formulation significantly increased the in vivo degradation rate of these scaffolds compared to similar 
implants made with minimally-degradable HDIt[30, 76]. However, PTK-UR scaffolds promoted a highly 
favorable regenerative response with enhanced tissue infiltration, thicker tissue ingrowth, and similar 
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presence of macrophages compared to conventional PEUR materials. These results supported the use of 
PTK-UR implants in subsequent studies. 
 
 
Figure 15. PEUR and PTK-UR scaffolds made with LTI and implanted into diabetic excisional wounds (A) were 
largely degraded by 14 days and covered by new epidermis. Implanted PTK-URs promoted (B) greater wound 
stenting/thicker granulation tissue formation and (C) supported more robust tissue infiltration over 7 days (mean ± 
SEM, n = 7 independent animals, *p<0.05). 
 
To demonstrate the therapeutic potential of localized, scaffold-based siRNA delivery to clinically-
relevant diabetic wounds, siRNA-carrying micellar nanoparticles (siNPs) were formulated with siRNA 
targeting PHD2 (PHD2-siNPs) or scrambled control siRNA (SCR-siNPs) and incorporated into PEUR and 
PTK-UR scaffolds. Both the scrambled and PHD2 siRNA sequences (Table A3) were pre-screened in vitro 
to ensure effective PHD2 gene silencing in rat cells as seen in Figure A13. The self-assembling, siRNA-
condensing nanoparticles were composed of a diblock copolymer synthesized by reversible addition-
fragmentation chain transfer (RAFT) polymerization, containing 2-(dimethylamino) ethyl methacrylate 
(DMAEMA), 2-propylacrylic acid (PAA), and butyl methacrylate (BMA) as previously described[28, 85, 
130, 250]. As depicted in Figure 16B, the final polymer, DMAEMA67-b-(DMAEMA29-co-BMA75-co-
PAA40), achieved a final molecular weight of 30,500 Da and was self-assembled into micellar nanoparticles. 
The addition of siRNA (5 nmol) to the micelle solution (1 mg polymer in 1 mg water) formed stable siNPs 
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(Dh = 31 nm, ζ-potential = +20.2 mV), which were optimized to achieve pH-dependent endosomal escape 
and intracellular siRNA delivery[130, 250]. After loading of the siRNA cargo, the excipient trehalose (60:1 
weight ratio to siRNA) was added to the siNP solution to both stabilize the nanoparticles through 
lyophilization[86, 259] and to increase in vivo siNP release from implanted scaffolds[28]. After 
lyophilization, the siNP-trehalose powder was mixed into the liquid PEUR or PTK-UR reaction (100 mg 
prepolymer), leading to homogenous distribution throughout the final 3D polymer structure following 
scaffold hardening. Corresponding to the rapid cellular infiltration seen in Figure 15, the specific dose of 
trehalose (5 wt% of the final scaffold weight) was chosen to facilitate relatively fast siNP release from 
implanted scaffolds with the aim of transfecting these early infiltrating cells. Initial testing of in vitro 
nanoparticle release from PTK-UR scaffolds using fluorescently-labeled double stranded DNA as a model 
for siRNA indicated that, similarly to in vitro siNP release data from PEUR scaffolds with the same dose 
of trehalose[28], much of the siRNA payload was released over a two-day time course (Figure A14).  
 
Figure 16. Structure of the micelle-forming diblock copolymer DMAEMA-block-(DMAEMA-co-BMA-co-PAA). 
As an initial screen of the effectiveness of siNP delivery from PEUR and PTK-UR implants, no 
treatment scaffolds (NT) along with PHD2 and SCR siNP-loaded scaffolds were implanted into excisional 
wounds in STZ-diabetic rats and histologically evaluated after 7 days. Blood vessel area in H&E sections 
was quantified for PEUR and PTK-UR scaffolds with NT, SCR-siNP, and PHD2-siNP treatments. As seen 
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in Figure A15, pilot in vivo data indicated that loading with PHD2-siNPs tended to cause increased vessel 
area in both PEUR and PTK-UR scaffolds. However, the NT PTK-UR scaffolds had a statistically higher 
vessel cross-sectional area than the NT PEUR scaffolds (Figure A15), indicating that PTK-UR scaffolds 
promoted more blood vessel growth than PEURs even without siNP treatment. Because PTK-URs 
encouraged both a more robust healing response (Figure 15) and enhanced baseline blood vessel formation 
(Figure A15) compared to the more conventional PEUR materials, a larger diabetic rat study was carried 
out using only the better-performing PTK-UR scaffolds loaded with siNPs.  
 
Figure 17. PTK-UR scaffolds loaded with PHD2-siNPs (A) significantly decrease PHD2 mRNA within the wound 
tissue scaffolds compared to NT and SCR-siNP implants, leading to (B) increased HIF-1α and (C) increased VEGF 
protein levels compared to SCR-siNP implants at day 4 post-implantation (mean ± SEM, n = 6 independent animals, 
*p<0.05). 
 
In the scaled up study, excisional wounds in STZ-diabetic rats were implanted with sterilized PTK-UR 
scaffolds made with LTI (NT, SCR-siNP, or PHD2-siNP treatments, 0.5 nmol siRNA per SCR or PHD2-
siNP scaffold). Tissue/scaffold samples from day 4 post implantation revealed 40% knockdown of PHD2 
messenger RNA in PHD2-siNP scaffolds compared to NT and SCR-siNP implants (Figure 17A) as 
determined by quantitative real-time polymerase chain reaction (qRT-PCR, primer sequences listed in 
Table A3). The downstream transcriptional impact of PHD2 silencing was also confirmed, since both HIF-
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1α and VEGF protein levels were also significantly increased in the treatment group as quantified by 
western blot analysis compared to SCR-siNP scaffolds (Figure 17B-C). qRT-PCR of day 7 tissue samples 
did not show a significant decrease in PHD2 expression compared to NT or SCR-siNP implants (data not 
shown), potentially due to the relatively fast in vivo release of siNPs with added trehalose[28]. However, 
day 7 histological sections immunostained for collagen IV (Col IV), a marker of vascular basement 
membranes[87], indicated a persistent increase in blood vessel density in PHD2-siNP scaffolds compared 
to SCR-siNP implants (Figure 18A). Enhanced vessel formation is a hallmark effect of PHD2 inhibition[18, 
19, 27, 29] and is heavily implicated in improved wound healing outcomes. Furthermore, there was a higher 
density of vessels in PHD2-siNP scaffolds expressing α-smooth muscle actin (α-SMA), a marker of vessel 
maturation[198], as visualized by α-SMA IHC in Figure 18B. These data collectively demonstrate that a 
higher density of both immature and mature blood vessels form within the PHD2-siNP scaffolds compared 
to control materials. This animal experiment was also repeated with siNP-loaded PTK-UR scaffolds made 
with HDIt to assess the effect of scaffold chemistry on the longevity of PHD2 silencing in vivo. As 
demonstrated in Figure A16, the HDIt scaffolds also promoted significant knockdown of PHD2 expression 
at day 4 post implantation but did not have significant silencing at day 7 (data not shown). However, the 
tissue infiltration response to HDIt materials in excisional wounds was significantly diminished compared 
to LTI scaffolds (Figure 15). These results indicate that though PTK-UR scaffolds made with HDIt achieve 
similar results in vivo silencing of PHD2 with scaffold-delivered siNPs, the relatively negative tissue 
response to HDIt materials limits the utility of these materials for wound healing applications. 
Immunostaining for Ki67, a marker for cell proliferation[87], also indicated that there was a significant 
increase in proliferating cells throughout the PHD2-siNP scaffolds (Figure 18C). Decreased PHD2 
expression in cutaneous tissue is known to increase cell proliferation and migration while enhancing overall 
wound closure in mouse skin lesions[17]. Closer inspection suggested that the proliferating cells were 
largely granulation tissue-forming fibroblasts. To confirm cellular identity, tissue sections immunostained 
for S100A4, a fibroblast marker[260], were compared to Ki67 IHC sections. As seen in representative 
images in Figure A17, comparing serial tissue sections immunostained for both markers indicated that 
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regions of dense Ki67-positive proliferating cells also had high levels of expression of S100A4. These data 
suggest that PHD2-siNP mediated cellular proliferation is generating fibroblasts that can aid wound 
restoration[261].  
 
Figure 18. PHD2-siNP scaffolds featured (A) improved overall tissue vascularization as visualized by Col IV IHC, 
along with (B) more mature vessel formation as denoted by α-SMA IHC. PHD2-siNP scaffolds also (C) had increased 
cellular proliferation as visualized by Ki67 IHC, leading to (D) an overall increase in tissue infiltration into implanted 
scaffolds (mean ± SEM, n = 7 independent animals, *p<0.05). 
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Although much past work has used surface wound closure percentage as a marker for overall healing 
in rodent models[17, 27], these biodegradable polyurethane scaffolds are designed to stent open contracting 
skin to decrease collagen alignment and scarring and improve the quality of new tissue formed[79, 80, 255, 
262], thus making topical measurements of wound closure a less relevant measure of healing in this system. 
This is highlighted in the macroscopic wound images in Figure A11, as wounds at day 7 are all roughly the 
same size between PEUR and PTK-UR implants due to the stenting effect of the scaffolds. Despite the 
similarity in apparent wound size, the amount of new tissue growth as gauged by histological evaluation 
was significantly different between the two formulations (Figure 15) thereby demonstrating the better 
sensitivity by measuring tissue growth within the wound histologically. To gauge overall wound healing of 
PHD2-siNP against SCR-siNP scaffolds at day 7, histological sections stained with Masson’s trichrome 
blue were evaluated for the level of tissue infiltration into the scaffold. PHD2-siNP scaffolds had a 
statistically significant increase in tissue infiltration compared to SCR-siNP scaffolds as depicted in Figure 
18D, indicating that the local delivery of PHD2 siRNA from biodegradable scaffolds increased the amount 
of tissue within scaffolds and improved refilling of the diabetic wounds with vascularized, reparative 
granulation tissue.  
 
4.4 Conclusion 
In conclusion, PTK-UR scaffolds support cell infiltration and granulation tissue formation in vivo, and 
their superior mechanical properties produced significantly greater stenting of subcutaneous implants 
compared to more standard PEUR scaffolds. Furthermore, the PTK-URs experienced controlled, first-order 
kinetics of biodegradation in vivo, in contrast to the PEUR scaffolds which experienced accelerated rates 
of degradation over time. PTK-UR scaffolds also represent a promising biomaterial technology for the 
healing of chronic diabetic wounds both as a regenerative tissue engineering scaffold and as a drug depot 
for localized therapeutic delivery. Implanted PTK-UR scaffolds promote more robust tissue regeneration 
in diabetic wounds than benchmark PEUR scaffolds. Furthermore, the local, scaffold-based delivery of 
siNPs to silence PHD2 expression is an effective and potent strategy for improving vascular development, 
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cellular proliferation, and new tissue growth in diabetic wounds. These results represent a promising, 
clinically translatable approach to treat non-healing skin wounds, and ongoing work will further elucidate 
the impacts of PHD2 knockdown kinetics in this diabetic wound healing model and in more advanced pre-
clinical settings. 
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CHAPTER 5 
 
Enhanced Cell Viability and In Vivo Degradation of PTK-Crosslinked PEG Hydrogels  
 
Text partially adapted from: 
Martin JR, Prarthana P, Gupta MK, Duvall CL. Enhanced Cell Viability and In Vivo Degradation of 
Injectable, Reactive Oxygen Species-Sensitive PEG Hydrogels. In preparation. 
 
5.1 Introduction 
Synthetic hydrogels have emerged as promising materials in regenerative medicine applications due to 
their highly hydrated nature and robust cross-linked polymer networks that mimic the natural three-
dimensional extracellular matrix[88]. Importantly, when compared to naturally derived materials such as 
collagen or gelatin, artificial matrices offer the advantages of much higher degrees of control over cellular 
adhesion molecule presentation, manufacturability, and material mechanical properties[89]. Due to their 
intrinsically low protein-adsorption[90], precedent for safe in vivo usage, and ease of functionalization[91], 
hydrogels fabricated from poly(ethylene glycol) (PEG) remain the most heavily investigated matrix-
mimicking class of synthetic biomaterials. These hydrogels are most commonly formed by the covalent 
cross-linking of PEG macromers, which swell upon exposure to water due to PEG’s hydrophilic nature but 
do not dissolve due to the covalently linked polymer network. Recent work in the area has focused on in 
situ cross-linking PEG hydrogels that can be delivered in a minimally invasive manner in the clinic while 
maintaining an active depot of living cells[92-94], proteins[95], or drugs[96]. 
Strategies for inducing in situ hydrogel formation include UV cross-linking of acrylate or ene-
terminated units in the presence of a photo-initiator[92, 95, 97], enzyme-mediated cross-linking with 
horseradish peroxidase[98-100], covalent cross-linking induced by click reactions[101, 102], or Michael-
type addition[103-105]. In particular, Michael-type addition does not require an exogenous light source or 
free radicals to achieve polymerization, but instead uses a nucleophilic reagent to catalyze the addition 
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reaction between a branched, end-functionalized PEG macromer and a multi-functional nucleophilic cross-
linker[111]. PEG macromers end-functionalized with acrylate and vinyl-sulfone groups have been 
previously investigated[103, 105, 112], and recently, García et al. have explored the use of maleimide-
functionalized PEG (PEG-MAL) macromers as precursors for injectable hydrogels formed by Michael-
addition cross-linking[93, 94, 263]. Maleimide groups have been extensively used in peptide biochemistry 
as they quickly and efficiently react with thiol groups with very high specificity at physiological pH 
levels[113]. When compared to more conventional Michael-addition hydrogel systems featuring acrylate 
or vinyl-sulfone groups, these PEG-MAL materials possess superior cytocompatibility, increased cross-
linking efficiency, and appropriate in situ gelation kinetics that make this system ideal for in vivo delivery 
applications[93]. Furthermore, PEG-MAL macromers demonstrate limited cytotoxicity and inflammation 
in vivo while possessing rapid renal clearance of the hydrogel degradation products[94]. In a therapeutic 
capacity, PEG-MAL hydrogels have shown promise as delivery vehicles for both bioactive proteins[94, 
263-265] and viable cells[94, 266].  
Importantly for their in vivo translatability, these PEG-MAL hydrogels are also fabricated with 
protease-cleavable peptide linkers specifically tailored to degrade in response to cell-produced matrix 
metalloproteinase (MMP) enzymes, providing these materials with a cell-mediated biodegradation 
mechanism[120]. The MMP-cleavable sequence is flanked by cysteine residues that provide free thiol 
groups that can participate in the Michael-addition crosslinking with PEG-MAL macromers to form 3D 
constructs. However, establishing peptide-crosslinked hydrogels as a generalizable tissue engineering 
platform suffers from a number of difficulties. These peptide sequences are cleaved by specific MMPs that 
are upregulated to different degrees across diverse pathological environments[120], and also feature highly 
variable levels across cellular subtypes[121] and patient populations[122]. Moreover, manufacturing 
peptides on the scale necessary to fabricate large tissue scaffolds is both inefficient and expensive with 
current strategies[37, 38]. This has motivated the development of synthetic biodegradable polymers to 
replace MMP-cleavable peptides in the formation of PEG-MAL hydrogels. The development of scalable, 
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affordably synthesized degradable polymers that target an abundant cell-mediated signal for polymeric 
degradation may provide a more translationally viable platform for cell delivery technologies. 
To this end, we have developed polymers that are selectively degraded by cell-generated reactive 
oxygen species (ROS). Though produced in many normal biological signaling cascades[39], elevated ROS, 
or “oxidative stress”, is a hallmark of disease states[40] and biomaterial implantation[44], making oxidative 
stress a promising candidate as a precise, cell-generated signal for triggering material degradation. This has 
motivated the recent emergence of new classes of ROS-responsive polymers[41], including poly(propylene 
sulfide) (PPS)[123, 142, 147, 150, 151], selenium-containing polymers[155, 267], arylboronic esters 
(ABEs)[171, 172], oligo(proline) peptide cross-linkers[187], and poly(thioketal) (PTK) polymers[30, 45, 
124, 177, 178, 268]. Of these ROS-degradable systems, PTK polymer chemistry in particular possesses 
many ideal attributes for synthesizing large-scale tissue engineering materials, though until recently had 
solely been utilized in targeted nanoparticle formulations for drug delivery applications[45, 124, 177]. PTK 
polymers are synthesized by simple condensation polymerization of low-cost, low-toxicity precursors to 
form polymer chains that are inert to hydrolysis but specifically degraded by ROS[45]. Due to their ROS-
specific degradation mechanism, PTK-based biomaterials more effectively match in vivo material 
degradation with tissue regeneration and foster more successful healing outcomes when compared to 
conventional polyester-based biodegradable implants[30, 268].  
Further highlighting the utility of PTK materials as components of tissue engineering constructs, PTK 
polymer synthesis can be easily tuned to produce homobifunctional thiol end groups which can selectively 
react with the maleimide groups on PEG-MAL macromers. However, similarly to most ROS-degradable 
polymers currently in use, previously developed PTK polymers are relatively hydrophobic due to the non-
polar units in the chemical backbone. This inherent polymer hydrophobicity hinders the employment of 
these PTK polymers in hydrogels since the water-insoluble PTK component cannot fully engage with the 
water-soluble PEG-MAL to form an effective covalent network. Herein, we have developed a fully water-
soluble, thiolated PTK component that readily reacts with PEG-MAL macromers for the fabrication of 
hydrogels. These novel, covalently-linked PEG-MAL-PTK hydrogels are specifically degraded by cell-
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generated ROS while retaining the benefits of previously reported PEG-MAL gels, serving to create a 
material platform with enhanced translational potential compared to conventional peptide-linked hydrogels. 
 
5.2 Materials and methods 
Materials 
All chemicals and reagents were purchased from Sigma-Aldrich (Milwaukee, WI) except the following. 
Cobalt chloride hexahydrate, TCEP Disulfide Reducing Gel, calcein-AM, ethidium homodimer, and 
Tissue-Tek O.C.T. Compound were purchased from ThermoFisher Scientific (Waltham, MA). 10kDa four-
arm PEG-maleimide (PEG-MAL) was obtained from Laysan Bio, Inc. (Arab, AL). The cysteine-terminated 
adhesive peptide GRGDSPC (RGD) was obtained from Genscript (Piscataway, NJ), while a 
GCRDVPMSMRGGDRCG peptide (VPM) was custom synthesized by Advanced Automated Peptide 
Protein Technologies (Louisville, KY). The fluorescent dye MTS-CF640R was purchased from Biotium 
(Fremont, CA). Cell culture reagents, including Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine 
serum (FBS), and penicillin/streptomycin were supplied by Gibco Cell Culture (Carlsbad, CA). Primary 
bone marrow-derived mouse mesenchymal stem cells (mMSCs) from C57BL/6 mice were obtained from 
Cyagen Biosciences, Inc. (Santa Clara, CA). CellTiter-Glo Luminescent Cell Viability Assay was 
purchased from Promega (Madison, WI). Male BALB/c mice were supplied by The Jackson Laboratory 
(Bar Harbor, ME). 
 
EDDT-PTK Dithiol Synthesis 
 The protocol for PTK dithiol polymer synthesis has been previously outlined by our group[30, 43] 
and was adapted from Wilson, et al[45]. Briefly, 1 g of p-toluenesulphonic acid monohydrate (PTSA) was 
re-crystallized in HCl at -20°C, extracted and dried, and then added to a tri-neck boiling flask and put under 
positive nitrogen pressure. 1x molar equivalent (9.8mL) of 2,2’-(Ethylenedioxy) diethanethiol (EDDT) was 
added to the flask, while 0.83x molar equivalent (6.2mL) of 2,2-dimethoxy propane (DMP) was added to 
an additional funnel attached to the boiling flask. Anhydrous acetonitrile was charged into the flask 
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(100mL) and the addition funnel (50mL), and both were purged with flowing nitrogen for 30min at room 
temperature. Next, the flask was placed in an oil bath at 80°C, allowed to equilibrate for 15min, and the 
addition funnel was set so that the acetonitrile-DMP solution was added drop-wise into the continuously 
stirring boiling flask and allowed to react for 18h. Post synthesis, the acetonitrile was removed by rotary 
evaporation and the EDDT-PTK polymer was isolated by precipitation into cold ethanol and dried under 
vacuum. Polymer molecular weight was analyzed by gel permeation chromatography (GPC, Agilent 
Technologies, Santa Clara, CA) using a mobile phase of N,N-dimethylformamide (DMF) with 100mM LiBr 
and quantified using a calibration curve generated from poly(ethylene glycol) (PEG) standards (400 – 
4000g/mol). The polymer composition was analyzed with 1H nuclear magnetic resonance spectroscopy 
(NMR, Bruker 400 MHz Spectrometer). 1H NMR chemical shifts were reported as δ values in ppm relative 
to the deuterated CDCl3 (δ = 7.26): δ = 1.60 (6H), δ = 2.72 (2H), δ = 2.84 (4H), δ = 3.59-3.78 (8H).  
 
PEG-MAL-PTK Macromer Synthesis 
 To improve the water-solubility of the synthesized EDDT-PTK polymer, a 4-arm PEG-MAL-PTK 
macromer was synthesized by combining thiolated PTK polymers with thiol-reactive PEG-MAL units. 
Briefly, 370mg of EDDT-PTK (8x molar equivalent) was added to a boiling flask and put under nitrogen. 
The PTK was dissolved in 25mL of anhydrous acetonitrile and then supplemented with 350μL of 
triethylamine (TEA) to deprotonate the polymer’s thiol groups and increase the efficiency of the Michael 
addition reaction with the maleimide groups on PEG-MAL[111]. 500mg of 10kDa four-arm PEG-MAL 
(1x molar equivalent) was dissolved in 60mL of anhydrous acetonitrile and then slowly added to the stirring 
PTK solution at room temperature and allowed to react for 16h. Following synthesis, acetonitrile was 
removed by rotary evaporation and the crude product was dissolved in a small amount of dichloromethane 
(DCM) and precipitated into -80°C diethyl ether to remove unreacted EDDT-PTK. The precipitant was 
spun down at 3000 × g, after which the ether was removed and the precipitant was collected and dried. The 
final molecular weight of the PEG-MAL-PTK macromer was determined by GPC, and the chemical 
composition was determined by 1H NMR in deuterated CDCl3. The thiol content of the PEG-MAL-PTK 
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was determined by Ellman’s assay to calculate the actual number of thiol groups per mass of polymer 
against the theoretical thiol content determined from GPC analysis of the macromer’s molecular weight.  
 
PEG-MAL Hydrogel Synthesis 
 Hydrogels formed from 10kDa 4-arm PEG-MAL macromers were fabricated by first separately 
pre-dissolving the PEG-MAL and respective thiolated crosslinking component (1:1 ratio of free thiols to 
maleimide groups) in phosphate buffered saline (PBS) supplemented with 4mM triethanolamine 
(TEOA)[93]. Three different thiolated crosslinkers were used in experiments: the synthesized PEG-MAL-
PTK macromer, a commercially-available 1000Da PEG dithiol (PEG-dt), and an enzymatically-degradable 
VPM peptide (molecular weight 1697g/mol)[93, 120]. The PEG-MAL and the thiolated component 
solutions were then combined and allowed to solidify for 15min, though gelation began immediately 
following component mixing. The polymer weight percent (wt%) of these hydrogels was also varied (7.5 
or 5 wt% in solution) to create hydrogels with different mechanical properties and swelling ratios.  
 
Physical Characterization of PEG-MAL Hydrogels 
 Mechanical properties of PEG-MAL hydrogels fabricated with PTK or PEG-dt crosslinkers at both 
7.5 and 5wt% were determined using parallel plate rheometry. Hydrogels were formed at a volume of 
200μL per gel using chambers of a 24-well plate as a mold and allowed to solidify for 15min; after 
hardening, the hydrogels were incubated in deionized water for 16h to fully swell. Gels were removed from 
the plate and then placed between stainless steel 25mm plates on an AR-G2 rheometer (TA Instruments, 
New Castle, DE) using a plate gap of 500 μm. The shear storage modulus (Gʹ) was determined over a 
frequency sweep from 0.1 to 10Hz at a strain of 1%. To determine the swelling ratio of PEG-MAL 
materials, 50μL hydrogels made at 7.5 and 5wt% from both PTK and PEG-dt crosslinkers were fabricated 
in the wells of 96-well plates, hardened for 15min, and then allowed to swell in deionized water for 16h. 
The incubating liquid was removed from each hydrogel before weighing each sample to determine the 
swollen wet weight. Gel samples were then frozen and lyophilized; the dried gel samples were weighed 
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again to determine the dry weight, with the ratio of wet weight to dry weight determining the swelling ratio 
values. This metric is given in Equation 2. 
𝐻𝑦𝑑𝑟𝑜𝑔𝑒𝑙 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑅𝑎𝑡𝑖𝑜 (𝑆𝑅)  =  
𝑊𝑒𝑖𝑔ℎ𝑡𝑊𝐸𝑇
𝑊𝑒𝑖𝑔ℎ𝑡𝐷𝑅𝑌
 
Equation 2. Swelling ratio determination for PEG-MAL hydrogels. 
 
In Vitro Degradation of PEG-MAL Hydrogels 
 50μL hydrogels made at 7.5 and 5wt% from both PTK and PEG-dt crosslinkers were fabricated 
and incubated in deionized water or varying concentrations of hydrogen peroxide (H2O2) with added cobalt 
chloride (CoCl2) to spur the generation of hydroxyl radicals[228]. Hydrogel samples were incubated in 1mL 
of 65mM H2O2 (1mM CoCl2), 25mM H2O2 (0.39mM CoCl2), 5mM H2O2 (77μM CoCl2), or deionized water 
with daily degradation media changes for up to seven days. Three independent gel samples per formulation 
were used for each time point. At each final time point, the degradation media was removed from each 
hydrogel sample before determining each sample’s wet and dry weights and subsequent swelling ratio 
value. To corroborate the swelling ratio data for hydrogel degradation, 200μL hydrogel samples were also 
fabricated and incubated in the same degradation media and characterized by rheometry as previously 
described. 
 
Cell Encapsulation in PEG-MAL Hydrogels 
 Hydrogel precursor components (PEG-MAL, PEG-dt, PEG-MAL-PTK, and VPM peptide) for 
50μL gels at both 7.5 and 5wt% were all dissolved in sterile PBS supplemented with 4mM TEOA. All 
components were dissolved at 2x their normal concentration for hydrogel formation to allow for the addition 
of RGD peptide and cell suspension solutions to give a final 50μL hydrogel volume. The PEG-MAL was 
reacted with cysteine-terminated RGD peptide (dissolved in sterile PBS) for 15min; to give a final RGD 
concentration of 2mM in each gel sample, 69μg of RGD (dissolved at 7mg/mL) was added per hydrogel. 
This RGD concentration theoretically consumes 9% and 14% of MAL groups in 7.5 and 5wt% gels, 
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respectively, and the complete reaction of these two groups had been previously validated using an Ellman’s 
assay to check for free thiols after component mixing. Next, minimally-passaged mouse MSCs seeded in 
cell culture flasks (less than 80% confluence) were trypsinized and concentrated to 7e6 cells/mL in order to 
minimize the liquid volume that must be added to the hydrogel precursor solutions. An aliquot of this cell 
suspension (enough to give 7e4 cells per 50μL gel) was then mixed with each thiolated component solution 
and added to its respective RGD-PEG-MAL solution in a 96-well plate and allowed to solidify in a cell 
culture incubator for 20min. After complete gelation was achieved, 200μL of cell culture medium 
comprised of DMEM with 1g/L glucose, 20% FBS, and 1% penicillin/streptomycin was added on top of 
each gel. The hydrogel-encapsulated cells were cultured for 72h with daily media changes. To evaluate the 
morphology and relative viability of encapsulated cells, the culture media was removed from the gels and 
they were washed three times with PBS before being stained with PBS containing 2μM calcein-AM and 
4μM ethidium homodimer for 40min. Hydrogels with live/dead stained cells were removed from their plate, 
sandwiched between glass coverslips, and then imaged with a Zeiss LSM 710 confocal microscope 
(Oberkochen, Germany) across multiple z-slices and represented with a maximum intensity projection 
across the z-planes. Finally, to quantify the overall number of viable cells encapsulated in all the hydrogel 
formulations after 72h of culture, 50μL gels with incorporated cells were incubated in 100μL PBS and 
treated with 100μL of CellTiter-Glo reagent for 10min while being vigorously disrupted with a pipette tip 
to ensure complete diffusion of the CellTiter-Glo throughout each gel sample. The luminescent signal per 
hydrogel sample, corresponding with the number of encapsulated viable cells, was then quantified with an 
IVIS Lumina III (Xenogen, Alameda, CA). 
 
In Vivo Degradation and Tissue Response of PEG-MAL Hydrogels Implanted Subcutaneously in Mice 
 50μL hydrogels made at 7.5wt% using PEG-MAL and the three thiolated crosslinkers (VPM peptide, 
PEG-dt, and PEG-MAL-PTK) were fabricated with a covalently conjugated fluorescent dye to allow for in 
vivo quantification of hydrogel persistence. The fluorescent probe MTS-CF640R, which features a 
methanethiosulfonate (MTS) group connected to the fluorescent molecule CF640R by a disulfide bond, 
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was dissolved in sterile water (2.5mg/mL) and incubated with TCEP disulfide reducing gel for 1h following 
the manufacturers protocol to cleave the disulfide-conjugated MTS group from the probe molecule. 
Following incubation, the dye/TCEP slurry was transferred to a centrifugal spin cup and centrifuged at 50 
× g for 1min to remove the dye solution from the TCEP gel. The slurry was re-suspended in sterile water 
and the centrifugation dye extraction was repeated 5x to remove the majority of the fluorescent probe from 
the TCEP gel. The disulfide-reduced CF640R dye was then frozen, lyophilized, and reconstituted in sterile 
PBS with 4mM TEOA. An Ellman’s assay was performed on the CF640R dye solution to confirm that free 
thiol group had been generated from the MTS disulfide reduction. 
 To prepare dye-conjugated hydrogels, the PEG-MAL component was dissolved at 4x the normal 
concentration in sterile PBS with 4mM TEOA for gel fabrication. Next, CF640R dye (0.75mg/mL to create 
a final dye concentration of 85μM dye per 50μL hydrogel sample) was mixed with the PEG-MAL solutions 
and allowed to react for 15min. As previously described, dissolved RGD (2mM RGD per 50μL gel) then 
was added to the CF640R/PEG-MAL solution and reacted for an additional 15min. Finally, each thiolated 
crosslinker was dissolved in sterile PBS with 4mM TEOA and added to its respective RGD/CF640R/PEG-
MAL solution in the chambers of a 96-well plate and allowed to solidify for 20min. Once the dye-
conjugated hydrogels were successfully fabricated, they were removed from the plate and implanted 
subcutaneously in male BALB/c mice (n=6 mice, overall n=8 individual gels per formulation). Following 
implantation, the mice were imaged with an IVIS system using 620/670 emission/excitation for a baseline 
measurement of hydrogel fluorescence and subsequently imaged over time. Half the mouse cohort was 
euthanized at 15 post-surgery while the other half were euthanized at day 35.  
 
Statistical Analysis 
 All data are reported as the mean and standard error of the mean unless otherwise indicated. 
Statistical analysis was performed using Student’s t-test for single comparisons or single factor analysis of 
variance (ANOVA) and Tukey post-hoc tests for multiple comparisons. P-values less than 0.05 were 
considered statistically significant. 
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5.3 Results 
EDDT-PTK and PEG-MAL-PTK Synthesis and Characterization 
 An EDDT-PTK dithiol polymer was successfully synthesized from the condensation 
polymerization of EDDT and DMP using a PTSA catalyst (Figure 19) and characterized by GPC and NMR 
as shown in Figure 20 and Table 3. Following purification, the EDDT-PTK dithiol polymer was combined 
with a thiol-reactive 10kDa 4-arm PEG-MAL to conjugate PTK polymers onto each arm of the branched 
PEG as demonstrated in Figure 19. The final product was purified and then characterized by GPC and NMR 
(Figure 20 and Table 3). GPC chromatograms indicate an increase in molecular weight for the PEG-MAL-
PTK compared to the parent PEG-MAL, and NMR spectra of both the precursor components and the final 
product further confirm successful conjugation as both EDDT-PTK and PEG-MAL characteristic peaks are 
present in the PEG-MAL-PTK spectra (Figure 20). GPC quantification of these polymers’ number average 
molecular weights (Mn, g/mol) strongly agree with theoretical values (Table 3), and Ellman’s assay 
quantification of the thiol content of the final PEG-MAL-PTK product further indicates that a 4-arm 
tetrathiol macromer was produced.  
 
Figure 19. Synthesis schemes for the EDDT-PTK dithiol polymer and the PEG-MAL-PTK macromer. 
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Physical Characterization of PEG-MAL Hydrogels  
 Hydrogels made from PEG-MAL and either a 1000Da PEG dithiol polymer (PEG-dt) or the PEG-
MAL-PTK macromer were fabricated at both 7.5 and 5wt%. The swelling ratio of hydrogel samples was 
evaluated from the ratio of each gel’s water-swollen weight divided by the weight of only the dried solid 
components (Equation 2). The 5wt% hydrogel samples were significantly more swollen than 7.5wt% gels 
for both formulations (Figure A18A), though PTK-based gels were less swollen than hydrogels made with 
PEG-dt. The mechanical properties of PEG-dt and PTK hydrogel formulations at both 7.5 and 5wt% were 
also measured by rheometry. Taken from a frequency sweep of the storage modulus Gʹ, the stiffness of 
7.5wt% PEG-dt gels was nearly 1000Pa while 7.5wt% PTK gels were closer to 700Pa (Figure A18B). The 
lower wt% samples had correspondingly lower modulus values with 5wt% PEG-dt gels around 500Pa and 
5wt% PTK gels near 300Pa as shown in Figure A18C. 
 
 
 
 
Figure 20. Polymer characterization by GPC and NMR. (A) GPC chromatograms indicating a shift towards higher 
molecular weight with PTK conjugation to PEG-MAL. (B) NMR spectra of PEG-MAL-PTK shows the appearance 
of characteristic peaks from both PTK and PEG-MAL polymers, indicating successful conjugation. 
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In Vitro Degradation of PEG-MAL Hydrogels under Oxidative and Non-Oxidative Conditions 
 PEG-MAL hydrogels made with PEG-dt or PEG-MAL-PTK crosslinkers at both 7.5 and 5wt% 
were incubated in media containing different concentrations of ROS to assess in vitro degradation of these 
materials. Gel samples were treated with either deionized water, 5mM H2O2 with 77μM CoCl2, 25mM H2O2 
with 0.39mM CoCl2, or 65mM H2O2 with 1mM CoCl2 for up to seven days and then weighed (wet and dry) 
to assess their swelling ratios as an indicator of degradation[67]. As shown in Figure 21, both 7.5 and 5wt% 
PTK-based hydrogels have significantly greater swelling after treatment with varying doses of the H2O2 
compared to H2O2-treated samples made with the PEG-dt crosslinker. PTK gels in 65mM H2O2 were only 
taken out to day 3 as samples incubated for longer times were completely degraded past this time point. 
Hydrogel samples made with PEG-dt were also minimally susceptible to ROS-mediated degradation as 
samples incubated in the 25mM H2O2 did have increased swelling ratio values at day 7 compared to samples 
incubated in water. Additionally, PTK gels at both 7.5 and 5wt% display dose-responsive degradation as 
their swelling ratios increase at a faster rate in higher concentrations of H2O2, though 5wt% samples were 
minimally responsive at the lowest 5mM H2O2 concentration compared to PEG-dt samples. To confirm 
these degradation results seen with swelling ratio assessment, hydrogels made with both crosslinkers at 7.5 
and 5wt% were incubated in the 65mM H2O2 media for three days and then characterized by rheometry. 
Both PEG-dt and PTK gel samples had decreased Gʹ values after incubation with the ROS media compared 
to day 0 values (Figure A18B-C), but PTK samples had a more substantial decrease in modulus values and 
mechanical integrity. 
Table 3. Polymer characterization values. 
Polymer Theoretical Mn GPC Mn Thiol Content Mn 
EDDT-PTK 850 875 - 
10kDa PEG-MAL 11000 10595 - 
PEG-MAL-PTK 14400 15890 14000 
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Figure 21. In vitro degradation of PEG-MAL hydrogels formed with PEG-dt or PTK crosslinkers. As assessed by the 
gel swelling ratio, (A) 7.5wt% PTK hydrogel samples display significantly more dose-responsive H2O2 degradation 
compared to PEG-dt hydrogels. (B) 5wt% PTK hydrogels also degrade in response to H2O2 levels but are not 
significantly different at 5mM unlike 7.5wt% samples. *65mM H2O2, #25mM H2O2, $5mM H2O2 denotes p<0.05 
significance for PEG-dt vs. PTK comparison, n=3 samples per treatment. 
 
Encapsulation and Cytocompatibility of MSCs in PEG-MAL Hydrogels 
 Mouse mesenchymal stem cells (mMSCs) were encapsulated in 7.5 and 5wt% PEG-MAL 
hydrogels made with either PEG-dt, PEG-MAL-PTK, or VPM peptide crosslinkers and cultured for three 
days. All hydrogels were also covalently tethered with 2mM RGD adhesive peptide to encourage cell 
attachment to the materials. As shown in Figure 22A, maximum intensity projections of multiple z-slices 
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from fluorescent confocal microscopy demonstrate that mMSCs were successfully encapsulated into the 
different hydrogel formulations and maintained their viability over three days in culture as indicated by 
characteristic calcein-AM green staining. Furthermore, the encapsulated mMSCs were evenly distributed 
in the 3D matrix and demonstrated significant spreading in all the different hydrogel formulations. In 
particular, cells in the 5wt% VPM and PTK hydrogels demonstrate high levels of cell spreading compared 
to the other gel formulations, and this finding is validated in a whole-sample measurement of viable cell 
number as shown in Figure 22B. The 5wt% VPM and PTK hydrogels contain a significantly higher number 
of viable cells than 5wt% PEG-dt samples, even as the 5wt% PTK hydrogels also contain a significantly 
higher number of cells than the gel samples featuring the well-validated VPM crosslinking peptide (Figure 
22B). The 7.5wt% formulations had statistically similar numbers of viable mMSCs encapsulated as shown 
in Figure 22B. 
 
 
Figure 22. Mouse MSCs encapsulated in both 7.5 and 5wt% PEG-MAL hydrogels (A) maintain a high level of 
viability and cell spreading as assessed by live/dead staining, though spreading is particularly enhanced in 5wt% 
samples made with degradable VPM and PTK crosslinkers. (B) Quantification of total viable cell number per gel 
sample, as assessed through a CellTiter-Glo luminescent readout, indicates that cell viability is not significantly 
different between formulations at 7.5wt%. But, 5wt% VPM gels have significantly more viable cells than PEG-dt gels 
while 5wt% PTK gels have significantly more viable cells than both 5wt% VPM and PEG-dt samples. N=3 samples 
per formulation, *p<0.05. 
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In Vivo Degradation of PEG-MAL Hydrogels in Mouse Subcutaneous Implants 
4-arm PEG-MAL polymers were pre-labeled with a thiol-terminated CF640R fluorescent dye and an 
RGD adhesive peptide and then used to fabricate 7.5wt% hydrogels made with PEG-dt, PEG-MAL-PTK, 
and VPM peptide crosslinkers. The fluorescently-labeled hydrogels were then implanted into ventral 
subcutaneous pockets in male BALB/c mice; the hydrogel-associated fluorescent signal from each 
implanted sample was measured at day 0 using an IVIS imaging system to obtain baseline gel signal values 
and then quantified over time to determine material retention at the implantation site. As shown in Figure 
23, both the PEG-dt and PTK hydrogels have significantly less fluorescent signal than the VPM samples 
over the first few days following implantation. However, the PEG-dt and VPM gel signals converge 
following this initial stage and are statistically equivalent for the remainder of the time course. The PTK 
hydrogels continue a relatively steady decrease in their fluorescent signal over time and have statistically 
lower values than both PEG-dt and VPM implants after day 11 until day 35. 
 
Figure 23. In vivo degradation of fluorescently-labeled PEG-MAL hydrogels. Degradation of PTK gels is significantly 
faster than VPM gels across all time points tested (*p<0.05) and is also significantly faster than PEG-dt gel degradation 
after 11 days (#p<0.05). The PEG-dt gels degrade significantly faster than VPM gels initially ($p<0.05) but are 
statistically equal after 4 days of implantation. N=8 samples until day 15, n=4 samples afterwards. 
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5.4 Discussion 
Injectable, in situ-forming PEG-based hydrogels represent an extremely promising class of synthetic 
biomaterial due to their minimally-invasive delivery, ease of functionalization, and inherent 
biocompatibility[88]. Injectable hydrogels formed from PEG-MAL macromers are particularly exciting due 
to their high gelation efficiency and amenability for in vivo cell and drug delivery. Like many injectable 
hydrogels, current PEG-MAL gels derive their biodegradability from the incorporation of enzymatically-
degradable peptide cross-linkers into their covalent network[93, 94]. While these hydrogels and other 
similar materials achieve cell-mediated biodegradation[115, 120, 269], the expenses of synthesizing 
peptides in quantities large enough to create large-scale tissue engineering materials will most likely limit 
these materials’ clinical usefulness[37, 38]. Therefore, creating a cost-effective, synthetic, cell-degradable 
crosslinker to replace peptides in the formation of PEG-MAL hydrogels would greatly enhance the 
translatability of these materials. To this end, we have synthesized water-soluble PTK polymers that are 
easily synthesized, feature terminal thiol end-chemistries, and successfully couple with PEG-MAL units to 
form covalently-linked networks. Previous work has demonstrated synthetic PTK polymers’ potential for 
creating cell-degradable materials[30, 45, 124, 177, 178, 268]; these novel PEG-MAL-PTK materials 
represent the first development of a covalently-tethered hydrogel that is specifically degraded by cell-
generated ROS while maintaining the benefits of previous PEG-MAL gels. 
Initial efforts in trying to synthesize a water-soluble PTK polymer were pursued using the same 
previously utilized condensation polymerization schemes for PTK synthesis[45] but utilizing more 
hydrophilic ethylene glycol (EG)-based dithiol monomers to increase the water-solubility of the final 
polymer (Figure A19). Dithiol monomers featuring 1, 2, 5, and 12 EG units were first used in attempts to 
synthesize water-soluble PTK polymers, with only the 12-EG dithiol monomer (600g/mol) yielding a 
polymer that dissolved in aqueous solutions. However, the 12-EG-PTK polymer also did not possess 
appropriate thiol end groups and only had a polymerization degree of two, yielding a polymer that did not 
form hydrogels with PEG-MAL, featured an inefficient condensation reaction, and was very difficult to 
purify due to the relatively small difference in monomer and polymer molecular weight. Interestingly, the 
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1 and 2-EG dithiol monomers both polymerized effectively (polymerization degrees > 3), potentially 
signifying that the PTK condensation polymerization under these reaction conditions is most effective using 
relatively small (<200g/mol) dithiol monomers. Unfortunately, PTK polymers made from 1 and 2-EG 
monomers were both hydrophobic; since the 2-EG dithiol monomer (EDDT) is more hydrophilic than the 
1-EG monomer, EDDT-PTK polymers were pursued in the further fabrication of water-soluble PEG-MAL-
PTK macromers as outlined in Figure 19.  
To encourage a fast conjugation of EDDT-PTK polymers to PEG-MAL units while limiting 
uncontrolled crosslinking of multiple PEG-MAL groups, three strategic aspects were incorporated into the 
synthesis of PEG-MAL-PTK macromers: using an eight-fold molar excess of PTK to PEG-MAL (two-fold 
molar excess of EDDT-PTK polymers to each maleimide-terminated arm of the PEG macromer), diluting 
the concentration of PEG-MAL compared to the more highly concentrated PTK, and using a slow, drop-
wise addition to apply PEG-MAL to the PTK solution. These synthetic protocol features were all designed 
to quickly react single thiol groups on different EDDT-PTK polymers with the four arms of more dilute 
PEG-MAL, thereby rapidly consuming all the available maleimide groups on single PEG-MAL units 
(Figure 20A). This approach spares the thiol group on the unconjugated end of each attached PTK polymer, 
generating a four-arm PEG-MAL-PTK macromer with terminal sulfhydryl groups (Table 3) that are free to 
participate in future thiol-ene reactions. The large hydrophilic PEG component of the macromer (10,000Da 
PEG vs. 3400Da PTK) pushes the entire polymer into aqueous solubility despite the hydrophobic PTK 
content and makes the water-soluble PEG-MAL-PTK tetrathiol amenable to hydrogel formation. Moreover, 
any excess EDDT-PTK is easily purified from the hydrophilic PEG-MAL-PTK macromer by precipitation 
of the macromer into diethyl ether (Figure 20A). 
Hydrogels fabricated using the PEG-MAL-PTK macromers were directly compared against control 
hydrogels made with the same PEG-MAL but utilizing a commercially-available 1000Da PEG dithiol 
(PEG-dt) to determine these materials’ physical attributes and degradation properties in vitro. The PEG-dt 
features the same ethylene glycol units that comprise most of the EDDT-PTK’s polymeric backbone but 
does not contain the ROS-sensitive thioketal moiety. Unsurprisingly due to the decreased crosslink density, 
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it was found that 5wt% hydrogels were significantly more swollen than 7.5wt% samples for both 
formulations (Figure A18A). However, PTK-crosslinked hydrogels were also less swollen than PEG-dt 
samples at both 7.5 and 5wt% (Figure A18A) most likely due to the incorporation of the hydrophobic 
EDDT-PTK component into the hydrogel’s 3D matrix. Rheometry of both PTK and PEG-dt hydrogels 
revealed a similar trend as the PTK materials had decreased modulus values compared to PEG-dt gels. Both 
hydrogel formulations experienced a roughly 2x decrease in stiffness values when decreasing from 7.5 to 
5wt%, displaying the mechanical tunability of this biomaterial system. Moreover, assuming the Poisson’s 
ratio of these hydrogels is around 0.5, the Elastic modulus of these hydrogels is approximately three times 
higher than the Gʹ storage modulus[270]. Given that these hydrogels range between 1000 and 300Pa for Gʹ 
values, it can be assumed these materials have Elastic moduli values between 1-3kPa, well in line with 
previously cited PEG hydrogel systems used for cell delivery[93, 271].  
When placed in degradation media containing H2O2 and hydroxyl radical-generating CoCl2, it was 
found that the swelling ratio of PTK hydrogels significantly increased compared to the PEG-dt samples at 
both 7.5 and 5wt% as displayed in Figure 21. Both PEG-dt and PTK hydrogels incubated in water over the 
same time frame were also unchanged over the same time period, signifying the selective ROS-mediated 
degradation of thioketal bonds in the PTK crosslinks and the overall breakdown of these samples as seen 
in other thioketal-based biomaterials[177, 268]. These hydrogel degradation data were also confirmed by 
rheometric mechanical testing of gel samples incubated in 65mM H2O2 for three days (Figure A18B-C). In 
agreement with swelling ratio degradation data (Figure 21), PTK hydrogels had decreased Gʹ values 
compared to PEG-dt samples as demonstrated in Figure A18B-C. Though to a significantly lesser degree 
than seen in the PTK hydrogels, the PEG-dt samples were also somewhat sensitive to the ROS media 
compared to water (Figure 21, Figure A18B-C), potentially indicating ROS-mediated degradation of ether 
bonds in the PEG-dt crosslinker or the PEG-MAL macromer. Ether bonds have well known susceptibility 
to ROS, particularly hydroxyl radicals[228], though the ROS-mediated degradation of thioketal groups is 
significantly faster than covalent ether bond cleavage in biomaterials[30]. However, these data further 
indicate that the PEG-dt crosslinked hydrogels, and PEG-based materials in general[272], should be 
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considered “minimally-degradable” as opposed to “non-degradable” due to ether bond sensitivity to ROS 
over longer time-frames. 
Injectable PEG hydrogels are particularly useful as cell-delivery vehicles due to a number of factors, 
but chiefly in situ gelation which encapsulates and protects cells after deployment of the hydrogel solution. 
Furthermore, PEG’s lack of protein adsorption[90] means that these materials can be specifically 
functionalized with chemical motifs to affect the behavior of encapsulated cells. In particular, RGD-based 
peptides are particularly effective at promoting cell viability and spreading within PEG hydrogels[92, 273]. 
As a proof of concept, mouse MSCs were encapsulated in RGD-containing 7.5 and 5wt% PEG-MAL 
hydrogels made with PEG-dt, PEG-MAL-PTK, and VPM peptide crosslinkers and cultured for 72h. PEG-
MAL hydrogels made with RGD and VPM crosslinkers are non-cytotoxic and promote robust cellular 
attachment[93, 94], making these materials a benchmark for cellular encapsulation applications. MSCs 
embedded in 7.5wt% gel samples achieved statistically similar viability levels across all three hydrogel 
formulations (Figure 22B), and roughly similar levels of cell spreading as qualitatively assessed from 
fluorescent microscopy images in Figure 22A. However, MSCs encapsulated in 5wt% PTK hydrogels had 
a significantly higher signal from viable cells than both 5wt% VPM and PEG-dt samples, while the VPM 
cell signal was also significantly higher than PEG-dt (Figure 22B). These results are reflected in the 
microscopy images in Figure 22A as the encapsulated cells in 5wt% VPM and PTK gels were notably more 
spread through the hydrogel matrix compared to cells in 5wt% PEG-dt samples. These collective data, in 
accordance with previous reports[93], indicate that the higher crosslinking density of 7.5wt% hydrogels 
limits spreading and expansion of encapsulated MSCs, while lower wt% hydrogels with a degradable 
crosslinker (VPM or PTK) allow for greater cellular trafficking through the matrix compared to the 
minimally degradable PEG-dt samples. The higher viable cell signal seen in 5wt% PTK hydrogels 
compared to the corresponding VPM samples further justifies the usage of these novel, ROS-degradable 
materials for cell delivery applications due to their enhanced cellular performance compared to a “gold-
standard” biomaterial. 
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Fluorescently-labeled biomaterials have been previously used for the longitudinal evaluation of in vivo 
hydrogel degradation[274-276], and this strategy was employed here to track the degradation of 7.5wt% 
PEG-MAL gels made with the three previously utilized crosslinking groups.  Instead of labeling the RGD 
peptide or thiolated crosslinker, the PEG-MAL was pre-conjugated with a thiol-terminated fluorescent 
probe to collect the most accurate determination of hydrogel degradation since the PEG-MAL component 
makes up the majority of the gel and the multi-armed PEG more effectively integrates the probe into the 
bulk of the hydrogel. All three fluorescently-labeled hydrogel formulations implanted subcutaneously in 
mice had decreased signals over time as seen in Figure 23, though the PTK hydrogels had significantly 
lower signal compared to VPM samples across the entire time course and also had significantly lower values 
compared to PEG-dt gels after day 11. Though some of the early decrease in the fluorescent hydrogel signal 
is likely due to loss of poorly conjugated dye, the PTK hydrogels lose their fluorescent signal at a faster 
rate than PEG-dt or VPM samples even after the initial burst of signal reduction. These data indicate that 
PTK hydrogels undergo more substantial in vivo degradation than MMP-degradable peptides, suggesting 
that targeting cell-generated ROS as a mediator of in vivo biomaterial breakdown could be a more effective 
strategy than utilizing protease-degradable systems. 
 
5.5 Conclusion 
We have successfully developed a PEG-based hydrogel that is crosslinked with ROS-degradable PTK 
polymers. These are the first reported hydrogels to feature water-soluble PTK macromers, with these novel, 
easily-synthesized hydrophilic PTK units possessing terminal thiol groups that allow for covalent bonding 
with maleimide-capped, multi-armed PEG molecules for hydrogel fabrication. PTK hydrogels are 
mechanically robust and undergo ROS-mediated, dose dependent degradation in vitro, while PEG 
hydrogels without PTK units are only minimally affected by ROS. Furthermore, mesenchymal stem cells 
were successfully encapsulated in PTK hydrogels and maintained their viability in 7.5wt% gels at 
comparable levels to cells encapsulated in benchmark hydrogels crosslinked with an enzymatically-
degradable peptide. However, MSCs encapsulated in less tightly bound 5wt% hydrogels maintained 
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significantly more viable cells in PTK gels than peptide-linked materials, indicating that PTK hydrogels 
perform better as cell delivery vehicles than enzymatically-degradable materials. Finally, fluorescently-
labeled PTK hydrogels subcutaneously implanted in mice underwent significantly faster degradation in vivo 
compared to minimally-degradable PEG gels or enzymatically-degradable hydrogel implants. These in vivo 
data demonstrate that PTK hydrogels undergo significant degradation following implantation and that ROS 
could be a more potent cell-generated signal for triggering material degradation than conventionally-used 
enzymatic activity.  Together, these results represent a paradigm shift in the creation of biodegradable 
hydrogels due to the enhanced performance of ROS-degradable PTK hydrogels in comparison to 
conventional benchmark materials, and further motivates the continued exploration of these novel materials 
for clinically-translatable applications. 
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CHAPTER 6 
 
Synopsis and Future Directions 
 
6.1 Summary 
With the increasing prevalence of diabetes and the corresponding increase in non-healing wounds 
arising from diabetic complications, there is a growing need for therapies that correct and treat these chronic 
wound pathologies. Biodegradable implants that enhance the local healing response while also serving as 
a depot for sustained, localized drug delivery could help improve outcomes for patients with these persistent 
lesions. However, currently developed materials that undergo in vivo biodegradation can suffer from a 
number of shortcomings, including material degradation kinetics that are misaligned with tissue 
regeneration rates and prohibitively expensive material components that limit economic feasibility of the 
implants in the clinic. Cheaply-synthesized poly(thioketal) (PTK) polymers that are biocompatible and 
specifically degraded by cell-generated reactive oxygen species (ROS) address these concerns and represent 
a promising material platform for fabricating new classes of biomaterials. These studies set out to develop 
PTK-based biomaterials in both hydrophobic and hydrophilic formats, and demonstrated the utility of these 
novel materials as therapeutic delivery vehicles that can enhance wound healing. 
In Aim 1, a family of PTK polymers was synthesized by condensation polymerization and incorporated 
into PTK-urethane (PTK-UR) scaffolds. These PTK-UR materials were compared against conventional, 
heavily investigated poly(ester-urethane) scaffolds and were found to have similar cytotoxicity profiles. 
However, PTK-URs were more mechanically robust despite having a lower crosslink density than PEURs 
and were completely inert to hydrolytic degradation unlike the ester-containing PEUR materials. Moreover, 
PTK-UR scaffolds were significantly degraded by ROS in a dose-dependent fashion, demonstrating the 
ROS-specific degradation mechanism of these new scaffold materials. 
In Aim 2, PTK-UR scaffolds were utilized in a number of animal models to determine their in vivo 
degradability and potential as drug delivery vehicles. PTK-URs underwent controlled, 1st-order 
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degradation kinetics when implanted subcutaneously in rats while PEUR scaffolds experienced accelerated, 
autocatalytic degradation over the same time period. PTK-UR scaffolds also promoted more robust tissue 
regeneration than benchmark PEURs when implanted in excisional diabetic rat wounds. Additionally, PTK-
UR scaffolds were able to load nanoparticles carrying small interfering RNA (siRNA) and release this drug 
payload in vivo to silence the expression of the angiogenesis regulator prolyl hydroxylase domain protein 
2 (PHD2). The reduction in PHD2 activity led to an increase in blood vessel formation, cell proliferation, 
and overall wound healing in these diabetic wounds. 
Aim 3 sought to take PTK polymer chemistry and apply it for the fabrication of hydrogels. Hydrophobic 
PTK polymers were combined with a maleimide-terminated, 4-arm poly(ethylene glycol) (PEG-MAL) 
molecule to create water-soluble PEG-MAL-PTK macromers. These novel, hydrophilic PTKs were then 
formulated with additional PEG-MAL polymers to form robust PTK hydrogels that were selectively 
degraded by ROS. These PTK hydrogels better maintained viable mesenchymal stem cells than benchmark 
peptide-crosslinked gels in in vitro culture, and PTK-based gels also underwent significantly faster in vivo 
degradation in subcutaneous mouse wounds than the enzymatically-degradable peptide hydrogels.  
Together, these results show that synthetic PTK polymers can be easily fabricated into a number of 
biomaterial platforms that are amenable to both cell and drug delivery to serve as regenerative constructs 
for the treatment of chronic wounds. 
 
6.2 Concerns and limitations 
Though the biomaterials developed in these studies were tested for cytotoxicity and in vivo 
biocompatibility in rodent models, it is important to note that evaluating the immune response to PTK-
based materials implanted over long periods of time presents major considerations for the clinical 
translation of PTK biomaterials in wound healing applications. It is anticipated that these potential hurdles 
can be overcome with proper in vitro screening efforts and appropriate use of preclinical animal models. 
Though PTK-UR scaffolds implanted in either subcutaneous or excisional wounds in rats did not elicit 
any obvious deleterious immune responses as assessed by histology (Figure 13, Figure 15), it is well 
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understood that rodent skin wounds poorly model wounds in human patients[277]. As such, the favorable 
biological response to these implants in rodents could be drastically different in actual patients. To address 
these concerns, we have recently begun studies to evaluate the in vivo tissue response to implanted PTK-
UR scaffolds in a novel model of impaired wound healing in pigs (see section 6.4 and Figure A21). Pig 
skin wounds are more similar to those seen in humans and are considered the “gold-standard” preclinical 
model for wound healing evaluation. As seen in trichrome histology images, PTK-UR implants made with 
either LTI or HDIt isocyanate chemistries have robust granulation tissue formation at day 10 and appear to 
be healing similarly to implants in excisional rat wounds (Figure A23A). However, at day 28 post surgery 
the scaffold remnants seem to have elicited an abnormal healing response as indicated by the bright-red, 
cell-dense patches of tissue that are selectively surrounding some scaffold sections. Interestingly, this 
response does not uniformly surround all scaffold remnants equally but seems to be associated with pieces 
that are deeper in the wound bed. Furthermore, this response does not seem to have hampered the formation 
of new collagen networks (green staining) in the scaffold interior or hampered re-epithelialization so it is 
difficult to say what impact this unusual tissue response is having on overall wound healing.  
Initial efforts to characterize the cellular immune response to these implants through IHC demonstrated 
that the scaffold remnants are directly covered with CD206+ cells (Figure A23B), indicating that the cells 
primarily interacting with the implanted materials are M2-polarized macrophages which have a more 
reparative phenotype[278]. However, the cell-dense areas corresponding with the unusual tissue response 
are positively stained for iNOS (Figure A23B), a marker of M1-polarized macrophages which are 
considered more pro-inflammatory[279]. These very preliminary data potentially indicate that the PTK-UR 
implants are encouraging immune activation and inflammation, though this effect does not seem to be 
hindering overall healing of the wound site. Since this possibly inflammatory tissue response only appears 
at day 28 but was not seen at day 10, it could indicate that PTK-UR scaffolds themselves do not elicit an 
immune response but that the degradation products (only present in substantial concentrations at later time-
points after material degradation) could be pro-inflammatory. Though more analysis is needed before 
drawing final conclusions, these data signify the importance of testing not only biodegradable materials 
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themselves for cytotoxicity and immune activation, but also their degradation products. They also 
demonstrate the importance of using advanced animal models for preclinical material evaluation. Therefore, 
future preclinical studies with PTK-based materials will also evaluate inflammatory capacity of material 
degradation products both in vitro and in vivo using rodent and porcine models. 
A final concern to evaluate is the choice of isocyanate used in the fabrication of PTK-UR and PEUR 
scaffolds. It has been previously shown that LTI and HDIt evoke drastically different degradation profiles 
in vitro[76] (Figure 12), but these materials also elicit different responses upon in vivo implantation. As 
shown in Figure A16, PHD2 siNP-loaded PTK-UR scaffolds made with HDIt and implanted into diabetic 
excisional rat wounds were able to significantly decrease PHD2 expression as evaluated by qRT-PCR, 
similar to results seen with LTI-based PTK-UR scaffolds. However, histological evaluation of PTK-UR 
(HDIt) implants reveals that these scaffolds are much less integrated with the native tissue than LTI-based 
implants in excisional wounds (Figure A16). A similar difference in tissue infiltration between LTI and 
HDIt scaffolds was also seen in mice in previous work[28]. Interestingly, PTK-UR (HDIt) scaffolds 
implanted subcutaneously in rats (Figure 13) behaved very similarly to PTK-UR (LTI) scaffolds in the 
same wound model (Figure A10) over a 7-day time period by demonstrating very minimal infiltration. 
Therefore, it appears that LTI-based scaffolds elicit a more favorable tissue response in the more severe 
excisional wound model than HDIt scaffolds, whereas both scaffolds perform equally as well in the less-
compromised subcutaneous model. This effect also seems to be apparent in the preliminary porcine wound 
healing data, with LTI-based PTK-UR scaffolds hosting more tissue infiltration and integration than 
analogous HDIt implants as demonstrated in Figure A23A. Though HDIt-based scaffolds might feature 
prolonged degradation times compared to LTI materials, its clinical usage could be limited by its reduced 
cellular adhesion properties and diminished cytocompatibility. 
 
6.3 Broader impacts 
Ongoing work discussed in section 6.4 outlines the application of PTK-UR scaffolds in a large animal 
model for wound healing studies. Successful outcomes from these tests may provide opportunities for 
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applying these materials in clinical trials either as a stand-alone scaffold material or as a drug delivery 
platform. The chronic wound healing market is estimated at $25B, and coupled with the rising number of 
diabetic patients and increased healthcare costs, there exists a great clinical need for therapies that improve 
wound healing. To date there is only a single siRNA/biomaterial platform in clinical trials for a wound 
healing application[192], indicating that there is both tremendous room for product growth in bioactive 
wound healing but also lingering hesitation by the pharmaceutical industry to invest in siRNA technologies. 
Conversely, the employment of stand-alone, biodegradable scaffold materials that improve wound healing 
without the use of a therapeutic agent would likely have a lower regulatory burden and could potentially 
find an easier path to market. PTK-UR formulations are protected by a recently approved US patent[280], 
and procurement of this technology through commercial licensing or acquisition could represent a viable 
strategy for clinical implementation of this biomaterial system. 
As PTK-based hydrogels are in earlier stages of development, their horizon for clinical use is on a much 
longer trajectory. Also, these materials were designed as cell delivery vehicles; the use of allogenic or even 
autologous cells in patients is notoriously difficult to clear through regulators[192], thus making PTK 
hydrogels less commercially exciting for cell implantation applications. However, the facile chemistry of 
the water-soluble PEG-MAL-PTK macromers makes these materials easily transferred to any number of 
PEG hydrogel technologies. This translational potential of water-soluble PTK polymers is also aided by the 
high cost of enzymatically-degradable peptides. As companies look for hydrophilic materials that are 
specifically degraded by cellular activity, cheap and easily scalable PTK polymers could represent a 
promising candidate for commercialization. 
 
6.4 Future work 
The long-term goal of this work is to deploy therapeutic-laded tissue engineering materials into non-
healing skin wounds to improve their healing outcomes. Initial efforts to delivery siRNA against PHD2 
from PTK-UR scaffolds in diabetic rats were successful in improving blood vessel formation and overall 
wound healing as outlined in Chapter 4. However, siRNA-mediated silencing of PHD2 only lasted for 4 
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days post scaffold implantation due to the fast rate of tissue growth and the high dose of excipient that 
ensured a relatively quick rate of the siRNA. Future work will look to modify the siRNA release rate from 
the scaffolds using different excipients while also utilizing a more severe rodent wound healing model [281] 
that will decrease the rate of healing to make it more representative of chronic wound. Preliminary work 
has gone into developing this impaired rat skin wound healing model using a bipedicle ischemic flap as 
seen in Figure 43. Furthermore, recent work has highlighted additional molecular targets that modulate 
HIF-1α, providing new therapeutic strategies which can be incorporated into these local drug delivery 
systems. Work from the Matsui lab has demonstrated that intracellular oxidation can modify HIF-1α with 
glutathione units to stabilize the protein by preventing the binding of HIF-1α with the degradative von 
Hippel-Lindau protein[282]. These glutathione adducts are removed by glutaredoxin-1 (Glrx), thus making 
Glrx a potent regulator of HIF-1α activity separate from the classical PHD2 regulatory pathway and a 
potential siRNA target. Future work will explore the use of PHD2 and Glrx siRNA delivered separately 
and in tandem from implanted scaffolds to assess their relative potency for HIF-1α stabilization and any 
possible synergism between the two drug targets for improving wound healing outcomes.  
For longer-term goals with PTK-UR scaffolds for local siRNA delivery, many efforts are underway to 
modify the siRNA delivery system to limit or eliminate the polymeric component needed to achieve 
intracellular siRNA distribution. Cationic polymer systems have well known toxicity issues due to their 
positive charge, and limiting the amount of polymer necessary for siRNA delivery will not only improve 
the effectiveness of these systems but also improve the clinical translatability of these technologies. Our 
lab is exploring the usage of hydrophobic tethers covalently attached to siRNA molecules to reduce the 
amount of nanoparticle-forming polymer necessary for effective payload delivery, and continuing work is 
underway to try and completely eliminate the need for cationic polymers as siRNA delivery vehicles. 
Efforts are also underway to develop an impaired skin wound model in pigs using bipedicle skin flaps 
Figure 44. Like the similar model developed in our lab for rats (Figure 43), this porcine model has shown 
impaired blood flow and a slowed healing rate compared to non-ischemic skin (Figure 45). Since skin 
wounds in pigs are the gold-standard for pre-clinical wound healing studies, the long-term goal of this work 
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is to implant our lead-candidate siRNA-containing PTK-UR scaffold formulation in these wounds 
following the guidance of the additional rat studies. It is anticipated that positive wound healing results in 
a large-scale, impaired wound healing model in pigs using our technology will effectively position this 
work for an easy transition into initial clinical trials.  
Finally, additional work with PTK hydrogels will first complete additional in vitro studies to explore 
the ability for gel-encapsulated cells to maintain their viability without the presence of adhesive RGD 
peptides in the hydrogel networks. Since the PTK hydrogels are more hydrophobic than the other 
formulations, it is anticipated these new gel formulations could naturally adsorb adhesive proteins, thus 
completely eliminating the need for external incorporation of adhesive moieties. Next, the effect of gel 
weight % on in vivo material degradation in mice will be evaluated before delivering hydrogel-encapsulated 
MSCs in vivo. These studies will utilize the best-performing hydrogel formulations with a luciferase-
expressing MSC cell line to non-invasively measure cell viability after in vivo implantation into wounds to 
assess cell survival over time. If these efforts prove successful, the long-term goals of this project involve 
tether siRNA into the hydrogel to transfect encapsulated MSCs and promote their proliferation to further 
enhance the wound healing potential of these cell/hydrogel materials. 
 
6.5 Conclusion 
The development of materials that are biocompatible, specifically degrade in the presence of cell-
generated ROS, and can be affordably-synthesized in large scales presents a paradigm-shifting new 
technology in the biomaterials field. These multi-purpose materials represent an exciting new advance in 
environmentally-responsive materials and have the potential to enhance the healing outcomes of patients 
with chronic wounds. 
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A.1 PTK polymer and scaffold characterization 
 
Figure A1 GPC chromatograms of PTK diols 
 
 
Figure A2. SEM images of PTK-UR scaffolds. Day 0 samples (top row) show representative untreated scaffolds. 
The day 10 degradation samples (middle row) were incubated in 20% H2O2 in 0.1M CoCl2 for 10 days at 37°C to 
demonstrate oxidative degradation of the PTK-URs (note visible changes in structure of “macro-pores” and 
appearance of “micro-pores” in the struts of the scaffold). Week 25 PBS samples (bottom row) were incubated in 
PBS for 25 weeks at 37°C to demonstrate the resistance of the PTKs to hydrolytic breakdown. White scale bar 
represents 600 μm, and the inset images display higher magnification views (2.6x magnification of large image). 
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Table A1. Thermomechanical properties of 
PTK-UR and PEUR scaffolds and neat 
polymers. 
  Polymer   Scaffold 
 
DSC T
g
 
(°C) 
  DSC T
g 
(°C) 
DMA T
g 
(°C) 
100% 
MEE-PTK -66.1   -25.2 20.7 
75% 
MEE-PTK -67.7   -36.0 14.9 
50% 
MEE-PTK -78.5   -11.1 13.9 
25% 
MEE-PTK -72.9   -27.9 20.3 
0% 
MEE-PTK -76.8   -19.3 23.1 
900 Triol 
Polyester -47.7   -1.7 34.4 
1500 Triol 
Polyester -56.9   -26.4 24.7 
1000 Diol 
Polyester -43.1   -30.1 18.2 
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A.2 PTK-UR and PEUR in vitro scaffold degradation 
 
 
Figure A3. Proposed mechanism for hydroxyl radical degradation of PTK polymers. 
 
Figure A4. In vitro degradation of full set of PTK-UR scaffolds incubated in accelerated oxidative conditions (20% 
H2O2 in 0.1M CoCl2). For simplicity, only 100%, 50%, and 0% MEE-PTK-UR samples were displayed with statistical 
comparisons (*p < 0.05).  
 124 
 
Figure A5. H2O2 dose-dependent degradation of 900t-PEUR scaffolds. 
 
Figure A6. In vitro degradation of PTK-UR (LTI) scaffolds in varying ROS media. Scaffolds were incubated in water 
or different ROS media containing 5mM of hydrogen peroxide with CoCl2 (produces hydroxyl radicals), 5mM 
potassium superoxide, 5mM hydrogen peroxide, or 5mM SIN-1 (produces peroxynitrite) for three days and then 
weighed for mass loss. Scaffolds incubated in the different ROS were all significantly degraded compared to samples 
incubated in water (p<0.05). 
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A.3 Scaffold cytocompatibility 
 
 
 
 
 
 
 
 
 
 
Figure A7. In vitro cell-mediated degradation and cytocompatibility of PTK-UR scaffolds. (A) PTK-UR scaffolds 
seeded with RAW 267.4 macrophages and incubated for 3 days in either control or activation media (containing LPS 
and IFN-γ). Qualitatively, it appears that the activated macrophages generated pitting on the scaffold surface (black 
arrows), potentially indicating ROS-dependent cell-mediated scaffold degradation. Scale bar = 20 μm. (B) In vitro 
cytotoxicity evaluation of porous 3D PTK-UR scaffolds.  The bioluminescence (indicative of cell number) from 3T3 
fibroblast-seeded scaffolds was normalized to day 0 values and remained stable over 3 days in culture.  
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B.1 Characterization of subcutaneous scaffold implants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A8. Subcutaneous wound lengths of implanted 100% MEE-PTK-UR and 900t-PEUR scaffolds made with 
HDIt over 7 weeks, *p < 0.05. 
 
Table A2. PTK-UR and PEUR scaffold components 
Component PPHP Mass 
(mg) Component PPHP 
Mass 
(mg) 
PTK Diol  
(1100 g/mol) 100.0 69.5 
PE Triol  
(900 g/mol) 100.0 62.7 
Water 1.5 1.0 Water 1.5 0.9 
TEGOAMIN33 2.3 1.6 TEGOAMIN33 2.3 1.4 
Calcium stearate 4.0 2.8 Calcium stearate 4.0 2.5 
LTI 36.1 25.1 LTI 51.8 32.5 
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Figure A9. Subcutaneous wound areas of implanted 100% MEE-PTK-UR and 900t-PEUR scaffolds made with 
HDIt over 7 weeks, *p < 0.05. 
 
 
Figure A10. PTK-UR scaffolds made with LTI implanted subcutaneously in rats for 7-days. 
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B.2 Characterization of excisional wound scaffold implants 
 
Figure A11. Diabetic rats with excisional wounds and implanted PEUR and PTK-UR scaffolds at day 0, day 7, and 
day 14 post surgery. 
  
Figure A12. Macrophage presence in PEUR and PTK-UR scaffolds. There was no statistical difference in macrophage 
number between PEUR and PTK-UR scaffolds at day 7 post implantation in diabetic rats as quantitatively determined 
from CD68 IHC tissue sections. 
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B.3 Scaffold-mediated delivery of PHD2 siRNA in diabetic excisional wounds 
 
 
Figure A13. In vitro screen of PHD2 siRNA in A7r5 rat smooth muscle cells by qRT-PCR (*p<0.05). 
 
 
Figure A14. In vitro release of nanoparticles with 5wt% trehalose from PTK-UR (LTI) scaffolds. Nanoparticles were 
loaded with fluorescently labeled double-stranded DNA as a model for siRNA. 
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Figure A15. Initial in vivo screen of PEUR and PTK-UR scaffolds made with LTI for both baseline vascularization 
and stimulation of vascularization through PHD2 siNP delivery (mean ± SEM, n = 4 independent samples, *p<0.05).  
 
Table A3. Nucleic acid sequences. 
Name Sequence 
Scrambled siRNA DS Scrambled Neg – From IDT 
PHD2 siRNA S: 5’-GGUACGCAAUAACCGUUUGGUAUTT-3’ 
AS: 5’-AAAUACCAAACGGUUAUUGCGUACCUU-3’ 
    
GAPDH Primers FWD: 5’-CTCACTCAAGATTGTCAGCAATG-3’ 
REV: 5’-GAGGGAGATGCTCAGTGTTGG-3’ 
PPIB Primers FWD: 5’-TTCCATCGTGTCATCAAG-3’ 
REV: 5’-GAAGAACTGGGAGCCATT-3’ 
PHD2 Primers FWD: 5’-ATCTCACAGGTGAGAAAGGT-3’ 
REV: 5’-ACAGAAGGCAACTGAGAG-3’ 
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Figure A16. PTK-UR scaffolds made with HDIt and containing PHD2 siRNA nanoparticles were (A) implanted in 
diabetic rat excisional wounds over 14 days. Scaffolds with PHD2 siRNA had a significicant decrease in PHD2 mRNA 
at day 4 post implantation. 
 
 
Figure A17. Representative comparison of Ki67 and S100A4 IHC staining. Serial tissue sections taken from day 7 
PHD2-siNP implants (PTK-UR made with LTI), stained for either Ki67 (proliferating cells) or S100A4 (fibroblast 
marker), indicate that the proliferating cells are fibroblastic in nature. 
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C.1 Physical characterization of PEG-MAL hydrogels 
 
 
 
Figure A18 Physical characterization of hydrogels. (A) Swelling ratios of 7.5 and 5wt% PEG-dt and PTK hydrogels 
indicates that PEG-dt gels swell with more water than PTK gels. The lower wt% gels also swell more than the 
7.5wt% materials. (B) 7.5wt% gels and (C) 5wt% gels made with both PEG-dt and PTK crosslinkers have decreased 
mechanical properties after three days of incubation in 65mM H2O2, though PTK modulus values are more 
decreased. 
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C.2 Alternate strategy for synthesis of water-soluble PTK polymers 
 
 
Figure A19. Alternatively pursued strategy for synthesizing hydrophilic PTK polymers. Increasing the number of 
ethylene glycol units per initial dithiol monomer increases the final polymer solubility, but a completely water-
soluble PTK polymer was only achieved a PEG dithiol with n=12 ethylene glycols. However, the reaction efficiency 
and degree of polymerization (k thioketal units) decreases with increasing monomer molecular weight. 
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D.1 Ischemic wound healing model in rats 
 
 
 
Figure A20. Optimized rat ischemic flap model featuring (A) one ischemic skin wound with two non-ischemic control 
wounds. (B) Flap and wounds at 1-day post-surgery with (C) laser Doppler perfusion image, highlighting the lack of 
blood flow in the ischemic flap skin (blue areas = less perfusion, red areas = high perfusion). 
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D.2 Ischemic wound healing model in pigs 
 
 
Figure A21. Impaired porcine wound healing model featuring surgical ischemic skin flaps. The 10cm x 15cm bipedicle 
flaps are raised from the underlying muscle to create a region of ischemia, and 1cm x 1cm wounds are placed in the 
flap and non-ischemic skin as controls. Wounds are either left empty or filled with PTK-UR scaffolds made with LTI 
or HDIt. 
 
Figure A22. Laser Doppler perfusion imaging of blood flow in wound-implanted PTK-UR scaffolds and the 
surrounding tissue demonstrates that (A) the surgical flap creates ischemia compared to normal skin. Though the re-
establishment of blood flow in HDIt vs LTI PTK-UR scaffolds is the same in normal skin, LTI materials create more 
perfusion than HDIt implants in the ischemic wounds. 
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Figure A23. Histology of PTK-UR scaffolds in ischemic and non-ischemic porcine wounds. (A) Ischemic wounds 
generate less tissue infiltration into both scaffold formulations compared to non-ischemic wounds at day 10, though 
infiltration is more complete at day 28. There is more LTI scaffold present in the wounds at day 28 compared to HDIt, 
indicating that the HDIt materials could have been extruded from the wound rather than integrated with new tissue. 
(B) IHC for iNOS and CD206 at day 28 indicates that iNOS+ cells are present in the cell-dense regions surrounding 
the scaffold remnants, potentially indicating an inflammatory response, while CD206+ cells are directly in contact 
with the scaffold remnants. 
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E.1 PTK-UR scaffold fabrication 
 
PTK-UR or PEUR scaffolds can be fabricated in a variety of molds to yield final materials that have 
certain geometries, including microcentrifuge tubes (circular geometry, ~8mm diameter), soft-plastic 
polyethylene tubes (circular geometry, 6 or 10mm diameter), or even disposable UV-VIS cuvettes (square 
geometry, 1cm x 1cm). The scaffold precursor components can be directly mixed (by hand or with the 
Hauschild DAC 150 FVZ-K SpeedMixer) and allowed to react in these vessels, or they can pre-mixed in a 
larger container and then transferred before gelation to a final vessel. A number of tri-functional isocyanates 
can be used in scaffold fabrication, including hexamethylene diisocyanate trimer (HDIt), lysine 
triisocyanate (LTI), or LTI chain extended with a linear 2000g/mol PEG diol (LTI-PEG). Polyurethane 
scaffolds can be made in many formats, but are most often utilized as foams, cements, or films. This format 
is primarily determined by the catalyst chosen; the tertiary amine catalyst TEGOAMIN33, composed of 33 
wt% triethylene diamine (TEDA) in dipropylene glycol, is a blowing catalyst and is the first choice for 
making polyurethane foams. An iron(III) acetylacetonate (FeAA) catalyst is the first choice for the 
fabrication of more cement-like polyurethanes, while the organobismuth catalyst Coscat83 is often used to 
make polyurethane films.  
A successfully fabricated polyurethane foam balances the foaming and gelling reactions so that both 
proceed in a controlled fashion to make a homogenous porous architecture. A standard foam is made up of 
the polyol, the isocyanate, the catalyst, water to drive the foaming reaction, a “pore opener”, and a “pore 
stabilizer” if needed. The polyol reacts with the isocyanate to form the actual polyurethane matrix, while 
the TEGOAMIN33 catalyst drives both this gelling reaction and also the reaction of water with isocyanate 
groups to produce CO2 bubbles that create the foaming. The amount of TEGOAMIN33 needed to make 
proper foams varies with the different isocyanates; in terms of parts per hundred parts polyol (PPHP), HDIt 
requires 10PPHP, LTI requires 2.3PPHP, and LTI-PEG requires 2.7PPHP. The pore opener, typically 
calcium stearate, is included in the reaction mix to promote connectivity between the forming pores. The 
pore stabilizer, sulfated castor oil, acts as a surfactant and decreases the surface tension of the gas bubbles 
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in the foaming polyurethane, encouraging large bubbles to burst and form smaller bubbles that yield a more 
homogenous porous architecture. 
For fabricating a polyurethane foam with a new batch of polyol (PTK or polyester as either a diol or 
triol), there are a number of variables that can be tweaked to yield an optimum foam. The first variable is 
the effective hydroxyl content of the polyol, or how many primary hydroxyl groups are available to react 
with the isocyanate groups. This is usually determined from either the theoretical number of hydroxyl 
groups from the polymer’s molecular weight (MW), or from a titration assay to determine hydroxyl content 
in the polymer. Once an estimated effective polyol molecular weight is determined, good practice is to 
make some foams using the estimated MW and then foams using the estimated MW at 125% and 75% its 
estimated value. Once the three foams are fabricated, they can be weighed, then incubated in 
dichloromethane (DCM) overnight, and finally dried and weighed again. The DCM will extract any foam 
components that are not covalently linked to the crosslinked polymer network, and the foam’s reaction 
efficiency can be determined from the ratio of the foam weight post and pre-DCM incubation. The MW 
value that yields the foam with the highest reaction efficiency can then be used for fabricating polyurethane 
foams with that batch of polyol. 
The final variables that can be tweaked are the relative amounts of water and pore stabilizer used in the 
foam. The amount of foaming is highly sensitive to the amount of water used and this is by far the most 
critical parameter for fabricating a high quality polyurethane foam. For most polyols, water at 0.5 – 
2.0PPHP mediates controlled foaming and yields final materials that are ~90% porous. However, 
sometimes the foaming reaction is uncontrolled and creates materials with large voids or heterogeneous 
pore sizes, thus necessitating the use of the pore stabilizer. The pore stabilizer is usually used in amounts 
from 0.5 – 2.0PPHP and will dampen the formation of large pores or voids in the foam. Unfortunately, too 
much pore stabilizer can hinder the gelling reaction so that the mechanical integrity of the foam is not 
maintained, i.e. the foam will collapse on itself during hardening. Therefore, the usual process for creating 
optimally porous foams is as follows: fabricate a 100mg foam with your new polyol batch using 1.5PPHP 
water and no pore stabilizer and allow to harden for 20min. Choose that amount of water if the foam reaches 
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the desired level of overall porosity, and adjust the amount of water up or down by 0.5PPHP to increase or 
decrease the overall foaming. If the foam produces large voids or irregularly sized pores, remake the sample 
using 0.5PPHP pore stabilizer oil and increase as needed until the pores seem homogenous. However, use 
a minimal amount of pore stabilizer if possible to ensure that the mechanical integrity of the polyurethane 
is maintained through the gelling process. After creating an optimal foam formulation for a new batch of 
polyol, the materials should be allowed to harden for at least 3-4 hrs but preferably at least 12 hrs or 
overnight. Scaffolds can be sterilized by ultraviolet light or gamma irradiation, though samples that contain 
drug payloads should be sterilized with ethylene oxide gas to avoid decomposition of the drug (though gas 
sterilized samples must be allowed to vent for at least 3 days to remove any excess gas from the material 
matrix). 
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E.2 siNP delivery from PTK-UR scaffolds for in vivo PHD2 knockdown 
The local delivery of siRNA from implanted PTK-UR scaffolds, though offering promising results in 
wound healing applications, is a complex system and must be optimized at many different stages before 
successful in vivo implementation can occur. The first step is to develop a mechanically-optimized PTK-
UR scaffold formulation (detailed in section E.2). The second step is to synthesize a nanoparticle with 
effective siRNA intracellular delivery. This is usually accomplished by synthesizing a small library of 
DMAEMA-block-(DMAEMA-co-BMA co-PAA) polymers (same block size of DMAEMA with varied 
block lengths of DMAEMA-co-BMA co-PAA) and then screening the nanoparticle activity by complexing 
siRNA that silences the gene luciferase with the polymeric micelles and treating luciferase-expressing cells. 
The polymer carrier that most effectively silences luciferase expression in vitro can then be used in the 
following studies. The third step is to screen a library of siRNA sequences against the target gene using 
your optimized nanoparticle carrier as screened by qRT-PCR. 
The final parameter that can be modulated is the selection of and concentration of excipient used to 
stabilize the siRNA nanoparticles through lyophilization. Previous work has used trehalose at a dose of 
60:1 weight ratio to siRNA, though this amount of trehalose has been shown to promote almost complete 
siRNA release over two days in vivo. This was reflected in the data presented in Chapter 4 as significant 
PHD2 silencing was seen at day 4 post scaffold implantation but was not sustained to day 7. Nelson et al. 
demonstrated that decreasing the amount of trehalose decreases the nanoparticle release rate, and in an 
unpublished study PTK-UR (LTI) scaffolds were loaded with PHD2 siRNA nanoparticles using a 12:1 
weight ratio of trehalose to siRNA and implanted subcutaneously in rats. Unfortunately, PHD2 levels in 
PHD2 siRNA samples were as high as scrambled control siRNA scaffolds silencing at day 7 post 
implantation. The lower dose of trehalose slowed the siRNA release rate, but this excipient is also critical 
for maintaining nanoparticle activity through lyophilization, potentially indicating that the reduced dose of 
trehalose compromised the particles. This motivates future studies either exploring intermediate trehalose 
doses that can maintain particle activity but slowing release, using new excipients that better stabilize 
particles, or using siRNA delivery vectors that are more stable through lyophilization. 
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B.3 Rat ischemic wound model 
 
As detailed in Chapter 4, excisional wounds in diabetic rats, despite their hyperglycemic state, still had 
almost complete tissue infiltration into implanted scaffolds after 4 days. This robust healing response makes 
it difficult to assess the viability of therapeutics which are designed to increase healing in chronic, non-
healing wounds. To create a more impaired wound model, we have attempted to create a bipedicle flap in 
the dorsal skin of rats as described in Figure A20. The raised skin flap limits blood flow to the skin in the 
central portion of the flap to create an area of ischemia and reduced healing. Initial efforts to develop this 
model tried to underlay the raised skin flap with a piece of medical grade silicone sheeting above to limit 
the re-establishment of blood flow from the underlying tissue. However, this sheeting served to trap fluid 
and made the skin flap too ischemic to the point of necrosis and was not used in subsequent studies. The 
initial iterations of this wound model also utilized two 8mm diameter wounds in the center flap, one frontal 
and one distal from the horizontal center of the flap. Though the inclusion of two wounds are designed to 
increase the statistical throughput of the model, the excised wounds themselves decreased blood flow to the 
tissue between the two wounds causing necrosis. The initial flap also featured dimensions of 9cm length by 
2cm width which was too narrow to allow for adequate blood flow to the center of the flap, causing necrosis. 
Therefore, the optimized flap did not have silicone sheeting and featured dimensions of 9cm by 2.5cm with 
a single 8mm diameter wound in the center of the flap. This configuration creates robust ischemia in the 
center of the flap which persists for 10 days, but not severe enough ischemia to create necrosis. 
  
 
 
